Improved blood coagulation composition

By using a combination of prothrombin activator and stabilizer in serum sample production, the problem of excessive coagulation time and incomplete coagulation is solved, and faster and more accurate serum sample preparation is achieved, suitable for emergency situations and anticoagulation Treat patients.

CN114703167BActive Publication Date: 2024-11-19Q SERA
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
CN202210215402.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2014-10-23
Filing Date
2015-10-23
Publication Date
2024-11-19
Estimated Expiration
2035-10-23

AI Technical Summary

Technical Problem

Prior art When producing serum samples for analyte testing, the coagulation time is too long, resulting in untimely and inaccurate analysis results, especially in emergencies or in patients with anticoagulation treatment, where coagulation is incomplete or latent coagulation. Generally, affects laboratory workflow and patient care decisions.

Method used

The coagulation compositions containing prothrombin activators and stabilizers, such as colloids, such as gelofusine or bovine serum albumin, are used to prepare serum samples, significantly improving the stability and coagulation activity of the coagulation composition, Ensure that coagulation capacity is maintained under different storage conditions.

Benefits of technology

It significantly shortens the coagulation time, improves the stability of serum samples and the accuracy of analysis results, reduces interruptions in laboratory work and equipment maintenance needs, and is suitable for a variety of blood samples, including samples from patients with anticoagulation treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114703167B_ABST
    Figure CN114703167B_ABST
Patent Text Reader

Abstract

The present invention relates to improved coagulation compositions for producing high quality serum samples for analyte testing, such as for pathology testing and other bioassays. In particular, the present invention relates to the use of prothrombin activators together with stabilizers, such as colloids, to produce high quality serum samples. The present invention also relates to related methods for preparing coagulation compositions, tubes, kits, and methods for diagnosis, prognosis, and monitoring responsiveness to treatment.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention is a divisional application of the application number 201580057842.3 filed on October 23, 2015, and entitled “Improved Coagulation Composition”. Technical Field

[0002] The present invention relates to improved coagulation compositions for producing high-quality serum samples for analyte testing. In particular, the present invention relates to the use of prothrombin activators together with stabilizers, such as colloids, for producing high-quality serum samples for analyte testing, such as for pathology testing and other bioassays. The present invention also relates to related methods for preparing coagulation compositions, tubes, kits, and methods for diagnosis, prognosis, and monitoring responsiveness to treatment.

[0003] Citations of Related Applications

[0004] not applicable.

[0005] Statement Regarding Federally Funded Research

[0006] not applicable. Background Art

[0007] Serum is typically produced by allowing a blood sample to clot and then centrifuging the sample to separate the clot, including cells, from the serum. Plastic tubes (instead of glass) are now commonly used and require procoagulants, also known as coagulation activators, to enhance the coagulation process. Procoagulants use either intrinsic or extrinsic pathways to achieve clot formation.

[0008] Clot formation via the intrinsic pathway is surface-dependent, whereby a greater density of activated surface sites enhances clotting time. Typically, siliceous materials such as glass, silicon dioxide, kaolin, bentonite, and diatomaceous earth are used in plastic tubing to accelerate clot formation, which is achieved through contact activation via the intrinsic pathway. However, clotting via the intrinsic pathway is relatively slow, typically requiring 30 to 60 minutes.

[0009] Activation of coagulation by the extrinsic pathway involves the initiation of coagulation by the addition of substances that are external to the blood and that initiate biochemical reactions in a concentration-dependent manner. Coagulation activators that operate by the extrinsic pathway include ellagic acid, thrombin, snake venom components, and thromboplastin. Although these coagulation activators produce rapid coagulation within 10 to 20 minutes, the clots that form are often colloidal and difficult to separate from the serum.

[0010] For analyte testing, serum is preferred over plasma conventionally, unless urgent result is needed, in which case, the clotting time for serum tube is considered too long. Even by means of existing procoagulants, in most commercial tubes, the clotting time recommended by manufacturers for the minimum requirement is 30 minutes for blood samples from normal patients, and longer (conventionally 60 minutes or longer) for samples from patients adopting anticoagulant therapeutic agents such as heparin. For samples from catheterization laboratories in emergency situations (emergency department, intensive care unit, operating room etc.), time is too long, and thus plasma, which can be produced faster, is preferred over serum conventionally.

[0011] By collecting blood in the tube containing anticoagulant, then centrifugation that can be carried out immediately after collection forms plasma with separation of cells, thereby obtains the plasma for analysis.In these tubes, lithium heparin is the most commonly used anticoagulant.Citrate, sodium fluoride / potassium oxalate and EDTA are other anticoagulants, which are used for some tubes to produce the estimated plasma for a small amount of other analytes.The coagulation process in the preparation serum sample consumes fibrinogen and traps platelets and other cells in the network of fibrin.After centrifugation, by the serum separator in the collecting device, or by serum being equally divided into auxiliary containers and separating serum from blood clot, to prevent contact with cells.This separation allows sample to remain stable for a long time.If the sample is not analyzed immediately, or if reanalysis or additional analysis is needed, then this stability is particularly important.

[0012] For some serum samples, after the recommended waiting time, coagulation remains incomplete. In patients undergoing anticoagulant therapy or in samples collected from anticoagulant droppers or intubations, the problem of incomplete coagulation or latent coagulation in samples is particularly common. In order to coagulate, such blood may need a longer time than the waiting time suggested by the manufacturer, or in fact may never coagulate completely in standard serum tubes (e.g., from the blood of fully heparinized cardiac surgery patients).

[0013] If the serum sample is centrifuged before coagulation is complete, coagulation can continue in the serum as the remaining fibrinogen is converted to fibrin, thereby causing the formation of blood clots, microclots or fibrin strings, which can cause problems unique to analyzers or analytes. Due to the lack of timely reversal of the lithium heparin tube after blood collection, the formation of microclots and fibrinogen strings may also occur in the plasma tube during sample preparation. Although heparin can prevent blood clot formation, it cannot disintegrate the blood clot after contact. Therefore, the blood clot will remain in the tube, regardless of further contact with heparin. Similarly, in other anticoagulant tubes (such as EDTA), coagulation may also occur. During platelet aggregation, due to the stimulation of platelet factor 4 (PL4) from the alpha granules of platelets, the lithium heparin plasma tube can also allow the formation of insoluble fibrin, thereby neutralizing heparin.

[0014] Additionally, other patient factors, such as disease state and medications, can reduce the efficacy of heparin activity and lead to increased fibrin formation. Over time, heparin activity decreases in stored lithium heparinized blood samples, primarily due to PL4 activity. When plasma is stored at low temperatures, the formation of insoluble fibrin is enhanced.

[0015] Even the smallest clot can produce clinically significant errors and / or cause automated analyzers to become clogged. Indeed, this problem is becoming increasingly prevalent over time, as the use of new automated analyzers continues to decline and as more patients are taking anticoagulants. Analyzer clogs mean that laboratory workflow is interrupted and the analyzer is subject to downtime, requiring cleaning and possibly replacement of affected components. Therefore, for accuracy, samples must be inspected manually, either visually or using automated inspection systems (if available) to ensure they are free of fibrin strands or clots. If strands or clots of insoluble material are present, the sample needs to be subsampled into a new container and re-centrifuged before analysis. Samples exhibiting recurrent latent coagulation may need to be transferred to lithium heparin tubes to stop ongoing clotting. These procedures require additional time. Furthermore, fibrin strands or clots are not always detected (e.g., they may even occur after the analyzer has sampled), and the resulting sampling errors can lead to patient care decisions based on inaccurate results.

[0016] Samples obtained in plasma tubes, specifically lithium heparin plasma, may also be contaminated with cells. When centrifuged, lithium heparin gel tubes always have a small "buffy coat-like layer" on top of the gel at the bottom of the plasma. This layer contains fibrin, cells, and cell matrix. During centrifugation, the rapid gel movement can leave some cells in the plasma. During centrifugation, the rapid gel and blood cell movement can cause the gel to form a barrier between the cells and the plasma and leave some cells in the plasma. If the plasma sample is mixed (for example, during subsampling or processing), it will become turbid due to the suspension of cell-containing material and fibrin, which can reduce the integrity of the sample. In addition, platelet aggregates can form, which can also contain fibrin and / or white blood cells. These aggregates can be large enough to be visible to the naked eye and have been referred to as "white particulate matter" due to their typical white color and pose similar problems to the incomplete coagulation discussed above. Therefore, the presence of cells in the sample may affect the analyte concentration. Certain analytes (eg, glucose) may be reduced by cell activity and other analytes (eg, lactate dehydrogenase, potassium, or phosphate) may be increased by leakage or cell breakdown.

[0017] Although there is generally no difference in analyte concentrations measured in serum or plasma tubes, some exceptions exist. Plasma tubes using heparin are not suitable for heparin analysis or cell-based assays. Lithium heparin plasma tubes are not suitable for lithium analysis. Plasma can be unreliable for additional testing or retesting due to the presence of cells and insoluble fibrin formation after prolonged storage at 2-8°C. In addition, some serum or plasma tubes may produce inaccurate results for analyte levels due to interactions with the procoagulant or anticoagulant within the tube.

[0018] It is also desirable to reduce the amount of sample that needs to be tested, particularly in critically ill patients, patients receiving blood transfusions, and infants, in order to reduce the volume of blood collected from the patient. It is therefore optimal to be able to run all necessary tests using samples taken in single blood collection tubes. To achieve this goal, test methods have been developed using very small sample volumes (e.g., 2 μL), so that typically one serum or plasma tube is used for at least 21 tests, but can be used for 50-60 or even 70-80 tests, depending on the volume of sample required for each test. However, in cases where there is doubt about the accuracy of measuring a particular analyte in a serum or plasma tube, it may be necessary to take a serum tube and plasma tube from the patient, and doing so defeats the goal of reducing the volume of blood taken from the patient.

[0019] Thrombin tubes have been developed that are as fast as coagulation tubes. Thrombin has procoagulant and proteolytic activity, and it is known that thrombin has high specificity for the cleavage bond in fibrinogen, activated protein C (APC) and factor Va. However, it has been found that thrombin tubes cannot be used with all blood samples. It is known that thrombin is quickly and completely inhibited by the heparin-antithrombin III complex present in heparinized blood samples. For example, it is reported that BD RST tubes are invalid in coagulation patient samples containing high doses of heparin (see, e.g., Dimeski et al., 2010).

[0020] Problems arising from the use of current methods for preparing serum and plasma from blood indicate that improvements are needed to generally achieve timely, reliable analytical results from a wider range of blood samples.

[0021] In response to this need, it was previously demonstrated in International Patent Application No. PCT / AU2011 / 001221, published as WO2012 / 037609 (the entire contents of which are incorporated herein by reference) that blood samples could be coagulated to produce high quality serum for analyte testing procedures using prothrombin activators isolated from snake venom.

[0022] It has now been demonstrated that the use of prothrombin activators isolated from snake venom, when formulated as coagulation compositions along with one or more additional agents, such as colloids, significantly increases the stability of coagulation compositions. This increased stability is significant under conditions that would previously compromise the efficacy of such compositions, due to the ability to manufacture, sterilize, transport, and store the coagulation compositions (e.g., in the form of collection tubes) without significant loss of coagulation activity. For example, the compositions of the present invention are stable after sterilization involving irradiation, high temperature storage, and prolonged storage. Summary of the Invention

[0023] In a first aspect of the present invention, a coagulation composition for preparing a serum sample is provided, wherein the coagulation composition comprises a prothrombin activator and a stabilizer. In some embodiments, the stabilizer can be a colloid.

[0024] In a second aspect of the present invention, a method for preparing the coagulation composition of the first aspect is provided, wherein the method comprises providing a prothrombin activator and a stabilizer. In some embodiments, the stabilizer can be a colloid.

[0025] In a third aspect of the present invention, a kit for preparing a serum sample is provided, wherein the kit comprises a prothrombin activator and a stabilizer. In some embodiments, the stabilizer can be a colloid.

[0026] In a fourth aspect of the present invention, a container is provided comprising a coagulation composition for preparing a serum sample, wherein the coagulation composition comprises a prothrombin activator and a stabilizer. In some embodiments, the stabilizer can be a colloid. In a specific embodiment, the container is a blood collection tube, the prothrombin activator is OsPa or Ecarin, and the colloid is gelofusine or bovine serum albumin.

[0027] In a fifth aspect of the present invention, a method for preparing a serum sample is provided, wherein the method comprises contacting a blood sample with the coagulation composition of the first aspect for a period of time under conditions sufficient to cause coagulation of the blood sample, and optionally separating serum from thrombocytes, thereby preparing the serum sample. The thrombocytes may include red blood cells, white blood cells, platelets and cell matrix.

[0028] In a sixth aspect of the present invention, there is provided a serum sample produced by the method of the fifth aspect.

[0029] In a seventh aspect of the invention, a method for diagnosing a disease or condition in a subject is provided, wherein the method comprises providing a blood sample from the subject, preparing a serum sample from the blood sample (according to the fifth aspect of the invention), and testing the serum sample for the presence or absence of an analyte in the serum sample, or for an indicative level or concentration of the analyte in the serum sample, wherein the presence, absence or indicative level or concentration of the analyte is indicative of the disease or condition in the subject.

[0030] In an eighth aspect of the invention, a method for providing a prognosis for a subject is provided, wherein the method comprises providing a blood sample from the subject, preparing a serum sample from the blood sample according to the fifth aspect of the invention, and testing the serum sample for the presence or absence of an analyte in the serum sample, or for an indicative level or concentration of the analyte in the serum sample, wherein the presence, absence or indicative level or concentration of the analyte indicates a prognosis for the subject.

[0031] In a ninth aspect of the invention, a method for monitoring a subject's responsiveness to a treatment is provided, wherein the method comprises providing a blood sample from the subject, preparing a serum sample from the blood sample according to the fifth aspect of the invention, and testing the serum sample for the presence or absence of an analyte in the serum sample, or for an indicative level or concentration of the analyte in the serum sample, wherein the presence, absence or indicative level or concentration of the analyte indicates the subject's responsiveness to the treatment.

[0032] definition

[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. For purposes of the present invention, the following terms are defined as follows.

[0034] The articles "a" and "an" are used herein to refer to one or to more than one (ie, to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0035] "About" refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% relative to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

[0036] The term "biologically active fragment" when applied to a reference or full-length polynucleotide or polypeptide sequence refers to a fragment that has at least about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%. Included within the scope of the present invention are biologically active fragments comprising at least about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000 nucleotides or residues in length comprising or encoding an activity of a reference polynucleotide or polypeptide. Representative biologically active fragments generally participate in interactions, such as intramolecular or intermolecular interactions. Intermolecular interactions can be specific binding interactions or enzymatic interactions (e.g., interactions can be transient and form or break covalent bonds). Biologically active fragments of full-length polypeptides include peptides that can comprise an amino acid sequence that is fully similar to or derived from the amino acid sequence of a (hypothetical) full-length polypeptide. Typically, a biologically active fragment comprises a domain or motif that has at least one activity of the full-length polypeptide. Suitably, the biologically active fragment has no less than about 1%, 10%, 25% or 50% of the activity of the full-length polypeptide from which it is derived.

[0037] "Coding sequence" refers to any nucleic acid sequence that contributes to encoding the polypeptide product of a gene. In contrast, the term "non-coding sequence" refers to any nucleic acid sequence that does not contribute to encoding the polypeptide product of a gene.

[0038] Throughout this specification, unless the context requires otherwise, the words "comprising," "including," and "containing" will be understood to imply the inclusion of the recited steps or elements, or groups of steps or elements, but not the exclusion of any other steps or elements, or groups of steps or elements. Thus, use of the terms "comprising" and the like indicates that the listed elements are required or mandatory, but other elements are optional and may or may not be present. "Consisting of" means including and limited to whatever follows the phrase "consisting of." Thus, the phrase "consisting of" indicates that the listed elements are required or mandatory, and no other elements may be present. "Consisting essentially of" means including any elements listed after the aforementioned phrase and being limited to other elements that do not interfere with or contribute to the activity or effect specified for the listed element in this disclosure. Thus, the phrase "consisting essentially of" indicates that the listed elements are required or mandatory, but other elements are optional and may or may not be present, depending on whether they affect the activity or effect of the listed element.

[0039] The terms "complementary" and "complementarity" refer to polynucleotides (i.e., nucleotide sequences) that are related by the base pairing rules. For example, the sequence "AGT" is complementary to the sequence "TCA." Complementarity can be "partial," where only some nucleic acid bases match according to the base pairing rules. Alternatively, there can be "complete" or "total" complementarity between nucleic acids. The degree of complementarity between nucleic acid strands has a significant impact on the efficiency and strength of hybridization between nucleic acid strands.

[0040] "Corresponding to" or "corresponding to" refers to (a) a polynucleotide having a nucleotide sequence that is substantially identical or complementary to all or a portion of a reference polynucleotide sequence or encoding an amino acid sequence that is identical to an amino acid sequence in a peptide or protein; or (b) a peptide or polypeptide having an amino acid sequence that is substantially identical to an amino acid sequence in a reference peptide or protein.

[0041] The term "derivable" includes, and is used interchangeably with, the terms "obtainable" and "isolatable." A composition or other subject matter of the invention that is "derivable," "obtainable," or "isolatable" from a particular source or process includes not only compositions or other substances derived, obtained, or isolated from such source or process, but also includes the same compositions or substances however derived or produced, for example, by recombinant DNA techniques or other genetic engineering methods.

[0042] As used herein, the term "detecting an analyte" means determining the presence, absence, amount, level, or concentration of one or more analytes in a sample.

[0043] "Gene" refers to a genetic unit that occupies a specific locus on a chromosome and consists of transcriptional and / or translational regulatory sequences and / or coding regions and / or untranslated sequences (ie, introns, 5' and 3' untranslated sequences).

[0044] "Homologs" refers to the percentage of nucleic acids or amino acids that are identical or constitute conservative substitutions. Homology can be determined using sequence comparison programs such as GAP (Devereux et al., 1984), which is incorporated herein by reference. In this way, sequences of similar or substantially different lengths to those cited herein can be compared by inserting gaps into the sequence alignment, for example, by determining such gaps using the comparison algorithm used by GAP.

[0045] The term "host cell" includes individual cells or cell cultures that can be or have been recipients of any recombinant vector or isolated polynucleotide of the present invention. Host cells include progeny of a single host cell, and progeny may not necessarily be identical (morphologically or in terms of total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutations and / or changes. Host cells include cells transfected or infected with a recombinant vector or polynucleotide of the present invention in vivo or in vitro. A host cell comprising a recombinant vector of the present invention is a recombinant host cell.

[0046] "Hybridization" is used herein to refer to the pairing of complementary nucleotide sequences to produce DNA-DNA hybrids or DNA-RNA hybrids. Complementary base sequences are those sequences related by the base pairing rules. In DNA, A pairs with T and C pairs with G. In RNA, U pairs with A and C pairs with G. In this respect, as used in this article, the terms "matching" and "mismatching" refer to the hybridization potential of paired nucleotides in complementary nucleic acid chains. Matched nucleotides effectively hybridize, such as the classic AT and GC base pairs mentioned above. Mismatching is other combinations of nucleotides that do not hybridize effectively.

[0047] "Isolated" refers to material that is substantially or essentially free from components that normally accompany it in its native state. For example, as used herein, an "isolated polynucleotide" refers to a polynucleotide that has been purified from the sequences that flank it in its naturally occurring state, e.g., a DNA fragment that has been removed from sequences that normally adjoin the fragment. Alternatively, as used herein, an "isolated peptide" or "isolated polypeptide" or the like refers to the in vitro separation and / or purification of a peptide or polypeptide molecule from its natural cellular environment and from association with other components of the cell, i.e., it is not associated with substances in vivo.

[0048] The terms "derived from" and "derivable" include, and are used interchangeably, the terms "obtained," "obtainable," "isolated," and "isolatable." A composition or other substance of the invention that is "derived from," "derivable," "obtained," "obtainable," "isolated," or "isolatable" from a particular source or process includes not only compositions or substances so derived, obtained, or isolated from that source or process, but also includes the same composition or substance regardless of how it is sourced or produced. For example, a prothrombin activator derived or derivable from snake venom can include not only a prothrombin activator isolated from snake venom, but also the same prothrombin activator expressed from a vector or other expression system by recombinant DNA technology.

[0049] As employed in this article, term " oligonucleotide " refers to the polymer that is made up of a plurality of nucleotide residues (deoxyribonucleotide or ribonucleotide or their related structure variant or synthetic analogue) that are connected by phosphodiester bond (or its related structure variant or synthetic analogue).Therefore, although term " oligonucleotide " refers generally to nucleotide polymers, wherein nucleotide residue and the key between them are naturally occurring, but it should be understood that, above-mentioned term also comprises various analogues within its scope, includes but not limited to peptide nucleic acid (PNA), phosphoramidate, thiophosphate, methylphosphonate, 2-O-methyl ribonucleic acid etc.The accurate size of molecule can change, and it depends on specific application.Oligonucleotide has quite short length usually, about 10 to 30 nucleotide residues usually, but above-mentioned term can refer to the molecule of any length, although term " polynucleotide " or " nucleic acid " are generally used for large oligonucleotide.

[0050] As used herein, the term "operably linked" means placing a structural gene under the regulation of a promoter, which then controls the transcription and, optionally, translation of the gene. In the construction of heterologous promoter / structural gene combinations, it is generally preferred to position the gene sequence or promoter at a distance from the gene transcription start site that is roughly the same as the distance between the gene sequence or promoter and the gene that it controls in its natural environment; that is, the gene from which the gene sequence or promoter is derived. As is known in the art, some variation can be accommodated within this distance without loss of function. Similarly, the preferred positioning of a regulatory sequence element relative to the heterologous gene to be placed under its control is defined by the positioning of the element in its natural environment; that is, the gene from which it is derived.

[0051] The terms "patient," "subject," and "individual" are used interchangeably and refer to human or other mammalian patients, subjects, and individuals, including any one for whom the present invention is intended to be used to detect analyte levels or diagnose the presence, absence, or severity of a disease or condition. However, it should be understood that "patient" does not mean that symptoms are present. Suitable mammals within the scope of the present invention include, but are not limited to, primates (e.g., humans, chimpanzees), livestock animals (e.g., sheep, cattle, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs), and captive wild animals (e.g., foxes, deer, wild dogs).

[0052] As used herein, the terms "polynucleotide" or "nucleic acid" refer to mRNA, RNA, cRNA, cDNA, or DNA. The above terms generally refer to a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides, or a modified form of either type of nucleotide. The above terms include single-stranded and double-stranded forms of DNA.

[0053] The terms "polynucleotide variant" and "variant" and the like refer to polynucleotides that exhibit substantial sequence identity to a reference polynucleotide sequence or polynucleotides when hybridized to a reference sequence under stringent conditions as defined below. These terms also include polynucleotides that are distinguished from a reference polynucleotide by the addition, deletion, or substitution of at least one nucleotide. Thus, the terms "polynucleotide variant" and "variant" include polynucleotides in which one or more nucleotides have been added or deleted, or replaced with different nucleotides. In this regard, it is well understood in the art that certain changes can be made to a reference polynucleotide, including mutations, additions, deletions, and substitutions, such that the altered polynucleotide retains the biological function or activity of the reference polynucleotide. The terms "polynucleotide variant" and "variant" also include naturally occurring allelic variants.

[0054] "Polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acid residues, as well as to variants and synthetic analogs thereof. Thus, these terms apply to amino acid polymers in which one or more amino acid residues is a synthetic non-naturally occurring amino acid, such as a chemical analog of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.

[0055] The term "polypeptide variant" refers to a polypeptide that is distinguished from a reference polypeptide by the addition, deletion, or substitution of at least one amino acid residue. In certain embodiments, a polypeptide variant is distinguished from a reference polypeptide by one or more substitutions, which may be conservative or non-conservative. In certain embodiments, polypeptide variants include conservative substitutions and, in this regard, it is well understood in the art that some amino acids may be changed to other amino acids that have broadly similar properties without altering the activity profile of the polypeptide. Polypeptide variants also include polypeptides in which one or more amino acids have been added or deleted, or replaced with a different amino acid residue.

[0056] "Primer" refers to an oligonucleotide that, when paired with a DNA chain, is capable of initiating the synthesis of primer extension products in the presence of a suitable polymerizing agent. Primers are preferably single-stranded to maximize amplification efficiency, but may alternatively be double-stranded. Primers must be long enough to initiate the synthesis of extension products in the presence of a polymerizing agent. The length of a primer depends on many factors, including application, temperature to be used, template reaction conditions, other reagents, and primer sources. For example, depending on the complexity of the target sequence, an oligonucleotide primer typically contains 15 to 35 or more nucleotide residues, although it may contain fewer nucleotide residues. A primer can be a large polynucleotide, such as approximately 200 nucleotide residues to several thousand bases or more. Primers can be selected to be "substantially" complementary to the sequence on the template designed to hybridize therewith and as a site for initiating synthesis. "Substantially complementary" means that the primers are fully complementary to hybridize with the target polynucleotide. Preferably, the primer does not contain mismatches with the template designed to hybridize therewith, but this is not necessary. For example, non-complementary nucleotide residues can be attached to the 5' end of the primer, wherein the remainder of the primer sequence is complementary to the template. Alternatively, non-complementary nucleotide residues or a stretch of non-complementary nucleotide residues can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to which it hybridizes and thereby forms a template for the synthesis of primer extension products.

[0057] "Probe" refers to a molecule that binds to a specific sequence or subsequence or other portion of another molecule. Unless otherwise indicated, the term "probe" generally refers to a polynucleotide probe that binds to another polynucleotide, often referred to as a "target polynucleotide," although complementary base-pairing probes can bind to target polynucleotides that lack full sequence complementarity to the probe, depending on the stringency of the hybridization conditions. The probe can be directly or indirectly labeled.

[0058] The term "recombinant," when used, for example, with reference to a cell, nucleic acid, protein, or vector, means a cell, nucleic acid, protein, or vector that has been modified by the introduction of a heterologous nucleic acid or protein or by alteration of a native nucleic acid or protein, or that is derived from a cell so modified. Thus, a "recombinant" cell expresses genes not found in the native (non-recombinant) form of the cell or expresses native genes that are otherwise abnormally expressed, underexpressed, or not expressed at all. The term "recombinant nucleic acid" refers to a nucleic acid that is initially formed in vitro, generally through manipulation of nucleic acids, e.g., using polymerases and endonucleases, and in a form not normally found in nature. In this manner, operative linkage of different sequences is achieved. Thus, for the purposes of the present invention, an isolated nucleic acid in linear form or an expression vector formed in vitro by ligating abnormally linked DNA molecules is considered "recombinant." It is understood that after a recombinant nucleic acid is constructed and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., utilizing the in vivo cellular machinery of the host cell rather than manipulations in vitro. However, for the purposes of the present invention, such a nucleic acid, after recombinant production, is still considered recombinant even though it subsequently replicates non-recombinantly. Similarly, a "recombinant protein" is a protein constructed using recombinant technology, ie, by expression of a recombinant nucleic acid as described above.

[0059] The term "reference result" includes results taken from the same subject at a different time, results taken from a normal subject or group of normal subjects, or a reference standard used in an analytical test.

[0060] "Regulatory elements" or "regulatory sequences" refer to nucleic acid sequences (e.g., DNA) that are necessary for expression of an operably linked coding sequence in a particular host cell. Regulatory sequences suitable for prokaryotes include, for example, promoters, optional cis-acting sequences such as operator sequences, and ribosome binding sites. Control sequences suitable for eukaryotic cells include promoters, polyadenylation signals, transcription enhancers, translation enhancers, leader or trailer sequences that regulate mRNA stability, and leader sequences that target the product encoded by the transcribed polynucleotide to an intracellular compartment within the cell or to the extracellular environment.

[0061] As used in this article, the term "sequence identity" refers to that, over a comparison window, based on nucleotide / nucleotide or amino acid-amino acid, a sequence is the same degree. Therefore, over a comparison window, "percentage of sequence identity" is calculated by comparing two optimally aligned sequences: the number of positions of the identical nucleic acid bases (e.g., A, T, C, G, I) or identical amino acid residues (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) that occur in the two sequences is used to produce the quantity of matching positions, the quantity of matching positions divided by the total number of positions (i.e., window size) in the comparison window, and the result is multiplied by 100 to produce percentage of sequence identity. For the purposes of the present invention, "sequence identity" is understood to mean the "percent match" calculated by the DNASIS computer program (Version 2.5 for Windows; available from Hitachi Software Engineering Co., Ltd., South San Francisco, California, USA) using standard default values ​​as used in the reference materials accompanying the software.

[0062] The term "sequence similarity" refers to the percentage of amino acids that are identical or constitute conservative substitutions (as defined in Table 2 below). Similarity can be determined using sequence comparison programs such as GAP (Devereux et al., 1984). In this way, sequences of similar or substantially different lengths can be compared to those cited herein by gap insertion alignment, for example, by determining the gaps using the comparison algorithm used by GAP.

[0063] Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence," "comparison window," "sequence identity," "percentage of sequence identity," and "substantial identity." A "reference sequence" is at least 12, but frequently 15 to 18, and often at least 25 monomer units, including nucleotides and amino acid residues, in length. Because two polynucleotides can each contain (1) a sequence that is similar between the two polynucleotides (i.e., only a portion of the complete polynucleotide sequence), and (2) a sequence that diverges between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing the sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of at least 6 contiguous positions, typically about 50 to about 100, more typically about 100 to about 150, wherein, after optimal alignment of the two sequences, a sequence is compared to a reference sequence having the same number of contiguous positions. For optimal alignment of two sequences, the comparison window may contain about 20% or fewer additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions). Optimal alignment of sequences for the comparison window can be performed by computerized algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, W1, USA) or by inspection, and the best alignment (i.e., resulting in the highest percentage homology over the comparison window) can be generated by any selected method. Reference can also be made to the BLAST family of programs, such as those disclosed by Altschul et al., 1997. A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel et al., "Current Protocols in Molecular Biology." John Wiley & Sons Inc, 1994-1998, Chapter 15.

[0064] As used herein, the phrase "stabilizer" includes any molecule that can contribute to the stability of a coagulation composition comprising a prothrombin activator, such as by preserving, increasing, prolonging, or otherwise enhancing the ability of the coagulation composition to coagulate blood (relative to a given time unit). Such stabilization may therefore result in a coagulation composition that is capable of coagulating blood in a shorter time than would be required to coagulate blood in the absence of the stabilizer. Together with the stabilizer, the time required for the coagulation composition to coagulate blood can be less than the time required to coagulate blood in the absence of the stabilizer due to a range of factors, including but not limited to preserving, increasing, prolonging, or otherwise enhancing the coagulation activity of the coagulation composition by the stabilizer, particularly in cases where the coagulation activity of the coagulation composition would otherwise be compromised, for example, due to exposure of the coagulation composition to various environmental conditions, such as during the manufacture of the coagulation composition, including exposure to heat and sterilizing radiation, as well as the storage time and storage conditions of the coagulation composition, including temperature and humidity, and further, the transportation conditions of the coagulation composition, including temperature, humidity, and atmospheric pressure.

[0065] As used in this article, " stringency " refers to the temperature and ionic strength conditions during hybridization and washing procedures, and the presence or absence of certain organic solvents. The higher the stringency, the higher the degree of complementarity between the immobilized target nucleotide sequence and the labeled probe polynucleotide sequence that remains hybridized to the target after washing. The term " high stringency " refers to temperature and ionic conditions under which only nucleotide sequences with a high frequency of complementary bases will hybridize. The stringency required is nucleotide sequence dependent and depends on the various components present during hybridization. Typically, for a specific sequence, under a determined ionic strength and pH, stringent conditions are selected to be approximately 10 to 20 ° C below the thermal melting point (Tm). Tm is the temperature (under a determined ionic strength and pH) at which 50% of the target sequence hybridizes to the complementary probe.

[0066] The term "transformation" means the alteration of the genotype of an organism, such as bacteria, yeast, mammals, birds, reptiles, fish or plants, by the introduction of foreign or endogenous nucleic acid.

[0067] "Vector" refers to a polynucleotide molecule, preferably a DNA molecule, which is derived from a plasmid, phage, yeast or virus into which a polynucleotide can be inserted or cloned. The vector preferably contains one or more unique restriction sites and can replicate spontaneously in the host cell to be defined, including target cells or tissues or progenitor cells or their tissues, or is integrated into the genome of the defined host so that the cloned sequence is repeatable. Therefore, the vector can be an autonomously replicating vector, that is, a vector that exists as an extrachromosomal entity, and its replication is independent of chromosomal replication, for example, a linear or closed circular plasmid, an extrachromosomal element, a minichromosome or an artificial chromosome. The vector can include any method for ensuring self-replication. Alternatively, the vector can be a vector that, when introduced into a host cell, is integrated into the genome and replicated together with the chromosome into which it has been integrated. The vector system can include a single vector or plasmid, two or more vectors or plasmids, which together include the total DNA of the genome to be introduced into the host cell, or a transposon. The selection of the vector will generally depend on the compatibility of the vector with the host cell into which the vector is introduced. In the present case, the vector is preferably a virus or virus-derived vector that is operably functional in animal and preferably mammalian cells. Such vectors may be derived from poxviruses, adenoviruses or yeast. The vector may also include a selectable marker such as an antibiotic resistance gene that can be used to select suitable transformants. Examples of such resistance genes are known to those skilled in the art and include the nptll gene, which confers resistance to the antibiotics kanamycin and G418. resistance to the antibiotic hygromycin B, and the hph gene, which confers resistance to the antibiotic hygromycin B.

[0068] The terms "wild-type" and "naturally occurring" are used interchangeably to refer to a gene or gene product that has the characteristics of a gene or gene product when isolated from a naturally occurring source. A wild-type gene or gene product (e.g., a polypeptide) is one that is most commonly found in a population and is therefore arbitrarily designated as the "normal" or "wild-type" form of the gene.

[0069] The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any suggestion that the prior art forms part of the common general knowledge of the person skilled in the art.

[0070] All publications, patents, patent applications, and other materials discussed in this specification are incorporated herein by reference in their entirety.

[0071] Brief Description of Sequence Listing

[0072] SEQ ID NO: 1 is the polypeptide sequence of ecarin from Echinodermata.

[0073] SEQ ID NO: 2 is a partial polypeptide sequence of basparin from the venom of Agkistrodon acutus.

[0074] SEQ ID NO: 3 is the partial polypeptide sequence of carinactivase-1 from Echinodermata venom (prepared as described in Yamada, D., et al., (1996)) - 62 kDa subunit.

[0075] SEQ ID NO: 4 is a partial polypeptide sequence of a multi-activating enzyme from the venom of Echis multisquamatus (prepared as described in Yamada, D., et al., (1997)).

[0076] SEQ ID NO: 5 is the nucleotide sequence encoding the Factor V-like component of PtPA (or pseudorin C) from Pseutaras truncatus.

[0077] SEQ ID NO: 6 is the nucleotide sequence encoding the Factor V-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0078] SEQ ID NO: 7 is the polypeptide sequence of the Factor V-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0079] SEQ ID NO: 8 is the polypeptide sequence of the Factor V-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0080] SEQ ID NO: 9 is the nucleotide sequence encoding the Factor V-like component of OsPA (or oscutarin C) from Snake Taipan.

[0081] SEQ ID NO: 10 is the nucleotide sequence encoding the Factor V-like component of OsPA (or oscutarin C) from Taipan scutellatus.

[0082] SEQ ID NO: 11 is the polypeptide sequence of the Factor V-like component of OsPA (or oscutarin C) from Taipan scutellatus.

[0083] SEQ ID NO: 12 is the polypeptide sequence of the Factor V-like component of OsPA (or oscutarin C) from Snake Taipan.

[0084] SEQ ID NO: 13 is the polypeptide sequence of the Factor V-like component of OsPA (or oscutarin C) from Snake Taipan.

[0085] SEQ ID NO: 14 is a nucleotide sequence encoding the factor V-like component of omicarin C from Taipan spp.

[0086] SEQ ID NO: 15 is a nucleotide sequence encoding Factor V from Homo sapiens.

[0087] SEQ ID NO: 16 is the polypeptide sequence of Factor V from Homo sapiens.

[0088] SEQ ID NO: 17 is a nucleotide sequence encoding Factor V from Boswellia bovis.

[0089] SEQ ID NO: 18 is the polypeptide sequence of Factor V from Boswellia bovis.

[0090] SEQ ID NO: 19 is a nucleotide sequence that encodes the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0091] SEQ ID NO: 20 is a nucleotide sequence that encodes the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0092] SEQ ID NO: 21 is a nucleotide sequence that encodes the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0093] SEQ ID NO: 22 is a nucleotide sequence encoding the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus textilis.

[0094] SEQ ID NO: 23 is a nucleotide sequence encoding the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus textilis.

[0095] SEQ ID NO:24 is a nucleotide sequence that encodes the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0096] SEQ ID NO: 25 is a nucleotide sequence that encodes the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0097] SEQ ID NO: 26 is the polypeptide sequence of the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0098] SEQ ID NO: 27 is the polypeptide sequence of the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0099] SEQ ID NO: 28 is the polypeptide sequence of the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus textilis.

[0100] SEQ ID NO:29 is the polypeptide sequence for the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus textilis.

[0101] SEQ ID NO:30 is the polypeptide sequence for the factor X-like component of PtPA (or pseudorin C) from Pseutarhinus naja.

[0102] SEQ ID NO: 31 is a nucleotide sequence encoding the factor X-like component of OsPA (or oscutarin C) from Snake Taipan.

[0103] SEQ ID NO: 32 is the polypeptide sequence for the factor X-like component of OsPA (or oscutarin C) from Snake Taipan.

[0104] SEQ ID NO: 33 is a nucleotide sequence encoding the factor X-like component of omicarin C from Taipan spp.

[0105] SEQ ID NO: 34 is the polypeptide sequence for the factor X-like component of omicarin C from Taipan spp.

[0106] SEQ ID NO: 35 is a nucleotide sequence encoding the factor X-like component of porpharin D from the Australian black snake.

[0107] SEQ ID NO: 36 is the polypeptide sequence for the factor X-like component of porpharin D from the Australian black snake.

[0108] SEQ ID NO: 37 is a nucleotide sequence encoding the factor X-like component of hopsarin D from Cobra viridis.

[0109] SEQ ID NO:38 is the polypeptide sequence for the factor X-like component of hopsarin D from Coleoptera: fulvidraco.

[0110] SEQ ID NO: 39 is a nucleotide sequence encoding the factor X-like component of notecarin D from tiger snake.

[0111] SEQ ID NO:40 is the polypeptide sequence for the factor X-like component of notecarin D from tiger snake.

[0112] SEQ ID NO:41 is a nucleotide sequence encoding the factor X-like component of trocarin D from Aeolus australis.

[0113] SEQ ID NO:42 is the polypeptide sequence for the factor X-like component of trocarin D from Snakehead snake.

[0114] SEQ ID NO: 43 is a nucleotide sequence encoding the factor X-like component of the prothrombin activator from the black whip snake.

[0115] SEQ ID NO:44 is the polypeptide sequence for the factor X-like component of the prothrombin activator from the black whip snake.

[0116] SEQ ID NO: 45 is a nucleotide sequence encoding the factor X-like component of the prothrombin activator from the black whip snake.

[0117] SEQ ID NO:46 is the polypeptide sequence for the factor X-like component of the prothrombin activator from the black whip snake.

[0118] SEQ ID NO:47 is a nucleotide sequence encoding factor X from Homo sapiens.

[0119] SEQ ID NO:48 is the polypeptide sequence for Factor X from Homo sapiens.

[0120] SEQ ID NO:49 is a nucleotide sequence encoding Factor X from Boswellia bovis.

[0121] SEQ ID NO: 50 is the polypeptide sequence for Factor X from Boswellia bovis.

[0122] SEQ ID NO:51 is the partial polypeptide sequence for carinactivase-1 from Echinodermata venom (prepared as described in Yamada, D., et al., (1996)) - 17 kDa subunit.

[0123] SEQ ID NO:52 is the partial polypeptide sequence for carinactivase-1 from Echinodermata venom (prepared as described in Yamada, D., et al., (1996)) - 14 kDa subunit.

[0124] SEQ ID NO:53 is the polypeptide sequence for the uncleaved form of wild-type ecarin from Echinodermata venom.

[0125] SEQ ID NO: 54 is the polypeptide sequence for ecarin from Echinodermata venom in which the signal peptide has been removed and the TEV protease site ENLYFQS has been inserted at the interface between the propeptide and the mature domain.

[0126] SEQ ID NO: 55 is the polypeptide sequence for the mature formation of wild-type ecarin from Echinodermata venom.

[0127] SEQ ID NO:56 is the polypeptide sequence for the mutagenesis of ecarin from Echinodermata venom in which the signal peptide has been removed and the TEV protease site ENLYFQS has been inserted at the interface between the propeptide and the mature domain, and the P396S mutation has been introduced.

[0128] SEQ ID NO: 57 is the polypeptide sequence for the mature formation of the P396S mutant ecarin from Echinodermata venom. BRIEF DESCRIPTION OF THE DRAWINGS

[0129] The invention will now be described, by way of example only, and with reference to the following figures.

[0130] Figure 1 SDS-PAGE gel patterns are shown: rFv (lane 2), five OsPA samples separated by different gels (lanes 3, 4, 5, 6 and 7) and purified Fxa (lane 8). The markers are in lane 1.

[0131] Figure 2 Thromboelastographic traces of coagulation of recalcified whole blood through a 31 ng aliquot of each of ten OsPA formulations are shown. The ten overlapping traces on the left (rapid coagulation) represent the ten formulations, while the markers + The Ca trace indicates repeated coagulation by calcium alone.

[0132] Figure 3 Chromatography of 1.05 g of Taipan venom using Superdex TM 200 (gel column: 5 cm diameter, 95 cm length) (April 17, 2012).

[0133] Figure 4 Shown is the whole blood coagulation activity curve of the concentrated OsPA fraction purified on Superdex resin.

[0134] Figure 5 A schematic diagram is shown which shows that during the coagulation of whole blood, (From Figure from the Haemostasis Analyzer 5000 Series Brochure.

[0135] Figure 6 Shown are development curves: S-2222 assay using pooled OsPA (17 / 4 / 12) (A) and standard curve (B).

[0136] Figure 7 The whole blood coagulation activity of freshly diluted OsPA is shown compared to the whole blood coagulation activity of desiccator-dried OsPA. The D0 data are for freshly diluted liquid samples of OsPA added to blood collection tubes; the D1 data are for samples dried in blood collection tubes in a vacuum desiccator overnight at room temperature.

[0137] Figure 8 Shown are whole blood clotting times in blood collection tubes containing freshly diluted OsPA and in similar tubes in which OsPA had been dried using Genevac.

[0138] Figure 9 Figure 2 shows the stability of whole blood clotting times in OsPA-dried Glucoside for 211 days at room temperature. Left panel: control, using 1 μg of freshly diluted OsPA in buffer pH 7.4; middle panel: test samples, in which 1 μg of OsPA was dried in the presence of Glucoside (20 μl); right panel: clotting times of recalcified blood samples without OsPA.

[0139] Figure 10 Shown using Figure 9 Line graph of the data. A: All points from 0 to 211 days; B: All points from 0 to 65 days.

[0140] Figure 11 Coagulation times (replicate means) of recalcified citrated whole blood by OsPA after storage at room temperature for up to 195 days in blood collection tubes. Left-hand series: control, using 1 g of freshly diluted OsPA in 0.1 M ammonium acetate buffer, pH 6.8; middle series: test samples, in which 1 μg of OsPA was dried in the presence of 0.5% w / v bovine serum albumin and 0.5% w / v dextran; right-hand series: coagulation times of recalcified blood samples without OsPA.

[0141] Figure 12 Line graph showing clotting times for fresh control and OsPA / BSA / dextran tubes. Data from Figure 11 .

[0142] Figure 13Coagulation time in seconds is shown for recalcified citrated blood after incubation at 50°C. Sample identification codes: 'B' = BD tube; '7' = pH 7.4; 'F' = freshly diluted OsPA, not dried; 'DR' = dried and kept at room temperature; 'D50' = dried and kept at 50°C; '0, 1, 2, or 5' = 0, 1, 2, or 5 g OsPA. Vertical bars indicate storage for zero, one, and seven days.

[0143] Figure 14 Clotting time in seconds of recalcified citrated whole blood after incubation at 50°C. Sample identification codes: 'B' = BD tube; '6' = pH 6.0; 'F' = freshly diluted OsPA, not dried; 'DR' = dried and held at room temperature; 'D50' = dried and held at 50°C; '0, 1, 2, or 5' = 0, 1, 2, or 5 μg OsPA. Vertical bars indicate storage for zero, one, and seven days.

[0144] Figure 15 Coagulation time in seconds for recalcified citrated blood after incubation at 50°C is shown. Sample identification codes: 'G' = Greiner tube; '7' = pH 7.4; 'F' = freshly diluted OsPA, not dried; 'DR' = dried and kept at room temperature; 'D50' = dried and kept at 50°C; '0, 1' = 0 or 1 μg OsPA. Vertical bars indicate storage for zero, 1, 3, 7, 14, and 30 days, respectively.

[0145] Figure 16 Coagulation time in seconds for recalcified citrated blood after incubation at 50°C is shown. Sample identification codes: 'G' = Greiner tube; '6' = pH 6.0; 'F' = freshly diluted OsPA, not dried; 'DR' = dried and kept at room temperature; 'D50' = dried and kept at 50°C; '0 or 1' = 0 or 1 μg OsPA. Vertical bars indicate storage for zero, 1, 3, 7, 14, and 30 days, respectively.

[0146] Figure 17 Shown from Figure 15 A line graph of the data.

[0147] Figure 18 Shown from Figure 16 A line graph of the data.

[0148] Figure 19A Coagulation times are shown for the tubes listed above, as well as for fresh controls and controls without OsPA in a whole blood coagulation assay. The irradiated tubes were treated with 15 kGy gamma irradiation. Each bar represents the mean of two estimates.

[0149] Figure 19B Coagulation times are shown for the tubes listed above, as well as for fresh controls and controls without OsPA in a whole blood coagulation assay. The irradiated tubes were treated with 15 kGy gamma irradiation. Each bar represents the average of two estimates (BD and GBO are codes for two different pure blood collection plastic tubes). All tubes, except the control, were prepared with trehalose dissolved in Glyoxal.

[0150] Figure 19C Coagulation times are shown for the tubes listed above, as well as for fresh controls and controls without OsPA. The irradiated tubes were treated with 15 kGy gamma irradiation. Each bar represents the average of two estimates (BD and GBO are codes for two different pure blood collection plastic tubes). All tubes, except the control, were prepared with trehalose dissolved in Glyoxal.

[0151] Figure 20 Coagulation times in whole blood are shown for tubes containing Ecarin and for fresh controls and controls without OsPA. The irradiated tubes were treated with 25 kGy gamma irradiation and stored at room temperature for 212 days. All tubes except the control were prepared with Glyoxal. Figure 21 The activity of OsPA in coagulated recalcified whole blood dried at 50°C in pure blood collection plastic tubes and in different sugar and other formulations is shown.

[0152] Figure 22 The activity of OsPA in coagulated recalcified whole blood at room temperature in pure blood collection plastic tubes and dried in different sugar and other formulations is shown.

[0153] Figure 23 The activity of dried OsPA formulated in Glyoxal and galactose (6 and 10%) in coagulated recalcified whole blood at room temperature and in pure blood collection tubes is shown.

[0154] Figure 24 The activity of dried Ecarin in coagulation recalcification of whole blood at room temperature in pure blood collection plastic tubes and in different sugar and other formulations is shown. DETAILED DESCRIPTION

[0155] The present inventors have discovered that the stability of coagulation compositions comprising a prothrombin activator is significantly increased when formulated in conjunction with one or more additional agents, such as a colloid. This increased stability is significant due to the ability to manufacture, sterilize, transport, and store the coagulation composition (e.g., in the form of a collection tube) without significant loss of coagulation activity under conditions that would previously compromise the efficacy of such a composition. For example, the compositions of the present invention are stable after sterilization involving radiation, storage at high temperatures, and storage for extended periods of time. Dose-response and ranging studies to determine an effective dose of OsPA for use in a coagulation tube spray-drying procedure were designed to achieve coagulation of whole blood in approximately 5 minutes. It was clearly demonstrated that a concentration of 0.1-1.0 μg of OsPA in 4 mL of non-anticoagulated blood would achieve this. The above studies first demonstrate in Example 1 that highly purified Ospa taipan venom prothrombin activator (OsPA), a Group C prothrombin activator, can be purified from Ospiorhynchus scutellaria (Os) venom using gel filtration chromatography, for example, on a Superdex 200 column, and its activity can be determined by coagulation in recalcified, citrated whole blood, by an S-2222 chromogenic assay designed for the detection of Factor Xa, or by an S-2238 chromogenic assay designed for the detection of thrombin. Example 1 also details how to concentrate the pooled OsPA-containing fractions using, for example, an Amicon ultrafiltration device and prepare a 50% glycerol solution for long-term storage at -20°C. The glycerol stock can then be dialyzed and freeze-dried as detailed in Example 1. Ecarin (extracted from Echidna scutellaria venom) used in the examples was purchased and assayed as detailed in Example 1.

[0156] To achieve similar results between experiments, standardized methods were developed. Example 2 details a standardized method for preparing blood collection tubes with prothrombin activator solutions and formulation components, including a standardized surfactant for coating the tube bottom and a standardized tube drying method. Example 3 details a standardized irradiation protocol to approximate the sterilization process found in commercial blood collection tube manufacturing. Blood samples to be used for evaluation of blood collection tubes were tested using the standard methods detailed in Example 4 to ensure normal coagulation parameters and thus suitability for testing. The coagulation properties of OsPA or other prothrombin activators were tested using the standard methods detailed in Example 5, including plasma coagulation assays, visual assessment of coagulation, thromboelastography (TEG), and chromogenic assays. Standards for stability testing of the generated serum and analyte measurements are also included in Example 5, completing the standard test description.

[0157] A formulation for improving the stability of OsPA in blood collection tubes is disclosed in Example 6, which compares tube drying conditions with and without the use of a surfactant and a colloid, BSA. The results show that the presence of a surfactant and a BSA colloid results in improved coagulation activity (reduced clotting time) when dried using the Genevac vacuum drying method. The data in Example 6 also show that the addition of 0.1% BSA to OsPA in tubes without surfactant results in improvement, however, optimal efficacy is achieved with the addition of a surfactant coating. All subsequent examples utilize a surfactant coating in the tubes. Example 7 continues this experimental procedure, demonstrating that when the formulation from Example 6 is stored at 25°C for 85 days, coagulation activity decreases from T0. Example 8 builds upon Examples 6 and 7 by testing a series of additives to enhance the stability of a formulation including colloidal BSA (at higher concentrations) and dextran. Results show that both BSA (0.5%) and dextran (0.5%) increase the stability of OsPA compared to buffer alone over 99 days at 25°C, with 1 μg of OsPA able to clot blood in approximately 5 minutes. Example 9 uses the colloid Xanax (4% succinylated gelatin) and achieves stability (with a 5-minute clotting time) for 1 μg of OsPA after 211 days of storage at 25°C. Data using fresh blood in tubes containing this formulation are also included. Xanax showed a greater impact on stability than either 0.5% BSA or 0.5% dextran, but all colloids imparted greater stability than buffer. Example 10 demonstrates that the combination of 0.5% dextran and 0.5% BSA yields stability exceeding 195 days at 25°C, as well as greater stability than either colloid alone over 99 days, as demonstrated in Example 8. In Example 11, the Xanax formulation was successfully stabilized for 30 days at 50°C, demonstrating that long-term stability is achievable. In Example 12, gamma irradiation, as used in commercial tube sterilization, was tested with OsPA tubes using BSA / dextran and Glucocorticoid formulations, as well as formulations containing Glucocorticoid and a non-reducing sugar (trehalose). All samples were exposed to a dose of 15 kGy. The results showed that after irradiation, OsPA formulated with BSA / dextran or Glucocorticoid retained activity above baseline, suggesting that the protective effect of Glucocorticoid was enhanced by the addition of trehalose. Another prothrombin activator was successfully tested with a Glucocorticoid and trehalose formulation. Example 13 exposed ecarin formulated with 4% Glucocorticoid to 25 kGy of gamma irradiation, demonstrating a significant % retention of coagulation activity. There was no significant difference in coagulation activity between irradiated tubes at T0 and those that had not been irradiated after 212 days of storage at room temperature.Example 14 tested OsPA formulated with Glycerol and a range of sugars and other agents at room temperature and 50°C and demonstrated that the Glycerol and trehalose / sucrose formulation provided acceptable clotting times for over 12 months after 10 weeks at 50°C and room temperature. Although with more limited stability data, galactose fructose shows promise as another stabilizing sugar. Example 15 tested Ecarin formulated with Glycerol and a range of sugars and other agents at room temperature and demonstrated that the Glycerol and trehalose / sucrose formulation provided acceptable clotting times for over 12 months at room temperature. Example 16 demonstrated that the presence of Glycerol in blood collection tubes had no effect on analyte testing.

[0158] In summary, the examples demonstrate that an extraction process and formulation for OsPA is required to achieve commercially acceptable stability (retention of coagulation activity) for prothrombin activators such as OsPA or Ecarin in blood collection tubes exposed to storage time, temperature, and irradiation. In this regard, the stability-enhancing properties of colloids, in particular, Xanax or BSA, alone or in combination with additives, are clearly demonstrated.

[0159] Prothrombin activators

[0160] The present invention is based, in part, on the discovery that the stability of coagulation compositions comprising a prothrombin activator is significantly increased when formulated with one or more additional agents, such as a colloid.

[0161] In some embodiments, the prothrombin activator is an exogenous prothrombin activator. As used herein, "exogenous prothrombin activator" means a prothrombin activator that is obtained from a source other than the blood sample from which the serum sample is prepared.

[0162] The prothrombin activators used in the present invention may comprise wild-type or naturally occurring, recombinant, mutated or genetically engineered forms of prothrombin activators, including those prothrombin activators obtained, derived or derivable from any suitable organism, including snake, human, bovine and bacterial prothrombin activators.

[0163] In some embodiments, the prothrombin activator of the present invention is a snake prothrombin activator. Suitably, the prothrombin activator is a snake venom prothrombin activator. Snake venom prothrombin activators are generally divided into four groups (A, B, C, and D) depending on their structure, function, and cofactor requirements.

[0164] In certain embodiments, the snake venom prothrombin activator is a Group A prothrombin activator. Group A prothrombin activators are metalloproteinases composed of three domains: a metalloproteinase, a resolvin, and a cysteine-rich domain. The metalloproteinase domain contains the consensus sequence HEXXHXXGXXH, which corresponds to the zinc chelation active site. These prothrombin activators are found in at least several venomous snake venoms and include ecarin from the venom of the saw-scaled viper and basparin from the venom of the pit viper Agkistrodon scaly.

[0165] In certain embodiments, the snake venom prothrombin activator is a group B prothrombin activator. Group B prothrombin activators are metalloproteinases composed of two non-covalently held subunits: a metalloproteinase and a C-type lectin-like disulfide dimer. These prothrombin activators are found in several venomous snakes and include carinactivase-1 and carinactivase-2 from Echis multisquamatus venom and multiactivase from Echis multisquamatus venom.

[0166] In certain embodiments, the snake venom prothrombin activator is a Group C prothrombin activator. Group C prothrombin activators are serine proteases and are similar to the mammalian Factor Xa-Factor Va complex. Pseutarin C (or PtPA) and oscutarin C (or OsPA) are Group C prothrombin activators from the venom of the eastern false cobra and the taipan snake, respectively. Omicarin C is a prothrombin activator from the venom of the inland taipan snake.

[0167] In certain embodiments, the snake venom prothrombin activator is a Group D prothrombin activator. Group D prothrombin activators are serine proteases and are functionally similar to mammalian factor Xa. Porpharin D (from the Australian black snake), notecarin D (from the tiger snake), trocarin D (from the eastern Australian snake), hopsarin D (from Hoplocephalus stephensi), and notenarin D (from the peninsular black tiger snake) are all Group D prothrombin activators.

[0168] A review of snake prothrombin activators is provided in Kini, RM (2005), and those prothrombin activators specifically from the venom of Australian cobras (Group C and D prothrombin activators) are provided in St. Pierre et al. (2005), the entire contents of each of which are incorporated herein by reference. Both of these reviews use the classification of snake prothrombin activators into Groups AD (as described above). This classification replaces the previous classification system in which groups I-III were used (Group I includes Groups A and B; Group II is now Group D and Group III is now Group C), and sometimes additional groups IV (snake venom activators that cleave the peptide bond in prothrombin but do not convert prothrombin to an enzymatically active product, i.e., thrombin or meizothrombin) and V (bacterial prothrombin activators), as described in earlier review articles, including Rosing, J. et al. (1991) and Rosing, J. et al. (1992), which are incorporated herein by reference in their entirety. For an explanation of the changes in the classification system, see Kini, R. M., et al. (2001), which is incorporated herein by reference in its entirety.

[0169] In a specific embodiment, the snake prothrombin activator is obtained from the family Elapidae, illustrative examples of which include species from the genera Naja, Naja, Australasian, Taipan, Agkistrodon, Pseudonaja, Australis, and Australis, including but not limited to Black Whip Snake, Yellow-Ringed Naja, Notechis ater humphreysi, Peninsular Black Tiger Snake, Notechis aterserventyi, Notechis flinkders, Notechis humphreysi, Notechis niger, Notechis occidentalis, Tiger Snake, Tiger Snake scutatus, Notechis serventyi, Inland Taipan, Taipan, Australian Black Snake, Pseudonaja affinis, Pseudonaja inframaculata, Western Mirror Snake, Eastern Mirror Snake, Australis small-eyed, and Australis.

[0170] In a specific embodiment, the snake prothrombin activator is obtained from the family Agkistrodon, illustrative examples of which include species from the genera Botrhops, Viper, and Trimeresurus, including but not limited to Bothrops atrox asper, Bothrops brasili, Bothrops castelnaudi, Bothrops scolumbiensis, Bothrops erythromelas, Agkistrodon fengyi, Agkistrodon sao paulo, Agkistrodon brasiliensis, Bothrops neuwiedi, Bothrops venezuelensis, Echis multisquamatus, Echis multisquamatus, and Trimeresurus okinavensis.

[0171] In a specific embodiment, the snake prothrombin activator is obtained from the family Flaviviridae, illustrative examples of which include species from the genera Polysquama, Otodesma, and Thelotomis, including but not limited to the arboreal snake, the tiger-spotted snake, the Clark's tree snake, and the wilderness vine snake.

[0172] In some embodiments, the snake prothrombin activator is derived from or obtained from snake venom. The purification and expression of PtPA from P. textilis venom are described in Masci (1986) and Masci et al. (1988), and OsPA from the venom of the snake Taipan snake is described in Speijere et al., (1986), the entire contents of which are incorporated herein by reference. The purification and characterization of ecarin from Echis multisquamatus venom are described in Morita, T et al. (1981) and Nishida, S et al. (1995), the purification and characterization of carinactivase from Echis multisquamatus venom are described in Yamada, D et al. (1996), the purification and characterization of multiactivase from Echis multisquamatus are described in Yamada, D. et al., (1997), and the purification and characterization of notecarin from tiger snake are described in Tans, G et al., (1985), the entire contents of each of which are incorporated herein by reference.

[0173] In certain embodiments, the prothrombin activator is a mammalian prothrombin activator. Mammalian prothrombin activators include those derived from human blood and / or tissue and those derived from bovine blood and / or tissue, or recombinant forms of these proteins.

[0174] In certain embodiments, the prothrombin activator is a bacterial prothrombin activator. Bacterial prothrombin activators include those from Staphylococcus aureus, Peptococcus indolegenes, Bacteroides melaninogenes, and Pseudomonas aeruginosa (Rosing, J. et al. (1991).

[0175] As will be understood by those skilled in the art, a prothrombin activator can comprise, consist essentially of, or consist of one or more polypeptides. In some embodiments, a prothrombin activator comprises, consists essentially of, or consists of a single polypeptide. In other embodiments, a prothrombin activator comprises, consists essentially of, or consists of more than one polypeptide, including but not limited to a complex of polypeptides. Where a prothrombin activator comprises, consists essentially of, or consists of more than one polypeptide, each polypeptide can be from an organism belonging to the same or different genus, and / or the same or different species.

[0176] In certain embodiments, the prothrombin activator comprises an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 18, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53, 54, 55, 56, and 57, or comprises an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of those set forth in SEQ ID NO: 5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 49.

[0177] In some embodiments, the prothrombin activator is derived or derivable from snake venom.

[0178] In some embodiments, the prothrombin activator is a serine protease group C prothrombin activator, which is similar to the mammalian Factor Xa-Factor Va complex.

[0179] In a specific embodiment, the prothrombin activator is selected from the group consisting of Pseutarin C (or PtPA) and oscutarin C (or OsPA), which are derived or derivable from the venom of Pseutaras naja and Oscutarin taipan, respectively.

[0180] In a preferred embodiment, the prothrombin activator is oscutarin C (or OsPA), which is derived or derivable from the venom of the snake Oscutarum taipan.

[0181] In particularly preferred embodiments, the prothrombin activator comprises the amino acid sequence set forth in SEQ ID NO: 11, 12, 13 or 32, or comprises an amino acid sequence encoded by a nucleotide sequence selected from those set forth in SEQ ID NO: 9, 10 or 31.

[0182] Chimeric prothrombin activators and fusion peptides

[0183] The present invention also contemplates the use of prothrombin activators comprising chimeric polypeptides. As used herein, a "chimeric polypeptide" includes a first polypeptide component comprising a polypeptide obtained from a first organism, linked to a second polypeptide component obtained from a second organism. In some embodiments, the first organism and the second organism are from different genera. In other embodiments, the first organism and the second organism are different species of the same genus. In certain embodiments, the prothrombin activator comprises a chimeric polypeptide that resembles a Factor Xa-Factor Va complex, wherein the first polypeptide comprises a Factor Xa-like polypeptide and the second polypeptide comprises a Factor Va-like polypeptide. In some specific embodiments, the first polypeptide comprises an amino acid sequence selected from those set forth in SEQ ID NO: 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, and 50, or comprises an amino acid sequence encoded by a nucleotide sequence selected from those set forth in SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 49, and the second polypeptide comprises an amino acid sequence selected from those set forth in SEQ ID NO: 7, 8, 11, 12, 13, 16, and 18, or comprises an amino acid sequence encoded by a nucleotide sequence selected from those set forth in SEQ ID NO: 5, 6, 9, 10, 14, 15, and 17.

[0184] The present invention also contemplates the use of prothrombin activators comprising fusion polypeptides. As used herein, a "fusion polypeptide" comprises a first polypeptide component linked to a second polypeptide component. The first polypeptide component may be obtained from a first organism and the second polypeptide component may be obtained from a second organism. In some embodiments, the first organism and the second organism are from different genera. In other embodiments, the first organism and the second organism are different species of the same genus. The first polypeptide component or the second polypeptide component of the fusion polypeptide may correspond to all or a portion (e.g., a fragment as described herein) of a wild-type or naturally occurring amino acid sequence. The second polypeptide component may be fused to the N-terminus or C-terminus of the first polypeptide component.

[0185] Fragments of wild-type or naturally occurring polypeptides

[0186] The prothrombin activator may comprise a fragment of a full-length wild-type or naturally occurring polypeptide, wherein the prothrombin activator exhibits prothrombin activating activity.

[0187] Generally, fragments of a full-length polypeptide can participate in interactions, e.g., intramolecular or intermolecular interactions. Such fragments include peptides comprising the amino acid sequences set forth in SEQ ID NOs: 2, 3, 4, 51, and 52, as well as peptides comprising an amino acid sequence sufficiently similar to or derived from the amino acid sequence of a (presumed) full-length polypeptide, e.g., the amino acid sequences set forth in SEQ ID NOs: 1, 7, 8, 11, 12, 13, 16, 18, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 53, 54, 55, 56, and 57, or a fragment selected from the group consisting of the amino acid sequences set forth in SEQ ID NOs: The amino acid sequences encoded by the nucleotide sequences set forth in NO:5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 49 include fewer amino acids than the full-length polypeptide and exhibit an activity of the above-mentioned polypeptide.

[0188] Naturally occurring variants of prothrombin activator (peptide)

[0189] The present invention also contemplates prothrombin activators comprising polypeptides that are variants of wild-type or naturally occurring polypeptides. Prothrombin activators comprising one or more variant polypeptides encompassed by the present invention are biologically active, i.e., they continue to possess prothrombin activating activity.

[0190] Such "variant" prothrombin activators include polypeptides derived from naturally occurring polypeptides, wherein the polypeptide is derived from the corresponding naturally occurring polypeptide by deletion (so-called truncation) or addition of one or more amino acids at the N-terminus and / or C-terminus of the naturally occurring polypeptide; deletion or addition of one or more amino acids at one or more sites in the naturally occurring polypeptide; or substitution of one or more amino acids at one or more sites in the naturally occurring polypeptide. These variant prothrombin activators may result from, for example, genetic polymorphisms or human manipulation.

[0191] Further non-limiting examples of variant polypeptides include a full-length or precursor polypeptide in zymogen form or a zymogen-formed processed form of a polypeptide or a polypeptide.

[0192] 48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence similarity or identity, including but not limited to the sequence in SEQ 45, 47, and 49, or the amino acid sequence encoded by the nucleotide sequence in SEQ ID NO: 5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 49, as determined by sequence alignment programs described elsewhere herein and using the default parameters. Variants of a wild-type or naturally occurring polypeptide, which fall within the scope of variant polypeptides, may differ from the polypeptides described above, typically by as many as 200, 100, 50 or 20 amino acid residues, or suitably by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue. In some embodiments, the variant polypeptide differs from the corresponding sequences in SEQ ID NO: 1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 18, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53 and 55, or the amino acid sequence encoded by the nucleotide sequence in SEQ ID NO: 5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, or 49, by at least 1 but fewer than 15, 10, or 5 amino acid residues.In other embodiments, it differs from the corresponding sequences in SEQ ID NO: 1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 18, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53 and 55, or the amino acid sequence encoded by the nucleotide sequence in SEQ ID NO: 5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, or 49 by at least one residue but less than 20%, 15%, 10% or 5% of the residues.

[0193] Polypeptides can be altered in various ways, including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally well known in the art. For example, amino acid sequence variants of polypeptides can be prepared by mutations in DNA. Methods for mutagenesis and nucleotide sequence alteration are well known in the art. See, for example, Kunkel (1985), Kunkel et al., (1987), U.S. Patent No. 4,873,192, Watson et al., (1987) and references cited therein. Guidance on appropriate amino acid substitutions that do not affect the biological activity of the protein of interest can be found in the model of Dayhoffe et al., (1978). Methods for screening gene products of combinatorial libraries constructed by point mutations or truncations, as well as methods for screening gene products of cDNA libraries with selected properties, are known in the art. Such methods are suitable for rapid screening of gene libraries generated by combinatorial mutagenesis of polypeptides. Recursive ensemble mutagenesis (REM), a technique that increases the frequency of functional mutants in a library, can be used in conjunction with screening assays to identify polypeptide variants, see, for example, Arkin et al. (1992) and Delagrave et al. (1993). Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be desirable (as discussed in more detail below).

[0194] Variant polypeptides may contain conservative amino acid substitutions at various positions along their sequence compared to a parent (e.g., naturally occurring or reference) amino acid sequence. A "conservative amino acid substitution" is a substitution in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been defined in the art and can generally be subdivided as follows:

[0195] Acidic: When the peptide is in aqueous medium at physiological pH, the residue has a negative charge (due to the loss of H ions at physiological pH) and the residue is attracted by the aqueous solution to seek a surface position in the conformation of the peptide in which it is contained. Amino acids with acidic side chains include glutamic acid and aspartic acid.

[0196] Basic: When the peptide is in an aqueous medium at physiological pH, the residue has a positive charge (due to association with H ions at or within one or two pH units of physiological pH) (e.g., histidine) and the residue is attracted by the aqueous solution to seek a surface position in the conformation of the peptide in which it is contained. Amino acids with basic side chains include arginine, lysine, and histidine.

[0197] Charged: Residues are charged at physiological pH and thus include amino acids with acidic or basic side chains (ie, glutamic acid, aspartic acid, arginine, lysine, and histidine).

[0198] Hydrophobic: When the peptide is in an aqueous medium, the residue is uncharged at physiological pH and the residue is repelled by the aqueous solution to seek an interior position in the conformation of the peptide in which it is contained. Amino acids with hydrophobic side chains include tyrosine, valine, isoleucine, leucine, methionine, phenylalanine, and tryptophan.

[0199] Neutral / Polar: When the peptide is in aqueous medium, the residue is uncharged at physiological pH, but the residue is not sufficiently repelled by the aqueous solution so that it seeks an interior position in the conformation of the peptide in which it is contained. Amino acids with neutral / polar side chains include asparagine, glutamine, cysteine, histidine, serine, and threonine.

[0200] This description also characterizes certain amino acids as "small" because their side chains are not large enough, even if polar groups are lacking, to impart hydrophobicity. "Small" amino acids, with the exception of proline, are those that have four carbon atoms or fewer when at least one polar group is present, and three carbon atoms or fewer when not present on the side chain. Amino acids with small side chains include glycine, serine, alanine, and threonine. The genetically encoded secondary amino acid proline is a special case due to its known effect on the secondary conformation of the peptide chain. The structure of proline differs from all other naturally occurring amino acids because its side chain is bound to the nitrogen of the α-amino group, as well as the α-carbon. However, several amino acid similarity matrices (e.g., the PAM120 matrix and the PAM250 matrix, as disclosed, for example, by Dayhoff et al. (1978) and by Gonnet et al. (1992)) include proline in the same group as glycine, serine, alanine, and threonine, and therefore, for the purposes of this invention, proline is classified as a "small" amino acid.

[0201] The degree of attraction or repulsion required to be classified as polar or nonpolar is arbitrary, and thus, the amino acids specifically contemplated by the present invention have been classified as one or the other. Most amino acids that are not specifically named can be classified on the basis of known behavior.

[0202] Amino acid residues can be further subdivided into the self-explanatory classifications of cyclic or acyclic, and aromatic or non-aromatic, with respect to the side-chain substituents of the residue, and into small or large. A residue is considered small if it contains a total of four carbon atoms or fewer, including the carboxyl carbon, as long as additional polar substituents are present; three or fewer (or not). Small residues are of course always non-aromatic. Depending on their structural properties, amino acid residues may belong to two or more classes. For naturally occurring proteinogenic amino acids, the subclassifications according to this scheme are listed in Table 1.

[0203] Table 1: Amino Acid Subclassifications

[0204] Subclass amino acids acidic Aspartic acid, glutamic acid Alkaline Non-cyclic, Arginine, Lysine, Cyclic, Histidine Charged Aspartic acid, glutamic acid, arginine, lysine, histidine Small Glycine, serine, alanine, threonine, proline Polar / Neutral Asparagine, histidine, glutamine, cysteine, serine, threonine Polarity / Large Asparagine, glutamine hydrophobic Tyrosine, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan Aromatic Tryptophan, tyrosine, phenylalanine Residues that affect chain orientation Glycine and proline

[0205] Conservative amino acid substitutions also include groupings based on side chains. For example, a group of amino acids with aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids with aliphatic hydroxyl side chains is serine and threonine; a group of amino acids with amide-containing side chains is asparagine and glutamine; a group of amino acids with aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids with basic side chains is lysine, arginine, and histidine; and a group of amino acids with sulfur-containing side chains is cysteine ​​and methionine. For example, it is reasonable to expect that replacing leucine with isoleucine or valine, replacing aspartic acid with glutamic acid, replacing threonine with serine, or similar replacements of amino acids with structurally related amino acids will not significantly affect the performance of the resulting variant polypeptide. By measuring its activity, it can be easily determined whether an amino acid change results in a functional polypeptide. Conservative substitutions are shown in Table 2 under the headings of exemplary and preferred substitutions. Amino acid substitutions within the scope of the present invention are generally accomplished by selecting substitutions that do not differ significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of ​​the substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. After the substitutions have been introduced, the variants can be screened for biological activity.

[0206] Table 2: Exemplary and preferred amino acid substitutions

[0207]

[0208]

[0209] Alternatively, based on the type of side chain, similar amino acids for making conservative substitutions can be divided into three categories. The first group includes glutamic acid, aspartic acid, arginine, lysine, histidine, all of which have charged side chains; the second group includes glycine, serine, threonine, cysteine, tyrosine, glutamine, asparagine; and the third group includes leucine, isoleucine, valine, alanine, proline, phenylalanine, tryptophan, methionine, as described in Zubay, G. (1993).

[0210] Therefore, the predicted non-essential amino acid residue in the polypeptide is usually replaced with another amino acid residue from the same side chain family. Alternatively, mutations can be randomly introduced along all or part of the polypeptide gene coding sequence, such as by saturation mutagenesis, and the activity of the parent polypeptide of the resulting mutant can be screened to identify mutants that retain the above-mentioned activity. After mutagenesis of the coding sequence, the encoded peptide can be recombinantly expressed and the activity of the peptide can be determined. A "non-essential" amino acid residue is a residue that can be changed from the wild-type sequence of the polypeptide without eliminating or substantially changing one or more of its activities. Suitably, the above-mentioned changes do not substantially change one of these activities, for example, the activity is at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, , 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%. An "essential" amino acid residue is one that, when changed from the wild-type sequence of a reference polypeptide, results in abrogation of an activity of the parent molecule such that less than 20% of the wild-type activity is present.

[0211] 52, 53, 54, 55, 56, and 57, or a parent or reference polypeptide sequence, such as, for example, a polypeptide sequence set forth in SEQ ID NO: 1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 18, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, ... 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 47, or 49, the variant will exhibit at least about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 47, or 49. 4, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% similarity.Desirably, relative to a parent polypeptide sequence, such as, for example, the polypeptide sequences set forth in SEQ ID NO: 1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 18, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53, 54, 55, 56 and 57, or a parent polypeptide sequence, such as, for example, the polypeptide sequences set forth in SEQ ID NO: NO: 5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, or 49, the variant will have at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209 In addition, sequences that differ from the native or parent sequence by the addition, deletion, or substitution of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids, but which retain the properties of the parent polypeptide, are contemplated. Polypeptides also include polypeptides encoded by polynucleotides that hybridize to a parent encoding polynucleotide sequence, or a non-coding strand thereof (as described below), under stringent conditions (as defined herein), particularly high stringency conditions. Illustrative parent polynucleotide sequences are set forth in SEQ ID NO: 5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 49.

[0212] In some embodiments, the variant polypeptide differs from the reference sequence by at least one but fewer than 50, 40, 30, 20, 15, 10, 8, 6, 5, 4, 3, or 2 amino acid residues. In other embodiments, the variant polypeptide differs from the corresponding sequences of SEQ ID NO: 1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 18, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53, 54, 55, 56, and 57, or the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, or 49, by at least 1% but less than 20%, 15%, 10%, or 5% of the residues. (If such comparison requires sequence alignment, the sequences should be aligned for maximum similarity. Sequences "de-looped" from deletions or insertions, or mismatches, are considered different). Such differences are suitably differences or changes in non-essential residues or conservative substitutions.

[0213] Variants of a protein can be determined by screening combinatorial libraries of mutants (e.g., truncation mutants) of the protein. Libraries or fragments, e.g., N-terminal, C-terminal, or internal fragments of a protein coding sequence can be used to generate a heterogeneous population of fragments for screening and subsequent selection of variants of the protein.

[0214] Methods for screening gene products of combinatorial libraries constructed by point mutations or brachymemma, and methods for screening gene products with selected properties of cDNA libraries are known in the art. Such methods are applicable to the rapid screening of gene libraries produced by proteinic combinatorial mutagenesis.

[0215] Some variants of the snake prothrombin activator ecarin are described in US Patent No. 6,413,737, the entire contents of which are incorporated herein by reference.

[0216] Naturally occurring variants of prothrombin activators (nucleotides)

[0217] The present invention also contemplates prothrombin activators comprising a polypeptide encoded by a variant of a wild-type or naturally occurring polynucleotide encoding the wild-type or naturally occurring polynucleotide.

[0218] Relative to the nucleotide sequence of a wild-type or naturally occurring polynucleotide, including but not limited to the sequences represented by SEQ ID NO: 1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 18, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53, 54, 55, 56, and 57 or SEQ ID NO: 34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,100,101,102,103,104,105,106,107,108,109,110 , 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% (and all partial integer percentages in between) sequence similarity or identity as determined by sequence comparison programs described elsewhere herein and using the default parameters.

[0219] Exemplary nucleotide sequences encoding polypeptides include full-length genes and full-length or substantially full-length nucleotide sequences of genes or their transcripts or DNA copies of these transcripts. Portions of nucleotide sequences can encode polypeptide portions or segments that retain the biological activity of the native polypeptide. A portion of a nucleotide sequence encoding a biologically active fragment of a polypeptide can encode at least about 20, 21, 22, 23, 24, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 300, or 400 consecutive amino acid residues, or nearly the total number of amino acids present in the full-length polypeptide.

[0220] It is also envisioned that variants of nucleotide sequences. Nucleic acid variants can be spontaneous, such as allelic variants (same locus), homologues (different loci) and straight homologues (different organisms) or can be non-spontaneous. Can be by using known molecular biology techniques, such as, for example, by means of polymerase chain reaction (PCR) and hybridization techniques (as known in the art) to determine spontaneous variants such as these variants. Can be by mutagenesis techniques, including those mutagenesis techniques applicable to polynucleotides, cells or organisms, to construct non-spontaneous variants.

[0221] Variants can include nucleotide substitutions, deletions, inversions, and insertions. Variations can occur in any one or both of the coding and non-coding regions. Variations can produce conservative and non-conservative amino acid substitutions (when compared in the encoded product). For nucleotide sequences, conservative variants include those sequences that, due to the degeneracy of the genetic code, encode the amino acid sequence of the reference polypeptide. Variant nucleotide sequences also include nucleotide sequences of synthetic origin, such as, for example, those nucleotide sequences produced by utilizing site-directed mutagenesis but which still encode polypeptides. Typically, relative to a specific nucleotide sequence as determined by a sequence alignment program described elsewhere herein and using default parameters, the variant of a specific nucleotide sequence will have at least about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 1, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity.

[0222] Nucleotide sequences can be used to separate corresponding sequences and alleles from other organisms, particularly other snakes. Methods for hybridization of nucleic acid sequences are readily available in the art. Coding sequences from other organisms can be separated according to well-known techniques and based on their sequence identity relative to the coding sequences set forth herein. In these techniques, all or part of the known coding sequences are used as probes, which selectively hybridize to other coding sequences present in a colony of cloned genomic DNA fragments or cDNA fragments (i.e., genome or cDNA libraries) from the organism selected (e.g., snakes). Therefore, the present invention also contemplates such polynucleotides that hybridize to reference nucleotide sequences, or hybridize to their complements, under the stringency conditions described below. As used in this article, the term "hybridization under low stringency, medium stringency, high stringency, or very high stringency conditions" describes the conditions for hybridization and washing.

[0223] Guidance for conducting hybridization reactions can be found in Ausubel et al., (1992), sections 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in the above references and any of them can be used. Low stringency conditions are referred to herein as comprising at least about 1% v / v to at least about 15% v / v formamide and at least about 1 M to at least about 2 M salt for hybridization at 42°C, and at least about 1 M to at least about 2 M salt for washes at 42°C. Low stringency conditions can also include 1% bovine serum albumin (BSA), 1 mM EDTA, 0.5 M NaHPO4 (pH 7.2), 7% SDS (for hybridization at 65°C), and (i) 2xSSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO4 (pH 7.2), 5% SDS for washes at room temperature. One embodiment of low stringency conditions comprises hybridization in 6x sodium chloride / sodium citrate (SSC) at about 45°C, followed by washing twice in 0.2x SSC, 0.1% SDS at at least 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions). Moderate stringency conditions comprise at least about 16% v / v to at least about 30% v / v formamide and at least about 0.5 M to at least about 0.9 M salt for hybridization at 42°C, and at least about 0.1 M to at least about 0.2 M salt for washing at 55°C. Moderate stringency conditions may also include 1% bovine serum albumin (BSA), 1 mM EDTA, 0.5 M NaHPO4 (pH 7.2), 7% SDS for hybridization at 65°C, and (i) 2x SSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO4 (pH 7.2), 5% SDS for washing at 60-65°C. One embodiment of moderate stringency conditions includes hybridization in 6x SSC at about 45°C, followed by one or more washes in 0.2x SSC, 0.1% SDS at 60°C. High stringency conditions include at least about 31% v / v to at least about 50% v / v formamide and about 0.01 M to about 0.15 M salt for hybridization at 42°C, and about 0.01 M to about 0.02 M salt for washing at 55°C. High stringency conditions can also include 1% BSA, 1 mM EDTA, 0.5 M NaHPO4 (pH 7.2), 7% SDS for hybridization at 65°C and (i) 0.2x SSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO4 (pH 7.2), 1% SDS for washing at temperatures above 65°C.One embodiment of high stringency conditions includes hybridization in 6x SSC at about 45[deg.]C, followed by one or more washes in 0.2x SSC, 0.1% SDS at 65[deg.]C.

[0224] In certain embodiments, the polypeptide is encoded by a polynucleotide that hybridizes to the disclosed nucleotide sequence under low, medium, high, or very high stringency conditions. One embodiment of very high stringency conditions comprises hybridization in 0.5 M sodium phosphate, 7% SDS at 65° C., followed by one or more washes in 0.2× SSC, 1% SDS at 65° C.

[0225] Other stringency conditions are well known in the art and those skilled in the art will recognize that various factors can be manipulated to optimize the specificity of hybridization. Optimization of the stringency of the final wash can be used to ensure a high degree of hybridization. For detailed examples, see Ausubel et al., (1992) at 2.10.1 to 2.10.16 pages and Sambrook, J. et al. (2001) at 1.101 to 1.104 sections.

[0226] Although stringent washing is usually carried out at a temperature of about 42 ℃ to 68 ℃, it will be understood by those skilled in the art that other temperatures may be suitable for stringent conditions. Maximum hybridization rate usually occurs at about 20 ℃ to 25 ℃ below the Tm for the formation of the DNA-DNA hybrid. As is well known in the art, Tm is the melting temperature, or the temperature at which two complementary polynucleotide sequences dissociate. The method for estimating Tm is well known in the art (see Ausubel et al., supra, at 2.10.8 pages). Generally, the Tm of the duplex of the perfect match of DNA can be predicted as an approximate value by the following formula:

[0227] Tm = 81.5 + 16.6 (log10 M) + 0.41 (% G + C) - 0.63 (% formamide) - (600 / length)

[0228] Where: M is Na + The concentration of guanine is preferably in the range of 0.01 to 0.4 molar; % G+C is the sum of guanine and cytosine bases as a percentage of the total number of bases, ranging from 30% to 75% G+C; % formamide is the % formamide concentration (by volume); and length is the number of base pairs in the DNA duplex. The Tm of duplex DNA decreases by approximately 1°C for every 1% increase in the number of randomly mismatched base pairs. Washes are typically performed at a Tm of 15°C for high stringency or 30°C for moderate stringency.

[0229] In one embodiment of the hybridization procedure, a membrane (e.g., nitrocellulose or nylon membrane) containing immobilized DNA is hybridized overnight at 42° C. in a hybridization buffer (50% deionized formamide, 5× SSC, 5× Denhardt's solution (0.1% Ficoll, 0.1% polyvinylpyrrolidone, and 0.1% bovine serum albumin), 0.1% SDS, and 200 mg / mL denatured salmon sperm DNA) containing the labeled probe. The membrane is then subjected to two consecutive washes of moderate stringency (i.e., 2× SSC, 0.1% SDS at 45° C. for 15 minutes, followed by 2× SSC, 0.1% SDS at 50° C. for 15 minutes), followed by two consecutive washes of higher stringency (i.e., 0.2× SSC, 0.1% SDS at 55° C. for 12 minutes, followed by a 0.2× SSC and 0.1% SDS solution at 65-68° C. for 12 minutes).

[0230] Preparation of prothrombin activator

[0231] Prothrombin activators can be prepared by any suitable procedure known to those skilled in the art. For example, prothrombin activators can be produced by any convenient method, such as by purifying or isolating the polypeptide from a naturally occurring source, including but not limited to snake venom, blood, and blood-derived products (e.g., serum). Alternatively, prothrombin activators for use in the present invention can be produced by recombinant DNA technology or other forms of genetic engineering, including, for example, the use of bacterial, insect, yeast, mammalian, or other expression systems.

[0232] Methods of purification include affinity chromatography, including lectin (e.g., wheat germ agglutinin) affinity chromatography, anion / cation exchange chromatography, or any other separation technique, e.g., Hex-His tag separation. The identity and purity of the derived prothrombin activator can be determined, for example, by SDS-polyacrylamide electrophoresis or chromatography, such as by high performance liquid chromatography (HPLC). For example, the purification and characterization of pseudorin C (also abbreviated as PtPA) from P. textilis snake venom are described in Masci (1986) and Masci et al. (1988), and the purification and characterization of oscutarin C (OsPA) from Taipan snake venom are described in Speijer et al. (1986), both of which are incorporated herein by reference in their entirety. The purification of ecarin from E. carinatus venom is described in Morita, T et al. (1981), also incorporated herein by reference in its entirety.

[0233] Alternatively, prothrombin activators can be produced from venom gland cells in culture using methods known in the art, including, for example, the methods described in Yamanouye, N., et al. (2007), which describes the primary culture of secretory cells from the venom gland of the Brazilian pit viper for in vitro venom production, the entire contents of which are incorporated herein by reference.

[0234] Alternatively, the prothrombin activator may be synthesized chemically, for example using solution synthesis or solid phase synthesis, as described, for example, in Chapter 9 of Atherton and Shephard (1989) and in Roberge et al. (1995).

[0235] Alternatively, the prothrombin activator can be prepared by recombinant technology. For example, the prothrombin activator used in the present invention can be prepared by a procedure comprising the following steps: (a) preparing a construct comprising a polynucleotide sequence encoding a polypeptide operably linked to a regulatory element; (b) introducing the construct into a host cell; (c) culturing the host cell to express the polypeptide; and (d) isolating the polypeptide from the host cell. If the prothrombin activator comprises a complex or two polypeptides, the prothrombin activator can be prepared by a procedure comprising the following steps: (a) preparing a construct comprising a polynucleotide sequence encoding a first polypeptide operably linked to a regulatory element; (b) introducing the construct into a host cell; (c) culturing the host cell to express the first polypeptide; (d) isolating the polypeptide from the host cell; repeating steps (a) to (d) to obtain a second polypeptide; and ligating the first polypeptide to the second polypeptide. The above procedure is also applicable to preparing a prothrombin activator that is a fragment, variant, mutant form, or chimeric form of a wild-type prothrombin activator. In illustrative examples, the nucleotide sequence encoding the polypeptide encodes at least a biologically active portion of the sequence set forth in SEQ ID NO: 5, 6, 9, 10, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, or a variant thereof.

[0236] Recombinant prothrombin activators can be readily prepared using standard protocols, such as those described, for example, in Sambrook, J. et al. (2001), particularly sections 16 and 17, and Ausubel et al. (1992), particularly sections 10 and 16. For example, recombinant production of snake factor V and snake factor X, which can be used to produce Group C and Group D prothrombin activators, is described in Filippovic, I. et al. (2005) and Bos, M.H.A. et al. (2009), each of which is incorporated herein in its entirety. Illustrative procedures for the recombinant production of ecarin and variants of ecarin are provided in Yonemura, H. et al. (2004) and U.S. Patent No. 6,413,737, the entire contents of each of which are incorporated herein by reference.

[0237] colloid

[0238] In one aspect, the invention includes formulations of coagulation compositions comprising a prothrombin activator and a stabilizer such as a colloid.

[0239] Colloids are one of the three main types of mixtures, the other two being solutions and suspensions. Colloids typically have particles with diameters between 1 and 1000 nanometers, where the particles remain evenly distributed throughout the colloid. Therefore, a colloid involves one substance being evenly dispersed throughout another substance. Thus, a colloidal dispersion remains dispersed and does not settle to the bottom of a container. The dispersed substance is in the dispersed phase, while the substance in which it is dispersed is in the continuous phase.

[0240] If the size of the substances in the dispersed phase is less than 1 nanometer, the mixture is called a solution. If the size of the substances in the dispersed phase is greater than 1000 nanometers, the mixture is called a suspension.

[0241] A common method for classifying colloids is based on the phase of the dispersed substance and the phase in which it is dispersed. Using this classification, types of colloids include sols, emulsions, foams, and aerosols, where sols are colloidal suspensions of solid particles in a liquid, emulsions are one liquid dispersed in another liquid, foams are where gas particles are trapped in a liquid or solid, and aerosols contain small particles of liquid or solid dispersed in a gas. When the dispersion medium is water, the colloidal system can be referred to as a hydrocolloid. Table 3 illustrates different types of colloids.

[0242] Table 3: Exemplary colloids

[0243]

[0244]

[0245] Colloids are commonly used for fluid resuscitation of critical or intensive care unit patients. Fluid volume deficit in a patient may be the result of excessive fluid loss, inadequate fluid intake, or a combination of the two, including, for example, blood loss, vomiting, diarrhea, and dehydration. Colloids are most commonly used as plasma expanders in the treatment of circulatory shock. Colloids have large molecules that do not readily pass through capillary walls and are retained in blood vessels. Thus, when severe bleeding occurs, vascular volume can be restored, circulatory hemodynamics can be stabilized, and tissue perfusion can be maintained. Common examples of colloids include plasma substitutes and It is composed of modified fluid gelatin, and it promotes osmotic diuresis. These colloids have a half-life of several hours, provide long-term volume replacement and are generally isotonic with the blood they replace on a volume basis. Other types of colloids used in fluid resuscitation include dextran colloids, starch colloids such as and Polyvinylpyrrolidone (PVP) and other synthetic polymers are also classified as colloids.

[0246] Gelatin-based colloids have been used as plasma substitutes for nearly 100 years. They are the most effective volume substitute, with approximately 80% volume effect. However, they carry an increased risk of allergic or anaphylactic reactions. is 4% w / v succinylated gelatin in saline. It is typically prepared by hydrolysis and succinylation of bovine collagen and has a gelatin content of 40 g / L, 154 mmol / L sodium, 120 mmol / L chloride, an average Mw of 30,000, an average Mn of 22,600, a pH of 7.4 + / - 0.3, a relative viscosity of 1.9 at 37°C, an isoelectric point of pH 4.5 + / - 0.3, an osmotic pressure of 453 mm H2O, a gelling point of 0°C, an osmotic pressure of 274 mOsm / L, and a half-life of approximately 4 hours. Other commercially available gelatin-based colloids include (succinylated gelatin) and (Urea-linked modified fluid gelatin).

[0247] Starch colloids include hydroxyethyl starch solutions and have been used since the mid-1960s. Commercial versions are available such as Used as volume expanders by using high molecular weight hydroxyethyl starch and chemical substitution, which advantageously resists biodegradation by α-amylase. Other starch colloids such as Elo- Smaller but heavily substituted hydroxyethyl starches are used. In addition, even smaller and less substituted hydroxyethyl starches such as HAES- Pentastarch or Tetrastarch appears to have an improved safety profile and a virtually 100% volume replacement effect that can be maintained for up to 6 hours.

[0248] Albumin colloids have several advantages, including no risk of disease transmission from the manufacturing process, no volume limitations, low allergenicity, no significant nephrotoxicity, and no inherent coagulopathy. However, for volume replacement, albumin colloids are significantly more expensive than crystalloids, starch colloids, and gelatin colloids. Bovine serum albumin is used in laboratory applications such as protein concentration standards and nutrients in cell and microbial cultures and is inexpensive.

[0249] In addition to colloids, crystalloids can also be used for fluid resuscitation. Crystalloids are balanced salt solutions that freely cross capillary walls. They are composed of water and electrolytes and are designed to remain in the intravascular compartment for a shorter period of time than colloids. Common examples include normal saline and sodium lactate preparations such as Hartmann and Ringer-Lactate solutions. Crystalloids can be used to maintain fluid balance when the patient is unable to drink, such as in the postoperative period or to replace intravascular volume after sudden blood loss.

[0250] The present invention demonstrates that the stability of a coagulation composition comprising a prothrombin activator is significantly improved when a stabilizer, such as a colloid, is added to the composition. In some embodiments of the present invention, the colloid is selected from or consists of a gelatin-based colloid, a starch-based colloid, an albumin-based colloid, or a dextran-based colloid.

[0251] In some embodiments, the gelatin-like colloid is selected from or consists of succinyl gelatin colloid or urea-linked modified fluid gelatin colloid. In a specific embodiment, the succinyl gelatin colloid is selected from or consists of or In an alternative embodiment, the urea-linked modified fluid gelatin colloid is In a preferred embodiment, the succinylated gelatin colloid is

[0252] In some embodiments, the albumin-like colloid is selected from the group consisting of human or bovine albumin produced by Cohn cold ethanol treatment or chromatography. In a specific embodiment, the albumin-like colloid is human serum albumin or bovine serum albumin. In a preferred embodiment, the albumin-like colloid is bovine serum albumin.

[0253] In some embodiments, the starch colloid is selected from or consists of hydroxyethyl starch colloid, hexastarch colloid, pentastarch colloid or tetrastarch colloid. In a specific embodiment, the hydroxyethyl starch colloid is In an alternative embodiment, the six starch colloids are Elo- In an alternative embodiment, the pentastarch colloid is HAES- In an alternative embodiment, the four starch colloids are selected from and The group composed of.

[0254] Composition

[0255] The present invention provides a coagulation composition comprising a prothrombin activator and a stabilizer such as a colloid.

[0256] In some embodiments, the ratio of prothrombin activator to colloid (w / w) is 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:110, 1:120, 1:130, 1:140, 1:150, 1:160, 1:170, 1:180, 1:190, 1:200, 1:210, 1:220, 1:230, 1:240, 1:250, 1:260, 1:270, 1:280, 1:290, 1:300 1:270, 1:280, 1:290, 1:300, 1:310, 1:320, 1:330, 1:340, 1:350, 1:360, 1:370, 1:380, 1:390, 1:400, 1:410, 1:420, 1:430, 1:440, 1:450, 1:460, 1:470, 1:480, 1:490, 1:500, 1:510, 1:520, 1:530, 1:540, 1:550, 1:560, 1:570, 1:580, 1:590, 1: 600、1:610、1:620、1:630、1:640、1:650、1:660、1:670、1:680、1:690、1:700、1:710、1:720、1:730、1:740、1:750、1:760、1:770、1:780、1:790、1:800、1:810、1:820、1:830、1:840、1:850、1:860、1:870、1:880、1:890、1:900、1:910、1:920、1 1 :900, 1 :1000, 1 :1100, 1 :1200, 1 :1300, 1 :1400, 1 :1500, 1 :1600, 1 :1700, 1 :1800, 1 :1900, 1 :2000, 1 :3000, 1 :400, 1 :5000, 1 :6000, 1 :7000, 1 :8000, 1 :9000, or 1 :10000 or more, or any integer or partial integer between the recited integers. In a specific embodiment, the ratio of prothrombin activator to colloid (w / w) is 1 :100 to 1 :800.

[0257] In some embodiments, the amount of the composition should be enough to effectively coagulate the blood sample and to produce a serum sample by separating the clear blood from the thrombocytes. In some embodiments, the time required for the coagulation blood sample is less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 minutes. In a specific embodiment, the time required for the coagulation blood sample is less than 2, 3, 4, 5, 6, 7, 8, 9 or 10 minutes. In a preferred embodiment, the time required for the coagulation blood sample is less than 2, 3, 4 or 5 minutes.

[0258] In some embodiments, the compositions of the invention are capable of achieving coagulation in an advantageously rapid time after storage or in less than -20, -21, -22, -23, -24, -25, -26, -27, -28, -29, -30, -31, -32, -33, -34, -35, -36, -37, -38, -39, -40, -41, -42, -43, -44, -45, -46, -47, - 48, -49, -50, -51, -52, -53, -54, -55, -56, -57, -58, -59, -60, -61, -62, -63, -64, -65, -66, -67, -68, -69, -70, -71, -72, -73, -74, -75, -76, -77, -78, -79, -80, -81, -82, -83, -84, -85, -86 , -87, -88, -89, -90, -91, -92, -93, -94, -95, -96, -97, -98 or -99 degrees Celsius or greater than 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99 degrees Celsius. In a preferred embodiment, the composition of the present invention is capable of achieving clotting in a beneficially rapid time after storage or transported at room temperature or at a temperature of 20, 21, 22, 23, 24 or 25 degrees Celsius or more. In another preferred embodiment, the composition of the present invention is capable of achieving clotting in a beneficially rapid time after storage at an elevated temperature of 50 degrees Celsius or more.

[0259] 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340、350、360、370、380、390、400、410、420、430、440、450、460、470、480、490、500、510、520、530、540、550、560、570、580、590、600、610、620、630、640、650、660、670、680、690、700、710、720、730、740、750、760、770、780 , 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 or 3000 days or more, or any number of days between stated integers, in a favorable rapid time to achieve blood clotting. In some embodiments, the compositions of the present invention are capable of achieving blood clotting in a favorable rapid time after storage greater than 200 days.

[0260] In some embodiments, the compositions of the present invention are capable of achieving coagulation in an advantageously rapid time after sterilizing the composition by irradiation. In some embodiments, sterilization is by electron beam or ethylene oxide exposure. In a specific embodiment, the radiation is gamma radiation and the amount of radiation received by the composition is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 kGy. In a preferred embodiment, the radiation is gamma radiation and the amount of radiation received by the composition is about 15 kGy to about 25 kGy. In a most preferred embodiment, the radiation is gamma radiation and the composition is exposed to about 15 kGy.

[0261] In some embodiments, the composition can be spray dried or otherwise adhered to the inner surface of a container suitable for collecting the subject's blood. In other embodiments, the composition can be provided in a separated form suitable for adding a blood sample previously taken from the subject. In other embodiments, the composition can be provided in a reaction vessel to which a blood sample previously taken from the subject is added. In further embodiments, the composition can be provided in an aqueous form, for example, in a container such as a blood coagulation tube to which a blood sample is added.

[0262] The amount of prothrombin activator used in the compositions of the present invention will depend on various factors, including the subject to be tested and the severity of any associated conditions, for example, the activity of the prothrombin activator and / or colloid, the patient's age, weight, general health, sex, and diet, and any medications the subject is taking, as well as other relevant factors well known in the art, such as whether the subject has been prescribed an anticoagulant such as heparin or warfarin. Thus, by routine experimentation, one skilled in the art will be able to determine the effective amount of prothrombin activator that will be necessary to coagulate a blood sample and provide a serum sample for analyte testing. The amount of prothrombin activator can be determined to ensure adequate blood coagulation in a specific patient group, such as patients with normal blood that achieves rapid coagulation, or to ensure adequate blood coagulation in a broader patient group, including, for example, patients undergoing anticoagulant therapy.

[0263] In certain embodiments, the composition can be used as part of a statistical tube, for example, for troponin, or in conjunction with cardiac surgery and / or catheterization, or in conjunction with hemodialysis. In other embodiments, the composition can be used as part of a standard blood collection tube.

[0264] In some embodiments, the amount of prothrombin activator used in the composition of the invention is 0.00, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3 μg of prothrombin activator. In other embodiments, the amount of prothrombin activator used in the compositions of the present invention is 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7 , 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or 10 μg of a prothrombin activator.

[0265] In other embodiments, the coagulation composition is measured in units by means of an assay based on a peptide p-nitroanilide substrate or a thrombin substrate. In a specific embodiment, OsPA comprises 0.001-0.2 units as measured in a standard assay in the hydrolysis of the chromogenic substrates S-2222 or S2238.

[0266] Surfactants may also be used as part of the coagulation composition to provide a physical barrier between the blood components and the walls of the container containing the composition (such as a blood collection tube). The presence of the surfactant does not affect the coagulation mechanism.

[0267] Therefore, the composition can also include any suitable surfactant such as anionic, cationic or nonionic surfactants such as sorbitan esters or polyoxyethylene derivatives thereof. Suitable surfactants can also include sodium lauryl sulfate (SDS), ammonium lauryl sulfate, sodium lauryl ether sulfate and sodium myristyl ether sulfate. Surfactants are generally used to reduce nonspecific adsorption and need to be carefully selected and optimized. Surfactants can also improve blood flow, distribute coagulation activators, and prevent proteins, RBCs, and platelets from adsorbing to the tube wall. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicon dioxide and other ingredients such as lanolin can also be included.

[0268] In a preferred embodiment, the surfactant is a hydrophilic surfactant. In another embodiment, the surfactant can be a hydrophobic surfactant. Hydrophilic and hydrophobic surfactants can have similar effectiveness in reducing the interaction between blood proteins and blood cells and the walls of a container, such as a blood collection tube. In a preferred embodiment, the surfactant can be a hydrophilic polysilane polymer, such as Dow Corning 7-9245.

[0269] Composition can be prepared according to methods known to those of ordinary skill in the art and can include other carriers, excipients or diluents. With regard to being compatible with other components of the composition and being harmless to the formation of serum samples, carriers, excipients and diluents must be "acceptable", with some advantageous features such as reduced fibrinogen concentrations. Fewer microclots, fewer cells, will be able to store longer periods (if necessary) and will result in more repeatable analyte results. Such carriers, excipients and diluents can be used to further enhance the integrity and half-life of the composition of the present invention.

[0270] Carriers such as polyvinyl pyrrolidone (PVP), carboxymethyl cellulose, polyvinyl alcohol, and polyethylene oxide can also be used to allow the coagulation composition to be added to the tube. Such carriers allow the rapid coagulation activator suspension to enter the blood so that, when coagulation is initiated, the carrier dissolves into the serum and clots. PVP and water-soluble surfactants can also release the coagulation activator into the blood sample to reduce the need for mixing.

[0271] Further examples of acceptable carriers or diluents are demineralized or distilled water; saline solution; vegetable-based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, corn oil, sesame oil, peanut oil, or coconut oil; silicone oils, including polysiloxanes, such as methylpolysiloxane, phenylpolysiloxane, and methylphenylpolysiloxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin, or squalane; cellulose derivatives such as methylcellulose, ethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, or hydroxypropylmethylcellulose; lower alkanols, such as ethanol or isopropanol; lower aryl alkanols: lower polyalkylene glycols or lower alkylene glycols, such as polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3-butylene glycol, or glycerol; fatty acid esters such as isopropyl palmitate, isopropyl myristate, or ethyl oleate; polyvinyl pyrrolidone; agar; gum tragacanth or gum arabic, and petrolatum.

[0272] Additional carriers that can be included in the compositions of the present invention include non-reducing sugars such as sucrose and reducing sugars such as galactose. Such carriers, as well as sugar alcohols such as mannitol, xylitol, glycerol, and sorbitol, can also be used for inclusion in the compositions of the present invention because they can act as antioxidants and potential stabilizers.

[0273] In some embodiments, the coagulation composition may comprise snake venom, including but not limited to crude snake venom. In some other embodiments, the coagulation composition may comprise a preparation of a prothrombin activator prepared by partial or complete purification of snake venom. Such preparations may be prepared by any suitable method known in the art, including chromatography and gel filtration methods, including those described herein and elsewhere. In some other embodiments, the coagulation composition may comprise a purified prothrombin activator or an isolated prothrombin activator. Purified and isolated prothrombin activators may be prepared by any suitable method known in the art, including those described herein and elsewhere. In other embodiments, the prothrombin activator may be recombinantly produced, wherein the prothrombin activator may be derived from snake venom.

[0274] The ability of the composition as defined herein to activate prothrombin to thrombin can be initiated or improved by the addition of cofactors, including but not limited to calcium, phospholipids and polypeptides (including FVa activity), as well as other coagulants or coagulants. In one embodiment, the coagulation composition is initially produced in the absence of a cofactor, or wherein the cofactor is provided separately to the coagulation composition, for example, wherein the coagulation composition and the cofactor are distributed at separate locations on the inner surface of a container such as a blood collection tube. After the tube is filled or partially filled with the patient's blood, the cofactor then contacts the blood and initiates or improves the coagulation reaction with the help of the prothrombin activator.

[0275] Depending on the blood cascade stimulated, coagulants or procoagulants are classified as intrinsic coagulants or extrinsic coagulants (see, e.g., U.S. Pat. No. 6,686,204). Suitable coagulants include, but are not limited to, diatomaceous earth, microparticles or granules of inorganic silicates, microparticles of silicon, glass microparticles, ellagic acid, thrombin, heparinase, thromboplastin, Aspergillus, hydrotalcite, kaolin, kaolin particles, prothrombin (including micronized prothrombin), fibrinogen, and depolymerized collagen.

[0276] In some embodiments, the composition comprises a reversible prothrombin activator, which may remain inhibited by an additional agent until activation of the coagulation process is desired. Such additional agents may include protease inhibitors such as benzamidine hydrochloride, aminobenzamidine dihydrochloride, antiprotease dihydrochloride, aprotinin, EGTA, or leupeptin hemisulfate, all of which are commercially available, for example, from Carl Roth GmbH & Co KG, or from Sigma-Aldrich Co. LLC.

[0277] In some embodiments, the composition comprises a prothrombin activator, a colloid, and a surfactant. In a specific embodiment, the composition comprises a prothrombin activator derived or derivable from snake venom, a gelatin- or albumin-based colloid, and a surfactant. In a preferred embodiment, the composition comprises a Group C prothrombin activator derived or derivable from snake venom or a recombinant form thereof, a gelatin- or albumin-based colloid, and a hydrophilic surfactant. In a particularly preferred embodiment, the composition comprises the Group C prothrombin activator oscutarin C (OsPa), derived or derivable from the venom of the snake Taipan snake, a gelatin-based colloid, and a hydrophilic surfactant. It is 4% w / v succinylated gelatin in saline and contains 40 g / L gelatin, 154 mmol / L sodium, 120 mmol / L chloride, and a hydrophilic surfactant.

[0278] container

[0279] The present invention relates to any suitable container for preparing a suitable serum sample. Many suitable containers are well known in the art and include those described in U.S. Patent No. 4,227,620, U.S. Patent No. 4,256,120, U.S. Patent No. 6,416,717, U.S. Patent No. 6,592,613, U.S. Patent No. 6,686,204, U.S. Patent No. 7,488,287, U.S. Patent No. 7,699,828, European Patent No. 0628816, and commercially available containers include those used in the examples of this specification.

[0280] In some embodiments, the container used in accordance with the present invention is a tube, including a glass or plastic tube. Suitable plastics include polyvinyl chloride, polypropylene, polyethylene terephthalate, and polystyrene.

[0281] The container can be emptied and the ends sealed with the aid of a suitable puncturable septum or cap. This allows the use of a double-ended needle, wherein one end is inserted into the patient's vein and the other end of the needle punctures the septum or cap covering the end of the tube so that the vacuum in the tube draws the blood sample into the tube through the needle.

[0282] The container can be of any suitable size. In some embodiments, the container is designed to hold 50 μL to 10 mL of a blood sample. Suitably, the container is designed to hold at least 50 μL, 70 μL, 100 μL, 150 μL, 200 μL, 250 μL, 300 μL, 350 μL, 400 μL, 450 μL, 500 μL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 8 mL, or 10 mL of a blood sample. In a specific embodiment, the container holds 4 mL of a blood sample, thereby providing a final concentration of a prothrombin activator of 25 ng / mL to 2.5 μg / mL in the 4 mL blood sample.

[0283] In some embodiments, the container contains a coagulation composition comprising, consisting essentially of, or consisting of a prothrombin activator and an additional agent such as a colloid.

[0284] In some embodiments, the coagulation composition may be present in the container before the blood sample is added to the container. In some embodiments, the coagulation composition may be added to the container after the blood sample is added to the container. If the coagulation composition is present in the container before the blood sample is added, the composition may be added to the container by any suitable method known in the art. In some embodiments, the coagulation composition is dissolved in a suitable solvent, then added to the container and dried onto the inner surface of the container. The solvent may be a neutral buffer. The coagulation composition in solution may be dried onto the inner surface of the container by spray drying, freeze drying, heat drying, or any other suitable method known in the art. In some embodiments, the coagulation composition is dried onto the inner surface of a container, such as a blood collection tube, using a stream of warm air heated to 60°C-70°C. In some other embodiments, the coagulation composition is dissolved in a suitable solvent and added to the container without drying, so that the container contains an aqueous solution containing the coagulation composition. The solvent may be a neutral buffer. In further embodiments, the coagulation composition is contacted with the inner surface of a container, such as a blood collection tube, by atomization.

[0285] In some embodiments, beads are coated with the coagulation composition and then added to a container. The beads can be glass beads or synthetic resin beads, including polystyrene and acrylic beads. The beads can have a spherical shape.

[0286] In some embodiments, the average diameter of the beads is 0.1 mm to 1 mm.

[0287] In a specific embodiment, the prothrombin activator is flash dried onto the inner surface of the container using a gentle vacuum at 37° C., for example, by using a Gene-Vac machine. In a specific embodiment, the prothrombin activator is flash dried directly into a container, such as a blood collection tube, by a jet of hot air at 50° C. or higher.

[0288] In some embodiments, after blood coagulation has occurred, container provides the separation of serum from coagulation cell.In some embodiments, container comprises or contains serum separation agent gel, and it is provided at the barrier between coagulation cell and serum sample.In some embodiments, container has suitable shape and suitable material to allow centrifugation, thereby separates or assists in maintaining the separation of coagulation cell and serum sample.In some embodiments, remove serum sample from coagulation cell, or remove coagulation cell from serum sample.For example, such embodiment is the use that is compatible with commercially available serum separation tube and plasma separation tube.

[0289] In some embodiments, the container can contain one or more additional components. In addition to the coagulation composition, other components may include, for example, one or more cofactors, one or more surfactants, and / or one or more coagulants.

[0290] In a preferred embodiment, the container is a Greiner Bio-One White Top or Red Top tube, or a Becton Dickinson venous collection tube. Such preferred collection tubes are made from polyethylene terephthalate and may contain no additives at all, or may be coated with a surfactant, contain silica as a coagulation activator, a gel separator, and a silicone-coated rubber stopper.

[0291] serum samples

[0292] As discussed above, the present invention is based in part on the discovery that prothrombin activators, when formulated with additional agents such as colloids, result in coagulation compositions having enhanced stability, thereby preserving coagulation activity and improving the quality of serum samples used for immunoassays or analyte detection, whether in the laboratory, at the point of care, or in a clinical or research setting. Serum samples suitable for detecting analytes are serum samples that are of suitable quality (as discussed herein) and / or are prepared within a suitable timeframe (as discussed herein).

[0293] An important factor in the preparation of serum samples suitable for detection of analytes is the extent to which the coagulation process removes fibrinogen from the serum. Serum containing residual fibrinogen or partially degraded fibrinogen or fibrin may cause analytical accuracy problems as a result of incomplete coagulation due to the formation of precipitates (microclots or strings), latent coagulation after centrifugation and storage of the serum. Therefore, complete or substantially complete coagulation is critical in ensuring the highest quality serum and accurate test results.

[0294] Thus, some embodiments of the present invention provide for use in the preparation of a coagulation composition for detecting an analyte, the composition comprising, consisting essentially of, consisting of a prothrombin activator and a colloid, wherein the serum contains ≤30 μg / mL of fibrinogen or fibrinogen / fibrin-related products. In more specific embodiments, the serum contains ≤25 μg / mL, ≤20 μg / mL, ≤15 μg / mL, ≤10 μg / mL, ≤8 μg / mL, or ≤6 μg / mL of fibrinogen or fibrinogen / fibrin-related products.

[0295] In some embodiments, the serum contains ≤30%, ≤20%, ≤10%, ≤9%, ≤8%, ≤7%, ≤6%, ≤5%, ≤4%, ≤3%, ≤2%, ≤1%, ≤0.5%, ≤0.2%, ≤0.1% fibrinogen or fibrinogen / fibrin related products that were present in the original sample from which the serum was produced.

[0296] The levels of fibrinogen and / or fibrinogen / fibrin-related products may be detected by any suitable method known in the art, including sandwich immunoassays utilizing antibodies from MP Biomedicals and standard fibrinogen preparations purchased from NIBSC, Potters Bar, Hertsfordshire, London, UK.

[0297] Another important factor in the preparation of serum samples suitable for detecting analytes is the activity or number of cells or cell fragments left in the serum after coagulation. During the storage and analysis of serum or blood plasma, the presence of cells can have two effects. First, cells may crack, thereby releasing cell contents (such as potassium, lactate dehydrogenase) into serum or blood plasma. This may lead to significant differences between the measurement results made immediately after centrifugation and the measurement results after storage for a period of time. Secondly, cells continue to have metabolic activity and may exhaust a large amount of nutrients (such as glucose) and release metabolites (such as lactate) (after storage). When the 30 minutes coagulation time that is usually recommended for storage samples and when samples are from healthy participants, changes can even be observed in the samples of many tubes. Thus, the degree of cell contamination is an important quality standard for serum samples and an important advantage of using serum rather than blood plasma.

[0298] Thus, in some embodiments, the serum sample comprises less than 50%, 40%, 30%, 20%, 10%, 5%, or 1% cells in the blood sample from which the serum sample has been prepared.

[0299] In some embodiments, the serum sample comprises a change in lactate dehydrogenase activity or phosphate concentration of <25%, <20%, <15%, or <10% within 24 hours, 12 hours, 8 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, or 30 minutes (typically measured in U / L and mmol / L, respectively). In some embodiments, the serum sample comprises a change in glucose concentration or potassium concentration of <5%, <4%, <3%, <2%, <1%, <0.5%, or <0.1% within 24 hours, 12 hours, 8 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, or 30 minutes (e.g., from the time the serum sample was prepared). Methods for measuring lactate dehydrogenase activity are well known in the art, see, for example, Dimeski, G., et al. (2004), the entire contents of which are incorporated herein by reference.

[0300] The hemoglobin concentration of a serum sample can also be used to determine whether the serum sample is suitable for detecting an analyte. Thus, in some embodiments, the serum sample comprises a hemoglobin concentration of <150 mg / L, <100 mg / L, <90 mg / L, <80 mg / L, <70 mg / L, <60 mg / L, <50 mg / L, <40 mg / L, <30 mg / L, <20 mg / L, or <10 mg / L.

[0301] Serum is generally preferred over plasma as the sample for testing unless urgent results are required, and the clotting time used for serum tubes is considered too long. Another disadvantage of prolonged clotting time is that it may lead to clinically significant changes in analyte concentration due to cellular activity in the blood sample, a problem that is most pronounced in leukocytosis (Dimeski and Bird 2009).

[0302] Thus, in some embodiments, the present invention provides a method for producing a serum sample for detecting an analyte of interest, the method comprising contacting the blood sample with a coagulation composition comprising, consisting essentially of, or consisting of a prothrombin activator and a colloid (as defined herein), wherein the serum sample is prepared within 25, 20, 15, 10, 8, 6, 5, 4, 3, 2, 1, or 0.5 minutes from contacting the coagulation composition.

[0303] blood samples

[0304] As discussed herein, it is desirable to provide a coagulation composition that is suitable for producing a serum sample from most, if not all, blood samples, or a container containing a coagulation composition that will coagulate most, if not all, blood samples within a suitable time, i.e., within a period of time that allows analyte testing to be performed consistent with the patient's clinical needs.

[0305] Examples of different types of blood samples for which testing may be desirable include fresh blood from healthy individuals, citrated blood, blood with added EDTA, blood from patients on anticoagulant therapy such as heparin, warfarin, citrate, oral anticoagulants such as factor Xa inhibitors (e.g., rivaroxaban), or direct thrombin inhibitors (e.g., dabigatran), patients taking antithrombotic agents including aspirin, thrombocytopenic patients (patients with low platelet counts), and patients with a prolonged PTT.

[0306] In some embodiments, blood sample is a whole blood sample. In some other embodiments, blood sample is a serum sample derived from a whole blood sample. In this case, exemplary serum sample comprises such serum sample, wherein a serum sample of higher quality is desired, including those samples, wherein, for a serum sample being applicable to a sample for detecting an analyte, the amount of fibrinogen or fibrinogen / fibrin-related products and / or the amount of cells or cellular material and / or the amount of hemoglobin in the serum sample is considered too high. For example, serum sample can present micro-clots or latent coagulation. In some other embodiments, blood sample is a plasma sample derived from a whole blood sample. For example, plasma sample can present micro-clots or insoluble fibrin formation or latent coagulation.

[0307] Detection of analytes

[0308] In some embodiments, the present invention further provides a method for detecting an analyte, the method comprising analyzing the presence or amount of an analyte of interest in a serum sample prepared by the method of the present invention.

[0309] In a specific embodiment, the serum sample prepared by the method of the present invention is suitable for more than one analyte test, so that the serum sample can be used to detect more than one analyte. As discussed herein, clinicians generally wish to perform more than one analyte test on a blood sample from a patient, and it is uncommon for a serum sample to be used for at least 20 tests, or even more, sometimes 50-60 or even 70-80 tests. It will be understood by those skilled in the art that in a specific embodiment, the invention provides the production of serum samples having sufficient volume and quality to be able to perform all desired analyte tests on a serum sample. The advantage of doing so is that the volume of blood taken from the subject and the time spent for performing analyte testing are reduced.

[0310] Illustrative analyte tests are described below.Methods for performing these analyte tests can be performed in many ways and are well known in the art.

[0311] Troponin: This test measures the levels of troponin T and / or troponin I in a serum or plasma sample, where high levels can indicate acute myocardial infarction.

[0312] Sodium (Na + ): This test measures the amount of sodium in a serum or plasma sample. Sodium plays an important role in salt and water balance in the body. Low sodium levels can indicate excessive water intake, heart failure, kidney failure, or sodium loss from the body due to diarrhea or vomiting. High sodium levels can indicate excessive salt intake or insufficient water intake.

[0313] Potassium (K + ): This test measures the amount of potassium in a serum or plasma sample. Too high a potassium level (hyperkalemia) may be the result of kidney disease, diabetes, ketoacidosis, or medications that reduce the amount of potassium excreted from the body. Too low a potassium level (hypokalemia) may be due to dehydration, such as from diarrhea or vomiting, or excessive sweating. Potassium levels may also be low as a result of medications that cause the kidneys to lose potassium, such as diuretics. Potassium levels should be monitored frequently in patients who take diuretics or heart medications, have high blood pressure or kidney disease, have critical acidosis and alkalosis conditions, and are receiving kidney dialysis or intravenous treatment (via an IV drip).

[0314] Chloride (Cl -): This test measures the amount of chloride in serum or plasma. Chloride is often measured to assess whether a patient has an electrolyte imbalance. Low chloride and normal sodium and elevated bicarbonate may indicate vomiting or loss of gastric fluid.

[0315] Bicarbonate (HCO3 - ): This test measures the amount of the three forms of carbon dioxide (bicarbonate, carbonic acid, and dissolved carbon dioxide) in serum or plasma. The bicarbonate / carbonate buffer in plasma is the most important: it is very effective in regulating body pH. This test is often performed in determining metabolic acid / base status. The buffer concentration is regulated by the kidneys. High levels can be seen in response to loss of chloride (vomiting), diuretic therapy, mineralocorticoid excess, or glucocorticoid excess (e.g., Cushing's disease). Low levels may result from the production of organic acids, as seen in diabetic ketoacidosis, decreased excretion of acid in renal failure, excessive loss of bicarbonate (nephropathy), diarrhea, and abuse of poisons such as methanol.

[0316] Glucose: This test measures the amount of glucose in the serum or plasma. Glucose levels are often tested in patients who present with symptoms of high blood glucose (hyperglycemia) or hypoglycemia, who are pregnant, or who have diabetes.

[0317] Urea: This test measures the amount of urea in the serum or plasma. This test can help assess kidney function and monitor the effectiveness of dialysis.

[0318] Creatinine: This test measures the amount of creatinine in the serum or plasma. This test is key in helping to assess kidney function and monitor treatment for kidney disease.

[0319] Urate: This test measures the amount of urate (or uric acid) in the serum or plasma. High levels of uric acid can be a sign of gout. Uric acid levels are also monitored in patients receiving chemotherapy or radiation therapy to detect tumor lysis syndrome.

[0320] Total protein (TP): This test measures the total amount of protein in serum or plasma. Although the results of a total protein test don't indicate a specific disease, high or low protein levels often indicate that additional testing is needed to determine if there is a problem. Total protein tests are often used to screen for certain liver diseases, kidney disease, multiple myeloma, and hydration status.

[0321] Albumin (Alb): This test measures the amount of albumin in serum or plasma. Albumin levels are often measured to screen for liver or kidney disease or to assess nutritional status, particularly in hospitalized patients.

[0322] Total bilirubin: This test measures the amount of bilirubin in serum or plasma. Bilirubin levels are measured to screen for and monitor liver disorders, such as jaundice, or liver diseases, such as cirrhosis. Bilirubin levels are also measured in infants to help detect certain rare genetic disorders and to prevent brain damage in those infants with jaundice.

[0323] Alkaline phosphatase (ALP): This test measures the amount of alkaline phosphatase in serum or plasma. This test is often done to screen for or monitor treatment of liver or bone disorders.

[0324] Gamma-glutamyltransferase (GGT): This test measures the amount of gamma-glutamyltransferase in serum or plasma. This test is used to screen for liver disease and alcohol abuse. It can also be used to determine if elevated ALP levels are due to liver or bone disease.

[0325] Alanine aminotransferase (ALT): This test measures the amount of alanine aminotransferase in serum or plasma. This test is used to screen for liver disease.

[0326] Aspartate aminotransferase (AST): This test measures the amount of aspartate aminotransferase in serum or plasma. This test is used to detect liver damage, muscle damage, and other conditions because the enzyme is present in many organs and tissue cells.

[0327] Lactate dehydrogenase (LDH): This test measures the amount of lactate dehydrogenase in serum or plasma. This test is often used to determine the cause and location of tissue damage in the body, tissue ischemia, and to monitor its progression.

[0328] Creatine kinase (CK): This test measures the amount of creatine kinase in the serum or plasma. Creatine kinase is measured in people with chest or muscle pain or fatigue to determine whether they have had a heart attack or whether other muscles in the body have been damaged.

[0329] Total calcium (TCa): This test measures the amount of calcium in serum or plasma. Calcium levels are often measured in people with kidney, bone, or nerve disorders, or when symptoms of significantly increased or decreased calcium are present.

[0330] Phosphate: This test measures the amount of phosphate in serum or plasma. Phosphate levels may be measured as a follow-up to abnormal calcium level test results. Phosphate levels may also be measured in patients with kidney disease, uncontrolled diabetes, or if the patient is taking calcium or phosphate supplements.

[0331] Magnesium (Mg 2+): This test measures the amount of magnesium in serum or plasma. It may be done if a person has symptoms of too much or too little magnesium, including fatigue, irritability, heart arrhythmias, nausea, or diarrhea. Magnesium levels may also be measured if abnormal calcium or potassium levels have been detected.

[0332] Lipase: This test measures the amount of lipase in the serum or plasma. This test is often used to diagnose pancreatitis or other pancreatic diseases.

[0333] Cholesterol: This test measures the amount of cholesterol in the blood serum or plasma. Cholesterol levels are measured to screen for the risk of developing heart disease.

[0334] Triglycerides: This test measures the amount of triglycerides in the blood serum or plasma. As with cholesterol levels, this test is often used to screen for the risk of developing heart disease.

[0335] High-density lipoprotein (HDL): This test measures the amount of HDL cholesterol in the blood serum or plasma. This test is often used to determine the risk of developing heart disease.

[0336] Iron (Fe 2+ ): This test measures the amount of iron in serum or plasma. Iron is measured to check whether a patient has low or high iron levels. Low iron levels can cause anemia and are usually due to prolonged or heavy bleeding, pregnancy, or rapid growth (in children). High iron levels can be due to genetic conditions or large blood transfusions.

[0337] Transferrin: This test measures the amount of transferrin in serum or plasma. Transferrin is a plasma protein that transports iron through the blood to the liver, spleen, and bone marrow. Therefore, blood transferrin levels are tested to determine the cause of anemia, to check iron metabolism (for example, in iron-deficiency anemia), and to determine the iron-carrying capacity of the blood.

[0338] C-reactive protein (CRP): This test measures the amount of C-reactive protein in serum or plasma. This test is used to determine the presence of inflammation, to determine its severity, and to monitor response to treatment.

[0339] Cortisol: This test measures the amount of cortisol in the serum or plasma. Measuring cortisol levels can help diagnose Cushing syndrome or Addison disease.

[0340] Free thyroxine: This test measures the amount of free thyroxine in serum or plasma. This test is often used to diagnose hypothyroidism or hyperthyroidism.

[0341] Thyroid-stimulating hormone (TSH): This test measures the amount of thyroid-stimulating hormone in serum or plasma. This test is often used to screen for, diagnose, and monitor thyroid disorders.

[0342] Ferritin: This test measures ferritin in serum or plasma. Low ferritin levels indicate iron deficiency. High levels indicate iron overload, as in hemochromatosis.

[0343] Hemolysis Index: The hemolysis index test measures the degree of red blood cell lysis. Hemolysis is the most common interference encountered in biochemistry laboratories. This test is primarily used to detect hemolysis in vitro and to report sample suitability for some or all analytes, as well as to detect hemolytic anemias (hereditary spherocytosis, spontaneous hemolysis, RBC enzyme deficiencies). Hemolysis or the hemolysis index (the concentration of free hemoglobin in serum or plasma) is currently estimated by all common chemistry analyzers. This value is then used as a guide to determine which analytes and at what level of hemolysis may be affected or not reported (Dimeski et al. 2005).

[0344] Icterus Index: The Icterus Index test returns a value that, by pure spectrophotometry, indicates the relative level of bilirubin in the test sample. In rare cases of interference with the total bilirubin photometric estimation method, it is used to determine the accuracy of the cross-check of sample suitability for reporting certain analytes and bilirubin results. In detecting cancer paraprotein interference (precipitation and false high total bilirubin) in the Roche total bilirubin method (Sheppard et al., 2005), the Icterus Index has been shown to be a value where the Icterus Index remains unaffected. As discussed in Dimeski et al., 2008, at high concentrations (e.g., >200 μM / L), bilirubin can interfere with some creatinine determinations.

[0345] Lipidemia index: The lipidemia index has been used to predict possible interference with the assay due to lipidemia (Dimeski 2009).

[0346] In addition to the above analyte tests, other assays can be performed using serum or plasma samples and by different analytical techniques such as immunoassays, including competitive, noncompetitive, reverse or sandwich enzyme-linked immunoassays.

[0347] Methods for diagnosis, prognosis, and monitoring responsiveness to treatment

[0348] The present invention provides methods for diagnosing a disease or condition in a subject, wherein the methods comprise providing a blood sample from the subject, preparing a serum sample from the blood sample by contacting the blood sample with a coagulation composition of the present invention, and testing the serum sample for the presence or absence of an analyte in the serum sample, or an indicative level or concentration of the analyte in the serum sample, wherein the presence, absence, or indicative level or concentration of the analyte is indicative of a disease or condition in the subject.

[0349] The present invention also provides a method for providing a prognosis for a subject, wherein the method comprises providing a blood sample from the subject, preparing a serum sample from the blood sample by contacting the blood sample with a coagulation composition of the present invention, and testing the serum sample for the presence or absence of an analyte in the serum sample, or an indicative level or concentration of the analyte in the serum sample, wherein the presence, absence or indicative level or concentration of the analyte indicates a prognosis for the subject.

[0350] The present invention also provides a method for monitoring a subject's responsiveness to a treatment, wherein the method comprises providing a blood sample from the subject, preparing a serum sample from the blood sample by contacting the blood sample with a coagulation composition of the present invention, and testing the serum sample for the presence or absence of an analyte in the serum sample, or an indicative level or concentration of the analyte in the serum sample, wherein the presence, absence, or indicative level or concentration of the analyte indicates the subject's responsiveness to the treatment.

[0351] In some embodiments, the methods of the present invention involve comparing the results of an analyte test to a reference interval or cutoff limit to arrive at a diagnosis.

[0352] The disease or condition can be any disease or condition that can be readily diagnosed, prognosed, or responsiveness to treatment determined using a serum sample, including but not limited to the diseases or conditions outlined above with reference to various analyte tests.

[0353] In some embodiments, the above methods can include diagnosing the presence or absence of a disease or condition that the subject has not previously presented with. In other embodiments, the above methods can include diagnosing the presence, absence, or severity of a disease or condition that the subject has previously presented with. The above methods can include referencing results obtained from the subject at an earlier time. Alternatively, the reference result can be a standard analytical reference.

[0354] In some embodiments, the above methods are performed in a testing facility such as a pathology laboratory. In some other embodiments, the above methods are "point-of-care" methods. As used herein, "point-of-care methods" means that the above methods are performed at or near the site of patient care. Point-of-care methods are becoming increasingly popular in hospitals and other settings where rapid results are required. This is often accomplished using mobile, portable, and handheld instruments and test kits.

[0355] Advantages of point-of-care testing include the ability to obtain rapid analytical results at the bedside in a hospital (particularly in emergency situations), as well as the ability to obtain analytical results at home, in a doctor's surgery, in remote areas, etc. (e.g., using small volumes of arterial, venous, or capillary blood).

[0356] Devices currently available on the market for point-of-care methods include the i-Stat (Abbott Diagnostics), the Retro-STATUS HIV / CD4350 rapid test device (Millenium Biotechnology, Inc.), and the Triage PLGF test (Alere International).

[0357] Reagent test kit

[0358] The present invention provides a kit for preparing a serum sample, wherein the kit comprises a prothrombin activator and a colloid.

[0359] The kits of the present invention facilitate the use of the methods of the present invention. Typically, a kit for performing the methods of the present invention contains all the reagents and means necessary to perform the methods described above. For example, in one embodiment, a kit can include a coagulation composition of the present invention and optionally a device for performing analyte detection, such as a device for use in a point-of-care method as defined herein.

[0360] Typically, the kits described herein will also comprise one or more containers. In the context of the present invention, compartmentalized kits include any kit in which compounds or compositions are contained in separate containers, and may include small glass containers, plastic containers, or strips of plastic or paper. Such containers can allow for efficient transfer of compounds or compositions from one compartment to another while avoiding cross-contamination of samples, as well as for quantitative addition of agents and solutions from each container from one compartment to another. In a preferred embodiment, the one or more containers comprising the kit are blood collection tubes.

[0361] Typically, the kits of the invention will also include instructions for performing appropriate methods utilizing the kit components.

[0362] The methods and kits of the present invention are also applicable to any animal, including humans, including, for example, non-human primates, equines, bovines, sheep, goats, rabbits, birds, cats, and canines. Thus, for application to different species, a single kit of the present invention may be applicable, or alternatively, different kits may be required, for example, containing compounds or compositions specific for each individual species.

[0363] The methods and kits of the present invention are applicable in any situation where it is desirable to generate a serum sample.

[0364] Research Tools

[0365] The present invention also contemplates the use of research tools employing serum samples produced according to the present invention. These methods generally comprise providing a serum sample prepared according to the methods generally described above; and employing the serum sample in research tool studies, including but not limited to genomics, proteomics, metabolomics, systems biology, molecular imaging, or assay studies.

[0366] Suitable research tools are well known in the art and include those described in Scaros, O. et al., 2005, the entire contents of which are incorporated herein by reference. Genomics includes pharmacogenomics, which studies the correlation between genetics and gene expression patterns in response to therapy. Proteomics allows analysis of the abundance and distribution of proteins in a system. Metabolomics, or biochemical analysis, is the study of metabolites in a system. Systems biology views entire biological systems as functional units, thereby generating behavioral models that can potentially predict how the aforementioned systems will respond to stimuli. Molecular imaging techniques have the ability to indicate the levels of specific molecular targets in the body and the functional status of the aforementioned targets, and can be used in diagnostic methods.

[0367] Those skilled in the art will understand and appreciate that the different features disclosed herein can be combined to form combinations of features that are within the scope of the present invention.

[0368] The present invention will now be further described with reference to the following examples, which are intended to be illustrative only and not limiting.

[0369] Example

[0370] A requirement for using a prothrombin activator in a coagulation composition is that the activity of the prothrombin activator remain stable over time and under variable conditions, such as exposure to heat and / or sterilizing radiation. For example, if the prothrombin activator is used in a coagulation composition in conjunction with a container, such as a blood collection tube, the coagulation activity of the prothrombin activator must be retained during storage of the prothrombin activator after purification or recombinant production and prior to tube production.

[0371] In addition, commercial blood collection tubes are typically manufactured in very large quantities on a production line, where the product may be a plastic tube containing additives such as procoagulants, surfactants, and layering gels. The contents of the tube are typically dried, sealed under vacuum, and sterilized. In the case where the procoagulant is a prothrombin activator, the prothrombin activator must be able to retain activity after the process of drying, sealing under vacuum, and sterilization (e.g., using radiation). Stability should generally be demonstrated across a wide range of temperatures (as disclosed herein). In specific embodiments, stability at room temperature should allow for a shelf life of at least 6 months, preferably greater than 12 months, and more preferably greater than 18 months.

[0372] Example 1 - Prothrombin Activator: Isolation and Characterization

[0373] In mammals, the prothrombin activator complex in vivo typically consists of the serine protease factor Xa and the protein cofactor factor Va, which are complexed on a phospholipid membrane in the presence of calcium ions (Jackson and Suttie, 1977). Factor Xa alone can activate prothrombin, but inefficiently. The presence of factor Va, calcium ions, and phospholipids enhances prothrombin activation by several orders of magnitude.

[0374] It is well known that the venom of many snakes causes rapid coagulation of blood. The first report of a prothrombin activator complex in snake venom came from Speijer et al (1986), who reported the discovery of a prothrombin activator complex from the venom of the snake Ophiuchus taipan (Snake Taipan) that had at least four polypeptide chains, two of which appeared to be factor Va-like components and two of which were factor Xa-like components linked by disulfide bonds.

[0375] The method used to purify the prothrombin activator in this study was essentially that previously described by Masci et al 1988 and Masci et al 2000. Briefly, 10 grams of venom (purchased from Venom Supplier Pty Ltd, South Australia) was purified in 1 gram batches using a single-step column chromatography process involving resolubilized venom on a suitable gel filtration resin (e.g., Sephacryl S300, Superdex 200). The activity of the concentrated OsPA-containing fractions was then determined in coagulation assays using recalcified citrated whole blood and recalcified citrated plasma, as well as by using a spectrophotometric substrate designed for factor Xa, S-2222.

[0376] Example 1.1 - Purification of prothrombin activator

[0377] Sephacryl S-300, Superdex 200, Toyopearl H55S and Toyopearl H65S resins were purchased from GE Healthcare Sydney and Toyo, Japan. A slurry of each resin was diluted 150% with column buffer, 0.05M tris-HCl, pH 7.4, containing 0.1M NaCl and 0.01% sodium azide. A glass column (5.0 x 95 cm or 2.5 x 95 cm) was filled with each resin in a cold room at 4°C. The column was balanced overnight at a flow rate of 1 ml / min and absorbance was monitored at 280 nm until it stabilized at zero (a minimum of 10 column volumes of buffer was run during this time).

[0378] Taipan snake (Os taipan venom, Os) venom was purchased in 2 x 5 gram batches (Venom Supplier Pty Ltd, South Australia) and a commercial supplier, Venom Supplier, confirmed that both 5 gram batches were from the same batch of venom milk. Approximately 1.0-1.5 gram batches of Os venom were reconstituted in 45 mL column buffer in a 37°C water bath until completely dissolved. This took approximately 30 minutes. A 1 / 50 dilution of Os venom solution was prepared and the A280 was measured, and the total protein concentration was then recorded. From the above stock solution, 2 x 1.0 mL aliquots, 1 x 0.5 mL, were diluted in 50% glycerol and stored at -20°C at a 1 / 50 dilution. The remaining 40-42 mL of Os venom solution was then loaded onto the equilibrated gel filtration column. Chromatography was carried out at a flow rate of 0.8-1.0 mL / min for more than 24 hours. LKB Redirac fraction collection was used and fractions were collected in time-based mode, collecting 8-10 mL fractions. 280 The absorbance of the eluent at 280 nm (A) was continuously monitored using a channel monitoring system and a dual pen recorder set to full scales of 2.48 and 1.24 absorbance units. 280 ).

[0379] Fractions containing OsPA coagulant activity were determined by a recalcified citrated plasma coagulation assay and an S-2222 chromogenic hydrolytic activity assay (described below). Fractions with high specific coagulant activity were pooled and concentrated (described below).

[0380] Example 1.2 - Concentration and Storage of OsPA

[0381] Fractions from Superdex 200, Sephacryl S300, and Toyopearl H55S and Toyopearl H65S chromatography, which contained plasma coagulation and S-2222 hydrolysis activity (designated "pooled OsPA fractions"), were pooled for characterization. Protein concentration was determined by measuring the absorbance of the pooled OsPA fractions at 280 nm and calculating the protein concentration in mg / mL using an absorption coefficient of 1.0 for a 1 mg / mL solution.

[0382] Pooled OsPA fractions were concentrated to a concentration of 2-4 mg / mL using a pressurized Amicon cell model 402 using a YM10 membrane (molar cutoff of 10,000 Da). In initial experiments, protein losses during the concentration step were 20-25%. In subsequent experiments, 5% glycerol was added to the pooled OsPA-containing fractions before concentration (to reduce losses due to protein binding). When 5% glycerol was used, protein losses during the concentration step were 0-5%. High-purity glycerol was then added to the concentrated OsPA solution to achieve a 50% glycerol concentration. The OsPA / glycerol solution was gently mixed to avoid foaming until the solution was homogeneous and then stored at -20°C in a dark glass bottle covered with aluminum foil. The protein concentration of the OsPA / glycerol solution was determined using a 1 / 10 dilution and measuring absorbance at 280 nm. OsPA Batch 17-Apr-2012 was used for all experiments.

[0383] Table 4 shows characterization data for 10 different formulations, which demonstrate that the different separation methods resulted in functionally similar formulations that were suitable and all capable of producing high quality serum, as can be inferred from the chromogenic substrate S-2222.

[0384] Table 4. Characterization Data of Prothrombin Activator Formulations

[0385]

[0386]

[0387] Table 4 provides quantitative information on the ten OsPA preparations described above, in terms of elution profiles and SDS PAGE band patterns. In summary, (1) the protein yield in the OsPA preparations was 126 ± 17 mg / g dry venom using either Sephacryl or Superdex, and (2) the plasma coagulant activity of 1 g venom was (1.031 ± 0.194) x 10 6 units, (3) the plasma coagulation activity in four Sephacryl or Superdex preparations was 526,417 ± 44,433 units, resulting in a yield of approximately 52% of the total plasma coagulation activity of the venom sample loaded on the column, and (4) two Toyopearl 65S runs produced higher recoveries of activity (60% and 75%) with very little purification between the prothrombin activator fraction and the taipan venom venom fraction.

[0388] Figure 1Shown are the banding patterns obtained using samples from six formulations of OsPA, including one stored from 1989. In all cases, there was a very consistent banding pattern in the high molecular weight region. The only noticeable difference was the presence of a larger amount of low molecular weight material in the Toyopearl formulation. This is consistent with the much poorer resolution of the venom fraction achieved using Toyopearl chromatography.

[0389] Coagulation of whole blood samples from each of the ten preparations (concentrated OsPA fractions, stored in 50% glycerol, were derived from each preparation) was studied by thromboelastography. Figure 2 And the parameters of each trace are shown in Table 5.

[0390] Table 5: Thromboelastography Data for Ten OsPA Preparations

[0391]

[0392] All OsPA formulations induced rapid and complete clotting as indicated by the R, K and angle values ​​(speed), and the MA value (clot strength).

[0393] Based on the results obtained, the OsPA formulation designated 17 / 4 / 2012 was used for all dose and stability experiments. The Superdex 200 chromatography elution profile for this formulation is shown in Figure 3 The SDS PAGE band patterns are shown in Figure 1 Comparison of the elution profile and banding patterns of this preparation demonstrates that it is a typical preparation. As shown in Table 1, the pooled fractions comprising this preparation contained 159 mg, equivalent to 151 mg / gram of venom. In the plasma coagulation assay, the specific activity was 3534 U / mg and the total activity recovered was 534,987 U / gram of dry venom, for a yield of 59%. These figures are generally consistent with the average values ​​achieved in several preparations (as shown in Table 1). The specific activity of 3534 U / mg indicates that 1 μg of OsPA, as used in many dose and stability experiments, contains 3.5 plasma coagulation units. The parameters for coagulation of whole blood by this preparation are given in Table 5.

[0394] The results of the assays of venom and 17 / 4 / 2012 OsPA preparations relative to the Factor Xa selective substrate S-2222 are shown in Table 6.

[0395] Table 6. S-2222 assay data for OsPA preparations on April 17, 2012

[0396]

[0397] Example 1.3 - Elution profile after gel chromatography

[0398] Solutions containing approximately 1-1.5 g of Snake Taipan venom (prepared by dissolving freeze-dried venom) were subjected to gel filtration chromatography as follows: on Sephacryl 300 (once); on Superdex 200 (six times), on Toyopearl HW55-S (once), and on Toyopearl HW65-S (twice). Figure 3 The elution curve of Taipan snake venom is shown, where the elution curve of Taipan snake venom was obtained by Superdex. TM 200 (gel column: 5 cm diameter, 95 cm length).

[0399] Example 1.4-Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-Page)

[0400] NuView Precast Mini Gels (#NB10-420, 4-20%) SDS PAGE gels were prepared. They contained Tris-glycine non-reducing sample buffer (#BG-145) (NuSep) and reducing sample buffer containing 5% β-mercaptoethanol. After a five-minute incubation, a 40 μL aliquot from each sample was transferred to an equivalent volume of reducing sample buffer. The samples were then incubated at 100°C in a heating block for 10 minutes. A 25 μL aliquot of each sample and 12 μL of a prestained molecular weight marker (#SM0671 Page Ruler Prestained Protein Ladder, Fermentas, Hanover, MD, USA) were loaded onto the gel. The gel was run at 100 V using a Mini-Protein II Cell PAGE instrument (Bio-Rad) until the dye front reached the bottom of the gel. The gel was stained with Coomassie Brilliant Blue G (#B-0770, Sigma) (0.25% w / v Coomassie Brilliant Blue G, 45% methanol, 10% acetic acid) and then excess stain was removed by destaining solution (45% methanol, 45% water and 10% acetic acid).

[0401] Example 1.5 - Storage of Freeze-dried OsPA as Freeze-dried Powder

[0402] In addition to storage of purified OsPA in 50% glycerol, OsPA can be produced as freeze-dried protein, which can then be stored at -20° C. This can be achieved by switching from a 50% glycerol OsPA stock solution or directly from an OsPA concentrate directly from the column.

[0403] Soak a 30 cm length of dialysis tubing (23 mm width, 12 kDa cutoff) in distilled water containing 1 mM EDTA and 0.2% sodium azide for 1-2 hours. The tubing is then washed 10 times with distilled water, and each piece is then filled with 80 ml of 10% BSA in H2O containing 0.2% sodium azide and stored in distilled water at 4°C for 8 weeks. Ensure that the tubing is always submerged. Before use, remove the BSA solution and rinse the tubing internally with 100 volumes of distilled water.

[0404] OsPA glycerol stock solution (2.0 mg / mL in 50% glycerol-0.05 M Tris HCl pH 7.4) was added to each tube, followed by the addition of 10% BSA (to a final concentration of 1%) and 10% sodium azide to a final concentration of 0.2%, and the tubes were then tied. OsPA in the dialysis tubing was dialyzed overnight at 4°C in 0.02 M hydroxyethylpiperazineethanesulfonic acid (hepes) buffer pH 7.4 (dialysis buffer) at 250-300 dialysate volumes with continuous slow magnetic stirring to produce an approximate final glycerol concentration of 10-15 mM. This ratio ensured that the final glycerol concentration in the blood (4 mL) in the collection tube containing OsPA was less than 0.1 mM.

[0405] After reaching equilibrium (i.e., 24 hours at 4°C), the dialyzed OsPA was carefully removed from the tube. The OsPA was separated and placed into dark glass bottles that had been pretreated and dried with a surfactant (2.41 g / L) and contained 10 mg of OsPA per bottle. The recovered OsPA / BSA suspension was shell-frozen using dry ice in a freeze-drying formulation. Freeze-drying was performed for 24 hours using a Christ freeze dryer (set to 0.08 mTorr and -60°C) as in Example 2.

[0406] After freeze-drying, the OsPA vials were reconstituted with 5 mL of Glyoxal to produce OsPA concentrations ranging from 1.0 to 2.0 mg / mL. A standard concentration curve of undialyzed OsPA at 0.125, 0.25, 0.50, 0.75, 1.0, 1.5, 2.0, and 3.0 μg was established to determine the recovery of dialyzed and freeze-dried OsPA. Four different dilutions of dialyzed and freeze-dried OsPA were used in the recalcified whole blood coagulation assay. The recovery of OsPA in both steps was calculated, and the results showed that approximately 100% of OsPA was recovered from the dialysis and freeze-drying steps.

[0407] Freeze-dried OsPA has been successfully stored and retained activity at -20°C for 6 months.

[0408] Note: OsPA used in the examples was obtained from a 50% glycerol stock solution.

[0409] Example 1.6 Characterization of Ecarin

[0410] Ecarin isolated from Echidna venom was obtained from Sigma Aldrich, catalog number EC0504, in vials of 45-55 units as a freeze-dried powder. The protein content was determined to be 110-110 mg / vial by Lowry protein assay (BioRAD DC Protein Assay, catalog number 500-01116). Ecarin was stored at -20°C.

[0411] Ecarin from Echidna venom is the primary reagent in the ecarin clotting time (ECT) test, which is used to monitor anticoagulation and thrombin inhibition. One unit is defined as the amount required to activate prothrombin to produce one unit of amidolytic activity at pH 8.4 and 37°C. At pH 8.4 and 37°C, one amidolytic unit will hydrolyze 1.0 μmol of N-tosyl-Gly-Pro-Arg-p-nitroanilide per minute. Ecarin activity is determined using a chromatographic assay according to Example 5.

[0412] Example 2 - Tube Preparation

[0413] The tubes used in this study were plastic Greiner White Top Smooth Tubes (Cat. #456001, Greiner Bio-One GmbH, Austria) or plastic Becton Dickinson Red Top Smooth Tubes (Cat. #3276916, Becton, Dickinson and Company, Franklin Lakes, USA).

[0414] Example 6 demonstrates that the presence of a surfactant in the tube formulation facilitates optimal release from the tube wall, and therefore facilitates the activity of the prothrombin activator. Although in this example, the addition of a colloidal carrier (in this case 0.1% BSA) was shown to be advantageous for the tubes without surfactant compared to tubes without BSA and without surfactant, activity was optimal in all cases with the addition of a surfactant. Therefore, the tubes used in the examples were produced with the addition of a surfactant.

[0415] To prepare the tubes, 20 μl of surfactant solution (as a liquid formulation) was added to the tubes, followed by vortexing for 10 seconds to ensure coating of the bottom of the tube. This process mimics the commercial spray coating process typically used by tube manufacturers. The tubes were then dried overnight in a vacuum desiccator or using a GeneVac centrifugal dryer. 20 μl of prothrombin activator was then dissolved in buffer or other formulation (as per Example 1) and added to the tubes, followed by centrifugal vacuum drying at 0.1 T at 29-30° C. using a Genevac Z-22 for 30 minutes. The tubes were then recapped with their original caps and wrapped snugly to protect from dust and moisture, then stored at room temperature until needed.

[0416] Alternatively, air dry the tube samples overnight at controlled ambient temperature without the caps. The tubes were then recapped with the original caps and wrapped tightly to protect from dust and moisture, then stored at room temperature until needed.

[0417] Freeze-drying was performed using a Christ freeze dryer. Samples were dried at -60°C under 0.01T vacuum for 1 hour. The tubes were then recapped with their original caps and tightly wrapped to protect from dust and moisture, then stored at room temperature until needed.

[0418] Example 3 - Radiation

[0419] The tubes were irradiated to ensure sterility of the finished product. Radiation can be accomplished by exposure to gamma radiation or electron beam (e-beam) technology. In this study, radiation was performed using a Gammacel 220 system (GC220) using gamma radiation at a commercial facility.

[0420] The blood collection tube containing the prepared coagulation composition is placed in a calibration device (GC220), then placed in the GC220 irradiation chamber and subjected to gamma irradiation (cobalt-60). Based on the known dose rate in this calibration device, the product is then irradiated for a desired period of time to ensure that the desired dose is achieved. The results are expressed as target dose (kGv); actual dose (kGv); and irradiation time.

[0421] Verify measurement traceability and uncertainty as follows. The dosimeter is calibrated in a Cobalt-60 radiation field, where the dose rate is determined from reference dosimeter measurements performed under similar conditions. The reference dosimeter measurements are traceable to an Australian standard for absorbed dose. This radiation exposure is performed based on the reference dose rate determined in the calibration radiation field.

[0422] The overall uncertainty associated with the reference dose rate includes the uncertainty of the calibration of the batch of dosimeters and the uncertainty due to within-batch variation and is calculated to be 2.0%. This expanded uncertainty is based on the standard uncertainty multiplied by a coverage factor of 2, providing a confidence level of approximately 95%. The uncertainty assessment was performed in accordance with the ISO Guide to the Expression of Uncertainty in Measurement. The quality management system complies with the following licenses and standards: TGA Licence No. 1182; ISO 9001:2008 and ISO 13485:2003 (excluding design and development). The quality management system also adheres to the principles of the following standards and guidelines: RSO 11137 International Best Practice in Dosimetry (ISO 17025 and ISO / ASTM standards for dosimetry in radiation processing).

[0423] Example 4 - Standardized method for evaluating blood samples

[0424] Citrated whole blood for all examples was collected from healthy individuals and patients receiving oral anticoagulant therapy (with written consent). The coagulation parameters used were: prothrombin time (PT), activated partial thromboplastin time (aPTT) and plasma fibrinogen concentration.

[0425] Platelet counts were also measured using a Sysmex XE-5000 hematology analyzer (Sysmex, Kobe Japan).

[0426] Normal coagulation parameters are: PT: 10-12 seconds; aPTT: 30-35 seconds; plasma fibrinogen concentration 1.5-2.5 g / L and platelet count 150-450 x 10 9 / mL blood.

[0427] The International Normalized Ratio (INR) is used to monitor patients receiving oral warfarin therapy. The INR is determined by plotting the ratio of the PT of patients receiving anticoagulation therapy to that of healthy individuals. The INR for effective warfarin therapy is 2.0-3.0.

[0428] Citrated whole blood from healthy individuals was pooled at approximately n=50 or used on an individual basis. Healthy individuals donated ~500 mL of blood, which was examined for recalcified whole blood clotting time, PT, aPTT, fibrinogen concentration, and platelet count.

[0429] In each example, whole blood recalcification time was measured and data was recorded for each batch of citrated whole blood. Normal whole blood recalcification time is 15-20 minutes. Pooled or single samples from patients with normal coagulation profiles or anticoagulation are suitable for blood coagulation testing.

[0430] In some embodiments, fresh blood is used, which is a single or multiple samples taken directly from volunteers without citration / recalcification. Control tubes are often used in parallel with the tubes being tested to test the samples for normal coagulation profiles. In some studies, blood from the same volunteers is also citrated and tested in parallel, including TEG measurements (as per Example 5).

[0431] Example 5 - Evaluation of Coagulation Composition Performance

[0432] Example 5.1 - Plasma coagulation assay

[0433] The recalcified citrated plasma coagulation assay was performed using a Hyland-Clotek apparatus as described by Austen et al (1975). Freshly pooled citrated plasma from normal volunteers was used for each experiment. The assay volume was 250 μL. Citrated normal human plasma (100 μL) was added to a glass coagulation tube (1 mL) containing 100 μL of 0.2 M hydroxyethylpiperazineethanesulfonic acid buffer and 0.1 M NaCl (pH 7.4). The sample was placed in a 37°C heating block of the Hyland-Clotek plasma coagulation machine and, after at least 1 minute, 25 μL of 0.2 M CaCl2 (to a final concentration of 20 mM) was added (when required), followed by 20 μL of a solution containing OsPA activity, at which time a timer was started.

[0434] The concentration of OsPA, based on protein concentration and the molecular weight of 250,000 for the Factor V-Factor Xa complex, ranged from 0.01 pM to 1.9 μM. Citrated plasma typically contains 20 mM citrate (as trisodium citrate), and after dilution, the citrate concentration in the reaction mixture is 8 mM, resulting in a net calcium concentration of 12 mM in the reaction mixture (molar excess over citrate). Clotting times are recorded in seconds. Each assay is performed in duplicate.

[0435] Figure 4 A standard curve is shown, which plots clotting time against the amount of protein from the April 17, 2012 OsPA fraction.

[0436] Example 5.2 - Visual Assessment of Coagulation

[0437] Pooled citrated normal blood with a PT = 10-12 seconds, aPTT = 35-40 seconds, fibrinogen concentration = 1.5-4.0 g / L and 150-400 x 10 9Platelet counts were calculated using a Greiner white-top tube or a BD smooth red-top tube containing a vacuum-dried hydrophilic surfactant (20 μL of 2.41 g / L surfactant in RO water). OsPA or ecarin, with or without Glyoxal (20 μL), was added to the tube. OsPA or ecarin was added as a wet solution or as a Genevac / vacuum desiccator-dried combination, to which 50 μL of 1 M calcium chloride was added. Using a Gilson P5000 pipette, 3.95 mL of citrated blood was then dispensed into the tube and a timer was started. The tube was immediately recapped and then gently tilted by inversion. Blood samples were tested in duplicate by two investigators. The tube containing the blood was repeatedly inverted until an initial clot was observed, at which point the time was recorded as the "initial clotting time." When a solid clot was observed after inversion, the time was recorded as the "complete clotting time."

[0438] Example 5.3 - Thromboelastography (TEG) assay

[0439] exist The operating procedures for the thromboelastography (TEG) and the parameters generated from each assay are provided in the Haemostasis Analyzer Series 5000 (Haemscope Corporation, IL, USA) operating manual and accompanying software.

[0440] Each reaction mixture was placed directly into a dedicated disposable cup (Cat No. 6211, Haemscope) and consisted of a maximum volume of 360 μL. Whole citrated blood was a component of all assays and was maintained at a constant volume of 320 μL.

[0441] The other components were added in the following order: 1. OsPA dilution, 2. calcium, when present (final concentration 20 mM = 3.6 μL of a 2 M solution), and 3. citrated whole blood (320 μL), resulting in an excess of calcium of approximately 10 mM relative to citrate, which was based on the hematocrit of the pool of 10 blood samples.

[0442] Figure 5 Schematic diagram showing traces from a thromboelastography experiment. Each test was monitored until the maximum amplitude (MA) value was established. The graph was generated by the TEG supporting software. The analyzer measures the shear elasticity of the clot (as it forms or breaks apart). The relevant parameters calculated by the accompanying software are: R - reaction time. The time from the start of the sample run until the first detectable clot is formed. This is the point in seconds at which most traditional plasma coagulation assays reach their endpoint; Angle - α. A measure of the rapidity of fibrin accumulation and cross-linking (clot strengthening); MA - maximum amplitude. The maximum stiffness or strength (maximum shear modulus) of the developing clot; A - amplitude. The width of the trace at any time and is equal to MA until MA is established; G - shear elastic modulus strength (SEMS). Using the relationship G = 5000 * MA / (100-MA), this value can be calculated from the maximum amplitude value.

[0443] The amplitude of the thromboelastograph curve was recorded at 5-second intervals and retrieved using the Lysis Tracker function in the TEG software. These data were then used to calculate the kinetic parameters of clot formation and lysis. The parameters were recorded for each sample and the replicates were averaged. The standard error was determined by first calculating the standard deviation and then dividing this value by the square root of the number of replicates.

[0444] Example 5.4 - Chromogenic / S-2222 Assay

[0445] S-2222 is a peptide-based chromogenic substrate that, upon hydrolysis, releases p-nitroaniline, which can be measured at 405 nm. S-2222 is designed to be specific for hydrolysis by Factor Xa.

[0446] Using a spectrophotometer, the assay mixture in the cell has a total volume of 1 mL and is composed of: (1) 900 μL of hydroxyethylpiperazineethanesulfonic acid buffer, pH 7.4; (2) 50 μL of S-2222 (3 mM solution in water), resulting in an initial substrate concentration of 150 μM; and 50 μL of a prothrombin activator, such as OsPA. This is diluted to a final working concentration of 10 nM. The molar extinction coefficient A405 for p-nitroaniline is 9600 M -1 , where the spectrophotometer provides the rate of increase of A405 (in absorbance units / second).

[0447] Figure 6 The development curve for the release of p-nitroaniline at various concentrations of OsPA (using the OsPA fraction designated 17 / 04 / 2012) is shown. The development curve is linear. A replot of the rate versus the amount of OsPA is linear and constitutes the standard curve for the assay. Based on the rate and the amount of prothrombin activator in the assay, the specific activity of the prothrombin activator can be calculated as units / mL of protein, where 1 unit (U) is the amount of protein required to hydrolyze 1 micromole of S-2222 / minute in the standard assay.

[0448] Example 5.5 - Chromogenic / S-2238 Two-Stage Assay

[0449] Another chromogenic assay that can be used is S-2238, a peptide-based chromogenic substrate that releases p-nitroaniline upon hydrolysis, which is measured at 405 nm. S-2238 is designed to be specific for hydrolysis by thrombin (Factor IIa). The assay relies on sampling timed aliquots of the first-stage assay mixture (prothrombin and activator) into a second-stage assay mixture containing S-2238 to measure the thrombin generated in the first stage.

[0450] The assay was performed in a 96-well microtiter plate and the absorbance was read on a plate reader. The first-stage assay mixture had a total volume of 100 μL and consisted of: (1) 25 μL of hydroxyethylpiperazineethanesulfonic acid buffer, pH 7.4, 5 mM CaCl2, 0.1% BSA; (2) 25 μL of activator (0.25 μg OsPA / mL); and (3) 50 μL of prothrombin (2 uM) to initiate the reaction.

[0451] Every 5 minutes, 10 μL of the first-stage assay mixture was added to 90 μL of 0.2 mM S2238 in an adjacent well of the microplate and the absorbance was monitored for 2 minutes. Under these conditions, the effective extinction coefficient A405 for p-nitroaniline was determined to be 2271 M using a p-nitroaniline standard. -1 This factor is used to convert the rate of increase expressed in absorbance units / s to micromoles S2238 hydrolyzed per second.

[0452] A linear development curve was generated, the slope of which gives the rate of S2238 hydrolysis in phase 1. Using the Michaelis-Menten equation, and substituting literature values ​​for kcat and Km (Sonder SA and Fenton JW, Clin. Chem. 1986, 32(6), 934-937A), these were converted to thrombin concentrations. Replotting these thrombin concentrations against sampling time was also linear, with the slope giving the concentration of prothrombin activator in the phase 2 assay (in units / mL), where 1 unit (U) is the amount of activator required to hydrolyze 1 micromole of prothrombin / minute in the standard assay (e.g., 9.98e-6 micromole / min). The linearity of the rate of thrombin production relative to OsPA concentration was also demonstrated, with the slope giving the specific activity of the prothrombin activator as units / mg of protein (e.g., 5.0e-3 units / mg).

[0453] Example 5.6 - Stability test

[0454] To determine the stability of the formulation under conditions of use, samples were stored under the following conditions: (1) for frozen stability testing: 4°C in a refrigerated environment (a thermostatically controlled cold room); (2) for room temperature stability testing, defined as 25°C (23.5-26.5°C) samples stored at ambient temperature; and (3) for accelerated stability testing: 50°C in a thermostatically controlled oven (49-51°C).

[0455] Example 5.7 - Analyte Measurement

[0456] The following panel of analytes was measured in serum prepared as described herein. The equipment used was a Beckman DxC800 general chemistry analyzer and a Beckman Dx1800 immunoassay analyzer (Beckman Coulter, Brea, CA, USA):

[0457]

[0458]

[0459] Example 6. Stability of Coagulation Compositions Relative to Drying Conditions and Surfactants

[0460] Example 6.1 - Introduction

[0461] This experiment aimed to investigate the effects of drying conditions and the use of surfactant on clotting time. In this example, freshly diluted samples of prothrombin activator (OsPA, 0.25 μg or 1 μg) were placed in Greiner White Top Smooth (Cat. #456001) blood collection tubes (+ / - 2.41 g / L of hydrophilic surfactant 20 μg in water, + / - 0.1% BSA in HEPES buffer). These tubes were prepared according to Example 2 and then tested according to Example 4 with 4 mL of blood from a pool of 50 healthy donors or individual patients and subjected to visual coagulation assays and TEG analysis (according to Example 5). Prior to the blood clotting experiments, the tubes were dried using a vacuum desiccator or Genevac (according to Example 2). All steps were performed at room temperature.

[0462] Example 6.2 - Results and Discussion

[0463] exist Figure 7The results in Figure 2 show the coagulation activity of freshly diluted OsPA in whole blood compared to that of vacuum desiccated OsPA. The D0 data are for freshly diluted liquid samples of OsPA added to blood collection tubes. The D1 data are for samples dried overnight at room temperature in blood collection tubes in a vacuum desiccator as in Example 2. The effects of including surfactant and BSA on fresh samples can be seen following the comparison of the dark column (D0). For control blood samples (no OsPA), adding surfactant and / or BSA to the tubes prior to blood addition had no significant effect on clotting time, as measured using a standard coagulation assay as in Example 5. For samples containing 0.25 μg of OsPA, the presence of surfactant reduced clotting time from 330 to 132 seconds, compared to 180 and 72.5 seconds for 1 μg of OsPA, respectively. BSA alone also significantly reduced clotting time (but not as much as surfactant), but the effects of BSA and surfactant were not additive. Without wishing to be bound by theory, a possible explanation for the effect of the surfactant is that it prevents binding of OsPA to the tube surface in such a way that it is not functionally available.

[0464] For each set of conditions, compare Figure 7 The checkered columns and dark columns (D0 and D1) in the Figures show the effect of drying in a vacuum desiccator, as performed in Example 2, compared to freshly diluted OspA samples. There is generally a loss of clotting activity caused by the drying process. For example, with 1 μg of OsPA, drying increased the clotting time: from 180 to 255 seconds in the absence of surfactant, and from 72.5 to 127.5 seconds in the presence of surfactant. The presence of surfactant and BSA, alone or together, resulted in lower clotting times after drying, but the loss was still significant. In all cases, the tubes with surfactant clotted faster than the tubes without surfactant. For example, a wet sample of 1 μg of OspA without surfactant clotted in 180 seconds, compared to 72 seconds with the addition of surfactant. The same tube with OsPA dissolved in 0.1% BSA and no added surfactant clotted in 97 seconds. This pattern was repeated for both wet and dry samples and suggests that, while colloids such as BSA can improve activity (if the prothrombin activator is in the tube environment), the addition of surfactant is optimal.

[0465] exist Figure 8 The results in the present invention relate to the use of a Genevac vacuum dryer (according to Example 2), which is better than the Figure 7 The vacuum dessicator used in the present invention achieves faster drying of the OsPA sample. For a total volume of 50 μL, the drying time is 30 minutes (as per Example 2). Figure 8As shown, the dried samples had the same clotting time as the corresponding fresh samples. A HEPES control was also included. This experiment demonstrated that drying in the Genevac resulted in 100% retention of clotting activity. Therefore, Genevac drying was used in most subsequent experiments to prepare blood collection tubes containing dried OsPA.

[0466] Figure 8 It was also shown that after 8 days of storage at room temperature, the samples maintained activity as evidenced by clotting times.

[0467] Example 7 - Stability of Coagulation Compositions with Respect to Storage Time

[0468] Example 7.1 - Introduction

[0469] This study investigated the effect of storage time on clotting times. Freshly diluted samples of prothrombin activator (OsPA, 0.25 μg or 1 μg) were placed in Greiner White Top Smooth (code #456001) blood collection tubes (+ / - hydrophilic surfactant (20 μL of 2.41 g / L in water), + / - 0.1% BSA) in HEPES buffer. The tubes were then dried using a Genevac vacuum desiccator (as per Example 2) and stored in a dry environment at room temperature (as per Example 2) for up to 85 days. Whole blood coagulation assays were performed weekly using citrated, pooled blood collected as per Example 4 (as per Example 5). After storage, the tubes were used for blood coagulation assays using visual coagulation and TEG analysis (see Example 5). All procedures were performed at room temperature. Weekly controls were performed using freshly diluted OsPA in liquid form, as well as controls using HEPES buffer alone.

[0470] Example 7.2 - Results

[0471] Table 7 shows the loss of coagulation activity for the 0.25 μg and 1 μg OsPA samples by day 85. Loss of activity sometimes occurred between days 15 and 22.

[0472] Table 7. Coagulation of recalcified citrated whole blood in blood collection tubes containing dry OsPA (χ clotting time in seconds)

[0473]

[0474]

[0475] Example 7.3 - Conclusion

[0476] From Table 7, it can be seen that the control tubes using freshly prepared liquid OsPA consistently gave the expected clotting times throughout the 85-day experimental period (see rows 1, 2, 5, and 6). For the dried samples, the clotting times remained stable for the first three measurements (days 1, 8, and 15). However, at the 22-day time point, there was a significant increase in clotting times, and this loss of clotting activity continued until day 85 (see rows 3, 4, 5, and 6). Thus, this example demonstrates the gradual loss of OsPA activity over time when formulated with only a surfactant, and when blood collection tubes containing OsPA are stored at room temperature.

[0477] Example 8 - Stability of Coagulation Compositions with Respect to Storage Time and Other Additives

[0478] Example 8.1 - Introduction

[0479] This experiment was designed to investigate the effects of ten agents known to stabilize proteins on clotting time under certain conditions. Freshly diluted samples of prothrombin activator (OsPA, 0.25 μg or 1 μg + / - ammonium acetate pH 6.8) were placed in Greiner white top smooth (code #456001) blood collection tubes in HEPES buffer (+ / - hydrophilic surfactant (20 μl of 2.41 g / L in water) + / - 0.5% BSA; and other potential stabilizers: + / - 0.1% PEG; + / - 0.5% + / -1mM glycine / arginine; + / -534nm skin protein; + / -1mM trisodium citrate; + / -0.5% mannitol; + / -0.5% sorbitol; + / -0.5% dextran; + / -0.5% gelatin). The tube was prepared according to Example 2 using The tubes were dried and stored in a dry environment at room temperature for up to 99 days. Whole blood coagulation assays were performed weekly using citrated, pooled blood prepared according to Example 4. After storage, the tubes were used for blood coagulation assays using the visual coagulation method according to Example 5. All steps were performed at room temperature. Weekly controls were performed using freshly diluted OsPA in liquid form, as well as controls using hydroxyethylpiperazine ethanesulfonic acid buffer alone.

[0480] Example 8.2 - Results

[0481] Table 8 shows the loss of coagulation activity for the 1 μg OsPA samples by day 85. Loss of activity sometimes occurred between days 15 and 22.

[0482] Table 8. Coagulation of Recalcified Citrated Whole Blood in Blood Collection Tubes Containing Dry OsPA

[0483]

[0484] Table 8 shows the results of experiments that included storage at room temperature for up to 99 days (over 3 months). The graph shown is the number of seconds required for clot formation. BSA and dextran each stabilized the blood clotting activity of OsPA compared to buffer alone. For example, after 99 days of storage, the clotting times for the OsPA / BSA and OsPA / dextran tubes were 380 and 310 seconds, respectively, compared to the fresh control (95 seconds), OsPA alone (510 seconds), and the control without OsPA (710 seconds). This result demonstrates the ability of 1 μg of OsPA to clot 4 mL of heavily calcified citrated whole blood in approximately 5 minutes after three months of storage at room temperature (with either dextran or BSA). Other reagents that produced some degree of stabilization were sorbitol, Gelatin and mannitol.

[0485] Example 9 - Stability of coagulation composition with respect to storage time, temperature and addition of colloidal Glucoside

[0486] Example 9.1 - Introduction

[0487] In the quest to further improve the stability of the coagulation activity of dry prothrombin activators such as OsPa, the plasma expander Glucocorticoid (B. Braun) is a sterile solution of succinylated gelatin in isotonic saline (4% w / v) and is low-cost and readily available.

[0488] This experiment was designed to investigate the effect of a protein colloid as a stabilizer to maintain clotting time function over time. Tubes were prepared as in Example 2, where the colloid was rolled onto the inner surface of the tube. A sample of freshly diluted prothrombin activator (OsPA, 1 μg + / - ammonium acetate pH 6.8) in 20 μL of Glyoxal pH 7.4 was placed in a Greiner White Top Smooth (Cat. #456001) blood collection tube (+ / - hydrophilic surfactant (20 μL of 2.41 g / L in water). The tubes were then heated using The tubes were dried as in Example 2 and then stored at room temperature for up to 211 days ( Figure 9 and 10 Whole blood prepared according to Example 4 was used for the whole blood coagulation assay and evaluated in this example by the visual coagulation assessment method (according to Example 5). After storage and at each time point, blood samples (citrated, pooled) were aliquoted into tubes with a final volume of 4 mL, and the tubes containing the samples were subjected to the standard whole blood coagulation assay (according to Example 5). All steps were performed at room temperature. In addition to the appropriate controls lacking OsPA, controls were performed at each time point using freshly diluted OsPA in liquid form.

[0489] In addition, 12 tubes were tested using fresh blood (as per Example 4) and by means of a visual coagulation assessment performed as per Example 5. Tubes were prepared as per Example 2 containing a sample of freshly diluted prothrombin activator (OsPA, 1 μg in 20 μL of Oxygenase pH 7.4) + hydrophilic surfactant (20 μL of 2.41 g / L in water) placed in Becton Dickinson smooth (Cat. #3276916) blood collection tubes. The tubes were dried (as per Example 2). The visual clotting time at T0 was 158.9 + / - 95 seconds, which was comparable to experiments performed with citrated blood in BD smooth tubes.

[0490] Example 9.2 - Results and Discussion

[0491] The results are shown in Figure 9 (histogram) and 10 (line graph). After seven months (211 days) at room temperature, the clotting time for 4 mL of blood using 1 μg of OsPA was 265 seconds, compared to 84 seconds for a fresh control and 950 seconds for a recalcified, citrated blood sample control (no additives). Excellent stability was observed up to 121 days, but then there was a loss of activity between the 121-day and 157-day measurements. The slope of the 'dry OsPA' line graph was 1.0 seconds / day (if all time points were considered) and 0.79 seconds / day (if only the time points from day 1 to day 121 were considered).

[0492] The rates of loss of coagulation activity in Example 10 and this example were then compared. The initial rate of activity loss was 1.67 seconds / day in Example 10 (in the presence of BSA and dextran) and 0.79 seconds / day in Example 9 (in the presence of Glucoside, as an exemplary colloid). Considering all data points in each experiment, the corresponding rates were 1.29 in Example 11 and 1.0 in Example 10. These data therefore indicate that colloidal dextran, BSA, and Glucoside effectively stabilize OsPA, with Glucoside appearing to have the greatest effect among the samples tested.

[0493] Example 10 - Stability of coagulation composition with respect to storage time, temperature, and addition of BSA and dextran

[0494] Example 10.1 - Introduction

[0495] This study aimed to investigate the effects of combined stabilizers of BSA and dextran on the preservation of coagulation function over time. Figure 11 and 12). Tubes were prepared as in Example 2. A sample of freshly diluted prothrombin activator (OsPA, 1 μg in 20 μL of ammonium acetate solution containing + / - 0.5% dextran, + / - 0.5% BSA pH 6.8) was placed in a Greiner white top smooth (code #456001) blood collection tube (+ / - hydrophilic surfactant (20 μl of 2.41 g / l in water). The tubes were then placed in a Greiner white top smooth (code #456001) blood collection tube (+ / - hydrophilic surfactant (20 μl of 2.41 g / l in water). The tubes were dried (as per Example 2) and stored at room temperature for up to 195 days (as per Example 5). Whole blood prepared as per Example 4 was used for whole blood coagulation assays, which were assessed in this example by a visual coagulation assessment method (as per Example 5). After storage and at each time point, blood samples (citrated, pooled) were aliquoted into tubes, and a standard whole blood coagulation assay (as per Example 5) was performed on the final volume of 4 ml and the tubes containing the samples. All steps were performed at room temperature. In addition to appropriate controls lacking OsPA, controls were performed using freshly diluted OsPA in liquid form at each time point.

[0496] Example 10.2 - Results and Discussion

[0497] Figure 11 The results of an experiment involving storage at room temperature for up to 195 days (about 6.5 months) are shown as a histogram, and Figure 12 The corresponding line graphs are shown. Comparison of these results with those in Table 8 indicates that BSA and dextran together give greater stabilization than either material alone. After 6.5 months of storage, the clotting time for the OsPA / BSA / dextran tube was 247 seconds compared to the fresh control (83 seconds) and the control without OsPA (957 seconds). Figure 12 The slope of the line graph including all time points is 1.29 seconds / day (increase in clotting time / day). If the last four time points are excluded, the slope is 1.67 seconds / day (R2=0.87).

[0498] Example 11 - Stability of Coagulation Compositions with Respect to Temperature and Addition of Colloidal Xanax

[0499] Example 11.1 - Introduction

[0500] The purpose of this study was to determine the stability of the whole blood coagulation activity of OsPA dried in Glucocorticoids when stored at 50°C. Forced degradation at temperatures higher than normal storage temperature is often used to obtain stability data more rapidly than by storing samples at elevated storage temperatures for a defined period of time. The rate of activity loss at higher temperatures can then be extrapolated to normal storage temperature, for example, by using the Arrhenius equation.

[0501] The authors also determined the stability of OsPA when dried in Glyoxetine at pH 7.4, and the effect of adjusting the pH of Glyoxetine to 6.0. The reason for studying the effect of a lower pH was to explore the possibility that the Factor Xa component of OsPA could catalyze the proteolysis of OsPA with a concomitant loss of activity. The catalytic activity of OsPA was lower at pH 6.0 than at pH 7.4.

[0502] Tubes were prepared according to Example 2. Two sets of samples were prepared, one using Greiner white top smooth (code #456001) blood collection tubes and the other using BD red top smooth blood collection tubes (code #3276916). For each set of samples, freshly diluted prothrombin activator (OsPA, 1 μg, 2 μg, or 5 μg) was placed in the tube + / - hydrophilic surfactant (20 μL of 2.41 g / L in water) + / - 50 μL of 4% w / v Glycerol; and buffered to pH 7.4 or pH 6.0. The tubes were then used. The tubes were dried (as per Example 2) and stored at room temperature for up to 211 days (as per Example 2). Whole blood prepared as per Example 4 was used for whole blood coagulation assays, which were assessed in this example by visual coagulation assessment (as per Example 5). After storage and at each time point, blood samples (citrated, pooled) were aliquoted into tubes, and a standard whole blood coagulation assay (as per Example 5) was performed on the final volume of 4 ml and the tubes containing the samples. All steps were performed at room temperature. At each time point, controls were performed using freshly diluted OsPA in liquid form, in addition to appropriate controls lacking OsPA.

[0503] Example 11.2 - Results and Discussion

[0504] Figure 13 and 14 The results of a 50° C. stability test using a BD tube are shown. Figure 15-18 The results are shown with the aid of a Greiner tube.

[0505] Based on these results, the corresponding experiments in Greiner tubes were modified to use a single amount of OsPA (1 μg). Figure 15 The results of 18 (pH 7.4) and 18 (pH 6.0) showed that OsPA was much more stable in Greiner tubes than in BD tubes (compare Figure 13 and 15 as well as Figure 14 and 16 ). Therefore, the experiment was continued for 30 days instead of the 7-day cutoff for the BD experiment.

[0506] After 30 days, the clotting time for the 50°C tubes was 153.5 seconds compared to 117.5 seconds for the tubes kept at room temperature and 83.5 seconds for the fresh control ( Figure 16 ). Figure 15 and 16 Comparison of the data also suggests that adjusting the pH to 6 has a smaller beneficial effect (see Figure 13 and 14 ).

[0507] exist Figure 13 Results in [ 1 ] showed that maintaining BD tubes containing OsPA at 50°C resulted in a progressive loss of activity, such that a high percentage of the initial activity was lost by day 7. Similar results were obtained with 1, 2, or 5 μg of OsPA, except that a higher percentage of the initial activity was lost in the 5 μg tubes than in the 2 μg tubes, which in turn lost more activity than the 1 μg tubes. This result is consistent with earlier suggestions that OsPA's proteolytic activity may lead to autodegradation, which occurs more rapidly at higher concentrations. Another possible reason for this concentration-dependency of activity loss is that the amount of Glyoxal / tube was the same in all tubes, while the amount of OsPA varied from 1 to 5 μg. A higher ratio of Glyoxal to OsPA may have conferred better protection. Figure 14 Similar results were obtained when the pH of Glyoxal was adjusted from 7.4 to 6.0 before the addition of OsPA and drying. However, a comparison of clotting times after 1 and 7 days of storage at 50°C suggested that there was a slightly slower loss of activity at pH 6 than at pH 7.4. This is also consistent with the "proteolytic loss of activity" hypothesis.

[0508] The results clearly show that activity loss is greater in BD tubes than in Greiner tubes. One possible reason is that the surfactant used may not be suitable for the type of plastic used in BD tubes. It should be noted that the rate of activity loss in Greiner tubes at 50°C was not significantly greater than the rate of loss in the corresponding experiment at room temperature. This may be due to excess moisture in the membrane at lower temperatures. It should be noted that commercially produced blood collection tubes are sealed under vacuum, which can limit the amount of moisture in the surface membrane.

[0509] Will be in Figure 15 and 16 The clotting time in the Figure 17 and 18 To determine the rate of activity loss at 50°C. Figure 17 The slope of the best fit line for the 50°C data in Example 9 is an increase in clotting time of 1.86 seconds / day of storage. The corresponding slope for room temperature storage in Example 9 is 0.79 seconds / day (based on the initial rate).

[0510] Example 12 - Stability of Coagulation Compositions Relative to Radiation

[0511] Example 12.1 - Introduction

[0512] Irradiation is routinely used in the commercial production of standard blood collection tubes as a sterilization method. This study aimed to investigate the effects of gamma irradiation on OsPA at an industrially relevant dose of 15 kGy. The experiment was conducted in two parts: Part 1: OsPA combined with Glucor, and Part 2: OsPA and snake venom-derived ecarin combined with Glucor and trehalose.

[0513] In Part 1, tubes were prepared according to Example 2. Freshly diluted prothrombin activator (OsPA, 1 μg or 5 μg) was placed in Greiner white-top blood collection tubes (code #456001) with a hydrophilic surfactant (20 μL of 2.41 g / L in water) and 50 μL of 4% w / v Glycerol; hydroxyethylpiperazine ethanesulfonic acid buffer, pH 7.4, or hydroxyethylpiperazine ethanesulfonic acid buffer, pH 7.4, 0.5% dextran, and 0.5% BSA. The tubes were then dried using a vacuum desiccator (according to Example 2) and stored at room temperature while irradiating (according to Example 3). Eight tubes were made using each formulation, four for irradiation (according to Example 3) and four for storage at room temperature (according to Example 2).

[0514] The tubes to be irradiated were sent to the irradiation facility on day 1 after preparation. After irradiation with 15 kGy, the tubes were returned and assayed on day 8. Irradiation was performed according to Example 3 at a Gammacell 220 irradiation facility (ANSTO, Building 23, New lllawarra Road, Lucas Heights, NSW 2234, Australia): 7.88 hours at 1.92 kGy / h and 7.88 hours at 23.4° C., delivering a total dose of 15.1 kGy.

[0515] For Part 2, tubes were prepared according to Example 2, including coating with a hydrophilic surfactant. Prothrombin activators (OsPA or ecarin) were prepared by diluting the concentrated solution into Glycerol containing 6% or 10% trehalose. Twenty μL aliquots containing 1 μg or 5 μg of OsPA or 2 IU of ecarin were placed in Greiner white-top smooth tubes (code number 456001) and BD red-top additive-free tubes (code number 366408). The tubes were then dried using a Genevac (according to Example 2) and stored at room temperature while irradiation was performed (according to Example 3). Thirty-two tubes containing OsPA and eight tubes containing ecarin were manufactured, twenty of which were used for irradiation (according to Example 3) and twenty were stored at room temperature (according to Example 2).

[0516] The tubes to be irradiated were sent back to the irradiation facility on day 1 after preparation. After irradiation with 15 kGy on day 8, the tubes were returned and tested on day 20. Irradiation was performed at a Gammacell 220 irradiation facility (ANSTO, Building 23, New lllawarra Road, Lucas Heights, NSW 2234, Australia) according to Example 3: 7.88 hours at 1.92 kGy / h and 7.88 hours at 23.4°C, delivering a total dose of 15.1 kGy.

[0517] Whole blood prepared according to Example 4 was used for the whole blood coagulation assay, which was evaluated in this example by the visual coagulation assessment method (according to Example 5). All steps were performed at room temperature. In addition to the appropriate controls lacking OsPA, controls were performed using freshly diluted OsPA in liquid form. After 35 minutes, all tubes containing coagulated blood were centrifuged. Serum from individual tubes was imaged and collected for biochemical analyte testing.

[0518] Example 12.2 - Part 1 Results and Discussion

[0519] The results in Figure 19 show that 15 kGy irradiation resulted in a substantial loss of coagulation activity in all samples containing 1 μg of OsPA. Axioxetine conferred significant protection of coagulation activity, i.e., tubes retained approximately 20% of the activity of non-irradiated tubes, whereas in the HEPES buffer alone, nearly all activity was lost. Dextran and BSA conferred protection of coagulation activity in both the HEPES buffer and Axioxetine. Axioxetine did so to a greater extent. There was also some loss of activity in tubes that had been dried and stored at room temperature but not irradiated ( Figure 19A), which is consistent with earlier experiments showing a loss of activity when samples were dried in a vacuum desiccator. This did not significantly affect the results in the Gelfusine tubes or in the tubes containing hydroxyethyl piperazine ethanesulfonic acid along with BSA and dextran. However, with hydroxyethyl piperazine ethanesulfonic acid alone, the tube containing 1 μg of OsPA lost most of its activity without irradiation, confirming earlier tests.

[0520] exist Figure 4 The concentration dependence of the clotting time shown in Figure 19 allows an estimate of how much coagulation activity has been lost due to irradiation. For example, the clotting time of the irradiated tube containing 5 μg of OsPA was 134 seconds (Figure 19a). The clotting time in the tube containing 0.3 μg of OsPA was 137 seconds (Figure 19b). Figure 4 Thus, after irradiation, the activity of 5 μg of OsPA was roughly the same as that of 0.3 μg of fresh OsPA. Similarly, 1 μg of irradiated OsPA in Glyoxal gave a clotting time of 733 seconds, compared to 744 seconds for 0.05 μg of fresh OsPA.

[0521] Example 12.3 - Part 2 Results and Discussion

[0522] Figure 19B Results of experiments performed with OsPA tubes formulated with 6% or 10% trehalose are shown. The results show that 15 kGy of radiation resulted in some loss of coagulation activity in all samples at day 12 after irradiation. However, compared to Figure 19A The results show that 6% and 10% trehalose-containing Glucoside significantly protected the coagulation activity of OsPA. Furthermore, after irradiation, the coagulation time of 1 μg of OsPA dried in 10% trehalose-containing Glucoside was approximately 5 minutes.

[0523] exist Figure 19C The results in

[15] showed that 15 kGy of radiation did not affect the coagulation activity of ecarin at 2 IU dried in 10% trehalose.

[0524] Example 13 - Stability of Coagulation Compositions Relative to Radiation II

[0525] This experiment aimed to investigate the effects of gamma irradiation on OsPA at an industrially relevant dose of 25 kGy using tubes formulated with Ecarin. The experiment was conducted in two parts: Part 1: Ecarin in combination with Glyoxaline, and Part 2: The stability of the irradiated tubes at room temperature.

[0526] In Part 1, tubes were prepared according to Example 2. Freshly diluted Ecarin 2U was placed in Greiner white-top blood collection tubes (Cat. #456001) plus hydrophilic surfactant (20 μL of 2.41 g / L in water) and 20 μL of 4% w / v Glycerol. The tubes were then dried using a Genevac (as per Example 2) and stored at room temperature while irradiating according to Example 3.

[0527] The tubes to be irradiated were sent to the irradiation facility on day 1 after preparation. After 25 kGy irradiation, the tubes were returned and assayed on day 7. Irradiation was performed according to Example 3 at a Gammacell 220 irradiation facility (ANSTO, Building 23, New lllawarra Road, Lucas Heights, NSW 2234, Australia).

[0528] For Part 2, tubes with and without radiation treatment were stored at room temperature (as per Example 2).

[0529] Whole blood prepared according to Example 4 was used for whole blood coagulation assays, which were evaluated in this example by the visual coagulation assessment method (according to Example 5). All steps were performed at room temperature. In addition to the appropriate controls lacking OsPA, controls were performed using freshly diluted OsPA in liquid form. After 35 minutes, all tubes containing coagulated blood were centrifuged.

[0530] Example 13.1 - Results and Discussion

[0531] exist Figure 20 The results in the example show that, in samples containing 2 U of Ecarin, irradiation with 25 kGy resulted in a slight loss of coagulation activity at day 7 (123 seconds) compared to dry and non-irradiated (119 seconds). After 212 days at room temperature, there was again a small difference between the irradiated tubes compared to those that were not irradiated (264 seconds compared to 254 seconds). This example demonstrates the stability of the prothrombin activator Ecarin in an appropriate formulation in the presence of irradiation and subsequent long-term storage at room temperature.

[0532] Example 14 - Stability of Coagulation Compositions with Respect to Storage Time, Temperature, and Other Additives II

[0533] Example 14.1 - Introduction

[0534] Experiments were conducted to determine whether the stability of OsPA could be enhanced by the use of sugars and other additives when stored or shipped at room temperature and at elevated temperatures, such as 50°C. Tubes were prepared as in Example 2. 1 μg of freshly diluted OsPA was placed in Greiner white top smooth blood collection tubes (code #456001) (+ hydrophilic surfactant (20 μL of 2.41 g / L in water) + / - 20 μL of 4% w / v Glycerol, and containing 10% trehalose, mannose, sucrose, and sorbitol, 1 mM benzamidine, and 0.1 mM EDTA. In Part 1, the tubes were then dried using a vacuum desiccator (as in Example 2) and stored at 50°C for up to 71 days (see Table 1). Figure 21 In part 2, the tubes were then dried using a vacuum desiccator (as per Example 2) and stored at room temperature for up to 392 days (see Figure 22 In Part 3, additional tubes were prepared according to Example 2 using OsPA 1 μg in BD Red Top Smooth Blood Collection Tubes (Cat. #3276916) + hydrophilic surfactant (20 μL of 2.41 g / L in water) + 20 μL of 4% w / v Glycerol and 6 or 10% galactose. In Part 3, the tubes were then dried using a Genevac vacuum desiccator (according to Example 2) and stored at room temperature for 22 days (see Figure 23 ).

[0535] Whole blood prepared according to Example 4 was used for whole blood coagulation assays and assessed by visual coagulation assessment (according to Example 5). After storage, blood samples (citrated, pooled) were aliquoted into tubes with a final volume of 4 mL. The tubes containing the samples were then subjected to a standard whole blood coagulation assay (according to Example 5). All steps were performed at room temperature. Controls were performed using freshly diluted OsPA at each time point, in addition to appropriate controls lacking prothrombin activator.

[0536] Example 14.2 - Part 1 - Results and Discussion

[0537] Figure 21A time course is shown, with a major loss of OsPA activity observed in all samples by day 7 when the samples were dried in a vacuum desiccator. Subsequent storage at 50°C did not result in further loss of activity. Indeed, some samples showed partial recovery of activity. It is possible that the initial loss of activity may have been due to incomplete drying of the samples, with the presence of moisture being the cause. After 10 weeks at 50°C, samples containing trehalose had a clotting time of 367 seconds, while samples containing other sugars had clotting times of approximately 580-600 seconds after the same period. This is highly encouraging for the hypothesis that initial loss of activity can be prevented and suggests that agents, such as colloids containing stabilizing additives, can effectively stabilize the activity of prothrombin activators when stored at elevated temperatures for extended periods.

[0538] Example 14.3 - Part 2 - Results and Discussion

[0539] Figure 22 This indicates that while the drying process resulted in a decrease in activity at T0, samples formulated with trehalose and sucrose showed retained activity for 425 seconds after subsequent storage for 392 days at room temperature. Formulations with other additives appear to have a negative impact on coagulation activity. This is highly encouraging for the hypothesis that initial loss of activity can be prevented and suggests that agents such as colloids with stabilizing additives can effectively stabilize the activity of prothrombin activators when stored at commercially relevant temperatures for extended periods.

[0540] Example 14.4 Part 3 - Results and Discussion

[0541] Figure 23 This suggests that galactose appears to have a protective effect on the drying process at T 0 when formulated with galactose. Although stored at room temperature for only 22 days, the results show an improvement in clotting time with 10% galactose, suggesting that the stabilizing effect on OsPA can be present over an extended period.

[0542] Example 15: Stability of Coagulation Compositions with Respect to Storage Time, Temperature, and Other Additives III

[0543] Example 15.1 - Introduction

[0544] Experiments were conducted to determine whether the stability of Ecarin could be enhanced by the use of sugars and other additives when stored or shipped at room temperature. Tubes were prepared as in Example 2. Freshly diluted Ecarin 1 U was placed in Greiner white top smooth blood collection tubes (code #456001) (+ hydrophilic surfactant (20 μL of 2.41 g / L in water) + / - 20 μL of 4% w / v Glycerol, and containing 10% trehalose, mannose, sucrose and sorbitol, 1 mM benzamidine and 0.1 mM EDTA. The tubes were then dried using a vacuum desiccator (as in Example 2) and stored at room temperature for up to 392 days (see Figure 23 ).

[0545] Recalcified, citrated whole blood prepared according to Example 4 was used for whole blood coagulation assays and assessed by visual coagulation assessment (according to Example 5). After storage, the blood samples (citrated, pooled) were aliquoted into tubes with a final volume of 4 mL. The tubes containing the samples were then subjected to a standard whole blood coagulation assay (according to Example 5). All steps were performed at room temperature. At each time point, controls were performed using freshly diluted OsPA in addition to appropriate controls lacking prothrombin activators.

[0546] Example 15.2 - Results and Discussion

[0547] Figure 24 This indicates that while the drying process resulted in a decrease in activity at T0, subsequent storage at room temperature for 392 days revealed that activity was retained for 350 seconds in samples formulated with trehalose and sucrose. While OspA was used as the activator, formulations with other additives appeared to have a negative impact on coagulation activity, although this was less pronounced in Example 13. This is also highly encouraging for the hypothesis that initial loss of activity can be prevented and suggests that agents, such as colloids containing stabilizing additives, can effectively stabilize the activity of prothrombin activators when stored at commercially relevant temperatures for extended periods.

[0548] Example 16 - Effect of Jialeshi on Analyte Detection

[0549] Example 16.1 - Introduction

[0550] This study aimed to determine whether the addition of Glucocorticoid to blood collection tubes had any clinically significant effect on the ability to detect a range of biochemical analytes.

[0551] The following tube samples were prepared according to Example 2 in the following tubes: Greiner white top smooth tubes (code number 456001, Greiner red top serum tubes (code number 456092), BD red top smooth tubes (code number 3276916), and BD no additive tubes (code number 366408): (1) Greiner smooth tubes with OsPA + hydrophilic surfactant A in hydroxyethyl piperazine ethanesulfonic acid buffer, (2) Greiner smooth tubes with OsPA + galactose + hydrophilic surfactant A, (3) BD smooth tubes with hydroxyethyl piperazine ethanesulfonic acid buffer OsPA + hydrophobic surfactant in the flush solution; (4) BD smooth tube with OsPA + Glycerol + hydrophobic surfactant, (5) Greiner serum tube, (6) Greiner serum tube + Glycerol, (7) Greiner serum tube + OsPA in hydroxyethylpiperazine ethanesulfonic acid buffer, (8) Greiner serum tube + OsPA + Glycerol, (9) BD serum tube, (10) BD serum tube + Glycerol, (11) BD serum tube + OsPA in hydroxyethylpiperazine ethanesulfonic acid buffer, and (12) BD serum tube + OsPA + Glycerol.

[0552] Each of these tube samples was then tested for a range of analytes as shown in Table 9. The analytes were tested as in Example 5.

[0553] Example 16.2 - Results and Discussion

[0554] The results are shown in Table 9. OsPA added to the top of the commercial serum tubes (Greiner tubes 7 and 8 and BD tubes 11 and 12) maintained normal analyte detection. The addition of Glucocorticoid had no clinical impact on any of the measured analytes. Therefore, the addition of Glucocorticoid to the blood collection tubes appears to have no effect on the ability to detect analytes.

[0555] Table 9 - Detection of Analytes Using Glyoxetine in Blood Collection Tubes

[0556]

[0557]

[0558] References

[0559] 1. Arkin, AP, Youvan, DC, "An algorithm for protein engineering: simulations of recursive ensemble mutagenesis" 1992 Proc. Natl. Acad. Sci. USA 89: 7811-7815.

[0560] 2.Atherton,E.,Shephard,R.C,Solid Phase Peptide Synthesis-A PracticalApproach 1989,IRL Press,Oxford England.

[0561] 3.Ausubel et al.,CurrentProtocols in MolecularBiology,GreenePubl.Assoc.and Wiley-Intersciences,1992.

[0562] 4.Bos,M.H.A.,Boltz,M.,St Pierre,L.,Masci,P.P.,de Jersey,J.,Lavin,M.F.,Camire,R.M.,“Venom factor V from the common brown snake escapeshemostatic regulation through procoagulant adaptations”Blood 16July 2009;114(3):686-692.

[0563] 5.Dayhoff,M.O.,Schwartz,R.M.,Orcutt,B.C.,et al.,“A model ofevolutionary change in proteins.Matrices for determining distancerelationships”1978In Atlas of protein sequence and structure(Dayhoff,M.O.ed.),vol 5,pp345-358,National Biomedical Research Foundation,WashingtonDC.

[0564] 6.Delagrave,S.,Goldman,E.R.,Youvan,D.C.,“Recursive ensemblemutagenesis”Apr 1993Protein Eng.6(3):327-31.

[0565] 7.Dimeski G.A commentary on the effect oflipid emulsions onpathologytests.Br J Anaesth 2009;64:1033-6.

[0566] 8.Dimeski G,Bird R.Hyperleukocytosis:Pseudohyperkalaemia and otherbiochemical abnormalities in hyperleukocytosis.Clin Chem Lab Med 2009;47:880-1.

[0567] 9.Dimeski G,McWhinney B,Jones B,Mason,R,Carter A.Extent ofbilirubininterference in Beckman-Coulter creatinine methods.Ann Clin Biochem 2008;45:91-2.

[0568] 10.Dimeski G,Masci PP,Trabi M,Lavin MF,de Jersey J.Evaluation oftheBecton-Dickinson Rapid Serum Tube:Does it provide a suitable alternative tolithium heparinplasma tubes?Clin Chem Lab Med 2010;48:651-6.

[0569] 11.Dimeski G,Badrick T,Flatman R,Ormiston B.The Roche IFCC Methodsfor Lactate Dehydrogenase tested for duplicate errors using Greiner and BDLithium-Heparin and Greinerserum samples.Clin Chem 2004;50:2391-2.

[0570] 12.Dimeski G,Clague AE,Hickman PE.Correcting and reporting ofpotassium results in haemolysedsamples.Ann Clin Biochem 2005;42:119-123.

[0571] 13.Filippovich,I.,Sorokina,N.,St Pierre,L.,Filght,S.,de Jersey,J.,Perry,N.,Masci,P.P.,Lavin,M.F.“Cloning and functional expression of venomprothrombin activator protease from Pseudonaja textilis with whole bloodprocoagulant activity”British Journal ofHaematology 2005;131:237-246.

[0572] 14.Gonnet,G.H.,Cohen,M.A.,Benner,S.A.,“Exhaustive matching of theentire protein sequence database”Jun 51992 Science 256(5062):1443-5.

[0573] 15.Jackson CM,Suttie JW,“Recent developments in understanding themechanism of vitamin K and vitamin K-antagonist drug action and theconsequences of vitamin K action in blood coagulation”,Prog Hematol.1977;10:333-59.

[0574] 16.Kini RM,Morita T,Rosing J.Classification and nomenclature ofprothrombin activators isolated from snake venoms.Throm Haemost 2001;86:710-711.

[0575] 17.Kini RM.The intriguining world of prothrombin activators fromsnake venom.Toxicon 2005;45:1133-45.

[0576] 18.Kunkel,T.A.,“Rapid and Efficient site-specific mutagenesis withoutphenotypic selection”1985 Proc.Natl.Acad.Sci.USA,82:488-492.

[0577] 19.Kunkel,T.A.,Roberts,J.D.,Zakour,R.A.,“Rapid and Efficient site-specific mutagenesis without phenotypic selection”1987 Methods inEnzymol.154:367-382.

[0578] 20.Masci,P.P.,“The Effects ofAustralian Snake Venoms on Coagulationand Fibrinolysis”Thesis for Masters of Science in the subject ofBiochemistry,July1986,University ofQueensland,St Lucia,Brisbane,Australia.

[0579] 21.Masci PP,Whitaker AN,de Jersey J.Purification and characterizationof a prothrombin activator from the venom of the Australian brown snakePsuedonaja textilis textilis.Biochem Int 1988;17:825-835.

[0580] 22.Masci PP,WhitakerAN,Sparrow LG,de Jersey J,Winzor DJ,Watters DJ,Lavin MF,Gaffney PJ,“Textilinins from Pseudonaja textilistextilis.Characterization oftwo plasmin inhibitors that reduce bleeding in ananimal model”,2000 Jun;11(4):385-93.

[0581] 23.Morita T,Iwanaga S.Purification and properties of prothrombinactivator from venom ofEchis carinatus.J Biochem 1978;83:559-570.

[0582] 24.Morita,T.,Iwanaga,S.,“Prothrombin activator from Echis carinatusvenom”Meth Enzymol 1981;80-pt.C:303-311.

[0583] 25.Nishida,S.,Fujita,T.,Kohno,N.,Atoda,H.,Morita,T.,Takeya,H.,Kido,I.,Paine,M.J.I.,Kawabata,S-i.,Iwanaga,S.“cDNA Cloning and Deduced Amino AcidSequence of Prothrombin Activator(Ecarin)from KenyanEchis carinatus venom.”Biochemistry 1995;34:1771-1778.

[0584] 26.Rao VS,Kini RM.Pseutarin C,a prothrombin activator from Pseudonajatextilis venom:its structural and functional similarity to mammaliancoagulation factor Xa-Va complex.Thromb Haemost 2002;88:611-9.

[0585] 27.Roberge,J.Y.,Beebe,X.,Danishefsky,S.J.,“A strategy for aconvergent synthesis of N-linked glycopeptides on a solid support”Science1995269(5221);202-204.

[0586] 28.Rosing J,Tans G.Inventory of exogenous prothrombin activators.Forthe Subcommittee on Nomenclature of Exogenous Hemostatic Factors of theScientific and Standardization Committee of the International Society onThrombosis and Haemostasis.Thromb Haemost 1991;65:627-30.

[0587] 29.Rosing J,Tans G.Structural and functional properties of snakevenom prothrombin activators.Toxicon 1992;30:1515-27.

[0588] 30.Sambrook et al.,Molecular Cloning:A Laboratory Manual,Cold SpringHarbor,New York,2001

[0589] 31.Scaros,O.and Fisler,R.“Biomarker technology roundup:from discoveryto clinical applications,a broad set oftools is required to translate fromthe lab to the clinic”Biotechniques 2005;38;S30–S32.

[0590] 32.Speijer H,Govers-Riemslag JW,Zwaal RF,Rosing J.Prothrombinactivation by an activator from the venom of Oxyuranus scutellatus(Taipansnake).J Biol Chem 1986;261:13258-67.

[0591] 33.St Pierre L,Masci PP,Filippovich I,Sorokina N,Marsh N,Miller DJ,Lavin MF.Comparative analysis of prothrombin activators from the venom ofAustralian elapids.Mol Biol Evol 2005;22:1853-64.

[0592] 34.Tans,G.,Govers-Riemslag,J.W.,van Rijn,J.L.,Rosing,J.J.,“Purification and properties of a prothrombin activator from the venomofNotechis scutatus scutatus”Biol.Chem.1985 Aug 5;260(16):9366-72.

[0593] 35.Watson,J.D.,Hopkins,N.H.,Roberts,J.W.,Steitz,J.A.,Weiner,A.M.Molecular Biology of the Gene.fourth edition,1987 The Benjamin / CummingsPublishing Co.,Inc.,Menlo Park,California.

[0594] 36.Yamada D,Sekya F and Morita T.Isolation and characterization ofcarinactivase,a novel prothrombin activator in Echis carinatus venom with aunique catalytic mechanism.J Biol Chem 1996;271:5200-7.

[0595] 37.Yamada,D.,Morita,T.,“Purification and Characterization of a Ca2+-Dependent Prothrombin Activator,Multactivase,from the Venom of Echismultisquamatus”J.Biochem.1997;122:991-997.

[0596] 38. Yamanouye, N., Kerchove, CM, Moura-da-Silva, AM, Carneiro, SM, Markus, RP,

[0597] 39.Yonemura,H.,Imamura,T.,Soejima,K.,Nakahara,Y.,Morikawa,W.,Ushio,Y.,Kamachi,Y.,Nakatake,H.,Sugawara,K.,Nakagaki,T.,Nozaki,C.,“PreparationofRecombinantα-Thrombin:High-Level Expression of Recombinant HumanPrethrombin-2 and Its Activation by Recombinant Ecarin”J.Biochem.2004:135:577-582.

[0598] 40.EP 0628816

[0599] 41.US 4,227,620

[0600] 42.US 4,256,120

[0601] 43.US 4,873,192

[0602] 44.US 6,187,553

[0603] 45.US 6,413,737

[0604] 46.US 6,416,717

[0605] 47.US 6,592,613

[0606] 48.US 6,686,204

[0607] 49.US 7,488,287

[0608] 50.US 7,699,828

[0609] 51.US 8,586,323. Sequence Listing <110> Q-Sierra Co., Ltd. <120> Improved coagulation composition <130> 41531QSE / VPB <160> 57 <170> PatentIn version 3.4 <210> 1 <211> 609 <212> PRT <213> saw-scaled viper <400> 1 Met Ile Gln Ile Leu Leu Val Ile Ile Cys Leu Ala Val Phe Pro Tyr 1 5 10 15 Gln Gly Cys Ser Ile Ile Leu Gly Ser Gly Asn Val Asn Asp Tyr Glu 20 25 30 Val Val Tyr Pro Gln Lys Val Thr Ala Leu Pro Lys Gly Ala Val Gln 35 40 45 Gln Pro Glu Gln Lys Tyr Glu Asp Ala Met Gln Tyr Glu Phe Glu Val 50 55 60 Lys Gly Glu Pro Val Val His Leu Glu Lys Asn Lys Glu Leu Phe Ser 65 70 75 80 Glu Asp Tyr Ser Glu Thr His Tyr Ser Ser Asp Asp Arg Glu Ile Thr 85 90 95 Thr Asn Pro Ser Val Glu Asp His Cys Tyr Tyr His Gly Arg Ile Gln 100 105 110 Asn Asp Ala Glu Ser Thr Ala Ser Ile Ser Ala Cys Asn Gly Leu Lys 115 120 125 Gly His Phe Lys Leu Arg Gly Glu Thr Tyr Phe Ile Glu Pro Leu Lys 130 135 140 Ile Pro Asp Ser Glu His Ala Val Tyr Lys Tyr Glu Asn Ile Glu Asn 145 150 155 160 Glu Asp Glu Ala Pro Lys Met Cys Gly Val Thr Gln Asp Asn Trp Glu 165 170 175 Ser Asp Glu Pro Ile Lys Lys Thr Leu Gly Leu Ile Val Pro Pro His 180 185 190 Glu Arg Lys Phe Glu Lys Lys Phe Ile Glu Leu Val Val Val Val Asp 195 200 205 His Ser Met Val Thr Lys Tyr Asn Asn Asp Ser Thr Ala Ile Arg Thr 210 215 220 Trp Ile Tyr Glu Leu Asn Thr Val Asn Glu Ile Tyr Leu Pro Phe Asn 225 230 235 240 Ile Arg Val Ala Leu Val Gly Leu Glu Phe Trp Cys Asn Gly Asp Leu 245 250 255 Ile Asn Val Thr Ser Thr Ala Asp Asp Thr Leu His Ser Phe Gly Glu 260 265 270 Trp Arg Ala Ser Asp Leu Leu Asn Arg Lys Arg His Asp His Ala Gln 275 280 285 Leu Leu Thr Asn Val Thr Leu Asp His Ser Thr Leu Gly Ile Thr Phe 290 295 300 Val Tyr Gly Cys Lys Ser Asp Arg Ser Val Glu Leu Ile Leu Asp Tyr 305 310 315 320 Ser Asn Ile Thr Phe Asn Met Ala Tyr Ile Ile Ala His Glu Met Gly 325 330 335 His Ser Leu Gly Met Leu His Asp Thr Lys Phe Cys Thr Cys Gly Ala 340 345 350 Lys Pro Cys Ile Met Phe Gly Lys Glu Ser Ile Pro Pro Pro Lys Glu 355 360 365 Phe Ser Ser Cys Ser Tyr Asp Gln Tyr Asn Lys Tyr Leu Leu Lys Tyr 370 375 380 Asn Pro Cys Ile Leu Asp Pro Pro Leu Arg Lys Asp Ile Ala Ser Pro 385 390 395 400 Ala Val Cys Gly Asn Glu Ile Trp Glu Glu Gly Glu Glu Cys Asp Cys 405 410 415 Gly Ser Pro Ala Asp Cys Arg Asn Pro Cys Cys Asp Ala Ala Thr Cys 420 425 430 Lys Leu Lys Pro Gly Ala Glu Cys Gly Asn Gly Glu Cys Cys Asp Lys 435 440 445 Cys Lys Ile Arg Lys Ala Gly Thr Glu Cys Arg Pro Ala Arg Asp Asp 450 455 460 Cys Val Ala Glu His Cys Thr Gly Gln Ser Ala Glu Cys Pro Arg Asn 465 470 475 480 Glu Phe Gln Arg Asn Gly Gln Pro Cys Leu Asn Asn Ser Gly Tyr Cys 485 490 495 Tyr Asn Gly Asp Cys Pro Ile Met Leu Asn Gln Cys Ile Ala Leu Phe 500 505 510 Ser Pro Ser Ala Thr Val Ala Gln Asp Ser Cys Phe Gln Arg Asn Leu 515 520 525 Gln Gly Ser Tyr Tyr Gly Tyr Cys Thr Lys Glu Ile Gly Tyr Tyr Gly 530 535 540 Arg Phe Pro Cys Ala Pro Gln Asp Val Lys Cys Gly Arg Leu Tyr Cys 545 550 555 560 Leu Asp Asn Ser Phe Lys Lys Asn Met Arg Cys Lys Asn Asp Tyr Ser 565 570 575 Tyr Ala Asp Glu Asn Lys Gly Ile Val Glu Pro Gly Thr Lys Cys Glu 580 585 590 Asp Gly Lys Val Cys Ile Asn Arg Lys Cys Val Asp Val Asn Thr Ala 595 600 605 Tyr <210> 2 <211> 63 <212> PRT <213> Rough-scaled pit viper <400> 2 Ser His Asp Asn Ala Gln Leu Leu Thr Ala Ile Lys Ala Tyr Ile Ala 1 5 10 15 Thr Met Cys Asp Pro Lys Met Ala Val Ile Met Ala His Glu Ile Gly 20 25 30 His Gly Gly Tyr Tyr Gly Tyr Cys Arg Lys Ile Pro Cys Ala Pro Glu 35 40 45 Asp Val Lys Asp Asp Asp Ile Gly Met Val Leu Pro Gly Thr Lys 50 55 60 <210> 3 <211> 32 <212> PRT <213> saw-scaled viper <220> <221> misc_feature <222> (23)..(23) <223> Xaa can be any naturally occurring amino acid <220> <221> misc_feature <222> (25)..(25) <223> Xaa can be any naturally occurring amino acid <400> 3 Ser Arg Lys Gln Lys Phe Asp Lys Lys Phe Ile Lys Leu Val Ile Val 1 5 10 15 Val Asp His Ser Met Val Xaa Lys Xaa Asn Asn Asp Leu Ile Ala Ile 20 25 30 <210> 4 <211> 29 <212> PRT <213> Echis carinatus <400> 4 Asp Cys Leu Pro Gly Trp Ser Val Tyr Glu Gly Arg Cys Tyr Lys Val 1 5 10 15 Phe Asn Gln Lys Thr Trp Lys Ala Ala Glu Lys Phe Cys 20 25 <210> 5 <211> 4737 <212> DNA <213> Pseudonaja textilis <400> 5 gagccacaga atacatttat gtggggaagt ggcaagttgc tgcaggcaga actgactttt 60 gtatatcttt cagcacatta gcctcaatgg gaagatacag tgtgagccct gtccccaaat 120 gtcttctact gatgttcctg ggttggtcag ggctgaagta ttacgaagtg aatgcagctc 180 agctcaggga gtaccatata gctgctcagc tggaagactg ggattacaac ccccaacctg 240 aggagctatc cagattatca gagtcagatc ttacgtttaa aaaaattgtc tatagagaat 300 atgaactaga tttcaaacaa gagaagccaa gagatgagct ctcagggctc ctagggccaa 360 cactacgtgg agaagtggga gacatcctca taatttattt caagaatttt gctactcagc 420 ctgtgagcat tcacccgcag agtgccgtgt acaacaaatg gtcagaaggt tcttcatatt 480 ctgatggaac atcagatgtg gaaagactgg atgatgctgt gcctccaggc cagtcgttca 540 agtatgtgtg gaatatcact gcagaaattg ggccaaagaa agctgatcct ccctgtctca 600 cttatgcgta ctactcacat gtaaacatgg tgcgagactt taattctggt ctcattggtg 660 ctttgctgat atgtaaagaa ggaagcctga atgcaaatgg ttcacaaaaa ttcttcaaca 720 gagaatatgt gctgatgttt tctgtgtttg atgaaagcaa gaactggtac agaaagccct 780 cactacagta cacaattaat gggtttgcca atggaacatt gcctgatgtt caggcttgtg 840 cttatgatca tattagctgg catttgatag gaatgagttc cagtcctgag atcttctctg 900 ttcacttcaa tggacaaacc ttggaacaaa accattacaa agtgtcaacc atcaaccttg 960 tcggaggtgc ctcagtaaca gccaacatgt cagtgagcag gacaggaaaa tggctaatat 1020 cttctctggt tgcaaagcat ctacaagctg ggatgtatgg ttatctaaat atcaaagact 1080 1140 actgggaata tttcattgct gcagaagaaa tcacctggga ttatgctcca gaaattccta 1200 gcagtgttga cagaagatac aaagctcagt atctggataa tttttcaaat tttattggca 1260 agaatacaa aaaggcagtt ttcaggcaat ataaagacag caatttcact aaaccgacct 1320 atgccatttg gcccaaagaa cgtggaattc tgggccccgt tatcagagct aaagtcagag 1380 acaataag tattgtattc aaaaatctgg ccagtcgacc ttacagcatt tatgtgcatg 1440 gagtttccgt ttcaaaagat gcaagaggag ctatttatcc ttcagatccc aaaagagata 1500 taactcatgg caaagcagtt gaaccaggac aggtctacac atataaatgg actgtgctgg 1560 1620 tggacatgac aagagatatt gcttcaggac ttatgggcc acttctggtt tgtaaacaca 1680 aggcactcag cgtcaagggc gtacagaata aagctgatgt ggaacagcat gcagtcttcg 1740 cagtgtttga tgaaacaag agctggtact tggagacaa tatcagaa tactgcagca 1800 atccttccac tgttaagaaa gatgacccta aattttacaa gtccaatgtt atgtacacac 1860 tcaatggcta tgcatcagat agaacagagg tttcagtct gaagttgttg 1920s aatggcacct caccagcgta ggtacagtgg atgagatgt tccagtacat ctttctggtc 1980 acaccttctt atccaaggga aaacatcaag atattttaaa tctttcccc atgagtggtg 2040 aatcggctac tgtacaatg gatatctag gaacctggct tctgtcatca tggggctcct 2100 gtgagatgag caatggcatg agatgagat ttttggtgc cattatgat catgagatg 2160 agggaaatga agaagaggaa gaagagatg gcgatatttt tgccgacatt ttcattccctc 2220 cagaagtagt aaaaaagaaa gaaaaggacc ccgtaaattt tgtatcagac ccagaatcgg 2280 aatagatagc aaagaatta ggattag atgacgagga tatcagaa gagtcacaca 2340 atgtacagac agaggatgat gagaacagc taatgatagc tacaatgctt gggttttcgat 2400 catttaaggg gtcagttgct gagagaat tgaatctcac agctctagct ttagagag 2460 atgcccatgc ttctgatcct cgaattgaca gtaatagtgc acgtaatcct gatgacatag 2520 ctggacgcta cctgcgtact atcaaccgtg gaaataaaag gaggtactac attgcagcag 2580 aagaagttt gtgggactac tcaccgatcg gaaaaagtca agtgagaagt cgcgcagcca 2640 agaccacatt caaaaaagct attttccgaa gttatcttga tgatactttc cagacaccta 2700 gcactggagg agaatatgaa aagcatcttg gtatactggg tcctatcatt agggctgagg 2760 tggatgatgt aatcgaagtt cagttcagaa atttggcctc cagaccatac tcacttcatg 2820 ctcatggcct tctctatgag aaatcttctg aaggcagaag ctatgatgac aagtctcctg 2880 aattgttcaa aaaggatgat gctatcatgc caaacggcac atacacatat gtctggcaag 2940 tccctccacg gtcaggacca acagacaata cagaaaaatg taaatcatgg gcctattact 3000 ctggtgtaaa tccggaaaaa gatattcact ctggcttaat tggacctatt ttgatctgcc 3060 agaaaggcat gattgacaag tacaacagga caatagacat aagggaattt gtcttgtttt 3120 ttatggtctt tgatgaggag aaaagctggt actttccaaa atctgacaaa agcactcgtg 3180 cagagaaact tataggagtc caatctcgcc acacatttcc tgcaattaat gggatccctt 3240 atcagctgca aggcttgacg atgtacaaag atgagaatgt ccactggcat ttgctgaaca 3300 tgggtgggcc siaagatatc catgttgtta atttcatgg tcagacattc actgaagagg 3360 gaagggaaga taatcaactt ggagtccttc ctctctctcc tggtacattc gcctccatca 3420 aaatgaaacc atccaaattt ggcacatggc ttttagaac agaagttggt gaaaatcagg 3480 aaagaggaat gcaggctctc tttactgtca ttgacaaga ttgtaatta ccaatgggac 3540 tggcaagtgg gataatacaa gactcacaga tcagtgcttc aggtcatgtt ggatattggg 3600 agcctaagct agcaagactg ataatactg gaaataata tgcttggagc atcataaga 3660 aggaacatga acatccgtgg atccagatag acctacaaag acagttgtc atcacaggca 3720 ttcagaccca aggagccatg caactactga aacatttgta tactgtggaa tatttttta 3780 cctacagcaa agatgggcaa aactggatta cttttaaagg aagacattcc gaacacaaa 3840 tgcattttga gggtaattca gatggcacca cagtaaaaga aaaccacatt gatcctccta 3900 ttattgccag atatattagg ctgcatccaa ccaagttcca caacagacct actttccgca 3960 ttgaactgtt aggttgtgaa gttgaaggct gctcagtgcc attgggaatg gaaagtgggg 4020 ctatcaagaa ttcagagatt acagcctctt cttataagaa gacttggtgg agttcatggg 4080 aaccatccct tgcacgactc aatctgaaag gacgaacaaa tgcttggcaa ccaaaggtaa 4140 acaacaaaga tcaatggcta caaattgacc tgcaacatct tacaaaaata acaagcataa 4200 taactcaagg agccacatca atgactacat caatgtatgt gaaaacattc tccatccatt 4260 atactgatga caattcaaca tggaagcctt atttggatgt tcgcacttcc atggaaaagg 4320 ttttcacagg aaatattaac agtgatggtc atgtcaaaca ttttttcaaa ccccctatat 4380 tgtccaggtt cattcgtatc atccctaaaa catggaatca atatattgca ctccggatag 4440 aattgtttgg ttgtgaagtt ttttaaggct tggacagaag actatcaaat caagcaactt 4500 caatgtttca agttttctta ttactaactc tgctttttaa aaggaaacaa aaacaaaagc 4560 ataataaac tgtcttagca taaaaaagct atccttctca atttcagct atagctttca 4620 aatagctttg aaaatatcaa tcaaaatatc ataactgaag tgactttaca atgattaatt 4680 ctagtgccac tttaatcatg actgtaatcc taatacataa accttatttt ttttgcc 4737 <210> 6 <211> 4383 <212> DNA <213> Eastern brown snake <400> 6 atgggaagat acagtgtgag ccctgtcccc aaatgtcttc tactgatgtt cctgggttgg 60 tcagggctga agtattacca agtgaatgca gctcagctca gggagtacca tatagctgct 120 cagctggaag actgggatta caacccccaa cctgaggagc tatccagatt atcagagtca 180 gatcttacgt ttaaaaaaat tgtctataga gaatatgaac tagatttcaa acaagaggag 240 ccaagagatg cgctctcagg gctcctaggg ccaacactac gtggagaagt gggagacagc 300 ctcataattt atttcaagaa ttttgctact cagcctgtga gcattcaccc gcagagtgcc 360 gtgtacaaca aatggtcaga aggttcttca tattctgatg gaacatcaga tgtggaaaga 420 ctggatgatg ctgtgcctcc aggccagtcg ttcaagtatg tgtggaatat cactgcagaa 480 attgggccaa agaaagctga tcctccctgt ctcacttatg cgtactactc acatgtaaac 540 atggtgcgag actttaattc tggtctcatt ggtgctttgc tgatatgtaa agaaggaagc ctgaatgcaa atggttcaca aaaattcttc aacagagaat atgtgctgat gttttctgtg 720. tttgatgaaa gcaagaactg gtacagaaag ccctcactac agtacacaat taatgggttt gccaatggaa cattgcctga tgttcaggct tgtgcttatg atcatattag ctggcatttg 780 ataggaatga gttccagtcc tgagatcttc tctgttcact tcaatggaca aaccttgga 840 900. cttgtcggag gtgcctcagt aacagccgac atgtcagtga gcaggacagg aaaatggcta attcttctc tggttgcaaa gcatctacaa gctgggatgt atggttatct aaatatcaaa gactgtgga atccagatac tttaacaaga aagttatcct ttagagaact gatgaagatt aagaactggg aatattcat tgctgcagaa gaaatcacct gggattatgc tccagaatt cctagcagtg ttgacagaag atacaaagct cagtatctgg ataatttttc aaatttttc ggcaagaaat acaaaaaggc agttttcagg caatatgaag acggcaattt cactaaccg acctatgcca tttggcccaa agaacgtgga attctgggcc ccgttatca agctaagtc agagacacag taacaatgt attcaaaat 1320 ctggccagtc gaccttacag catttatgtg catggagttt ccgttttcaa agatgcagaa 1380 ggagctattt atccttcaga tcccaagg atattactc atggcaagc agttgaacca 1440 ggacaggtct acacatataa atggactgtg ctggatacag atgacctac agtaaaggat 1500 tctgagtgca ttactaatt atatcatagt gctgtggaca tgacaagaga tattgcttca 1560 ggacttattg ggccacttct ggttgtaaa cacaagcac tcagcgtca gggggtacag 1620 aaaagctg atgtggaaca gcatgcagtc ttcgcagtgt ttgatgaaa caagagctgg 1680 tacttggaag acaatca gaaatactgc agcaatcctt ccgctgttaa gaagatgac 1740 cctaaatttt acagtccaa tgttatgtac acaccaatg gctatgcatc agatagaaca 1800 gaggttttga gtttcatca gtctgaagtt gttcaatggc acctcaccag cgtaggtaca 1860 gtggatgaga ttgttccagt acatctttct ggtcacacct tcttatcca gggaaaacat 1920 cagatattt taaatcttt cccatgagt ggtgaatctg ctactgtaac atggacaat 1980 ctaggaacct ggcttctgtc atcatggggc tcctgtgaga tgagcaatgg catgagattg 2040 agatttttgg atgccaatta tgatgatgaa gatgagggaa atgaagaaga ggagaagat 2100 gatggtgata ttttgccga cattttcatt ccttcagaag tagtaaaaa gaagaagag 2160 gttcccgtaa attttgtacc agacccagaa tcggatgcgc tagcaaaaga attaggatta 2220 atagatgacg aggtaatcc aataatacag ccacgcaggg aacagacaga ggatgatgaa 2280 gaacagctaa tgaaagcttc aatgcttggg cttcgatcat ttaaggggtc agttgctgaa 2340 gaagaattga aacacacagc tctagcttta gaagaagatg cccatgcttc tgatcctcga 2400 attgacagta atagtgcacg taatcctgac gacatagctg gacgctacct gcgtactatc 2460 aaccgtggaa ataaaaggag gtactacatt gcagcagaag aagtttgtg ggactactca 2520 ccgatcggaa aaagtcaagt gagaagtcgc gcagccaaga ccacattcaa aaaagctatt 2580 ttccgaagtt atcttgatga tactttccag acacctagca ctggagaga atatgaaaag 2640 catcttggta tactgggtcc tatcattagg gctgaggtgg atgatgtaat cgaaattcag 2700 ttcaaaaatt tggcctctag accatactca cttcatgctc atggccttct ctatgagaaa 2760 tcttctgaag gcagaagcta tgacgacaag tctcctgaat tgttcaaaaa ggatgatgct 2820 atcatgccaa atggcacata cacatatgtc tggcaagtcc ctccacggtc aggaccaaca 2880 gacaatacag aaaaatgtaa atcatgggcc tattactctg gtgtaaatcc ggaaaaagat 2940 attcactctg gcttaattgg acctattttg atctgccaga aaggcatgat tgacaagtac 3000 aacaggacaa tagacataag ggaatttgtc ttgtttttta tggtctttga tgaggagaaa 3060 agctggtact ttccaaaatc tgacaaaagc acttgtgaag agaaacttat aggagtccaa 3120 tctctccaca catttcctgc aattaatggg atcccttatc agctgcaagg cttgacgatg 3180 tacaaagatg agaatgtcca ctggcatttg ctgaacatgg gtgggcccaa agatatccat 3240 gttgttaatt ttcatggtca gacattcact gaagagggaa gggaagataa tcaacttgga 3300 gtccttcctc ttcttcctgg tacattcgcc tccatcaaaa tgaaaccatc caaaattggc 3360 acatggcttt tagaaacaga agttggtgaa aatcaggaaa gaggaatgca ggctctcttt 3420 actgtcattg acaaagattg taaattacca atgggactgg caagtgggat aatacaagac 3480 tcacagatca gtgcttcagg tcatgttgga tattgggagc ctaagctagc aagactgaat 3540 aatactggaa aataatgc ttggagcatc ataaagaagg aacatgaaca tccgtggatc 3600 cagatagacc tacaaagaca agttgtcatc acaggcattc agacccaagg aaccgtgcaa 3660 ctactgcaac attcgtatac tgtggaatat tttgttacct acagcgaaga tgggcaaaac 3720 tggattactt ttaaaggaag acattccgaa acacaaatgc atttgaggg taattcagat 3780 ggcaccacag taaaagaaaa ccacattgat cctcctatta ttgccagata tattagactg 3840 catccaacca agttctacaa cagacctact ttccgcattg aactgttagg ttgtgaagtt 3900 gaaggttgct cagtgccatt gggaatggaa agtggggcta tcaagaattc agagattaca 3960 gcctctctt ataagaagac ttggtggagt tcatgggaac catcccttgc acgactcaat 4020 ctggaaggag gaacaaatgc ttggcaacca gaggtaaaca acaaagatca atggttacaa 4080 attgacctgc aacatcttac aaaaataaca agcataataa ctcaaggagc cacatcaatg 4140 actacatcaa tgtatgtgaa aacattctcc atccattata ctgatgacaa ttcaacatgg 4200 aagccttatt tggatgttcg cacttccatg gaaaaggttt tcacaggaaa tattaacagt 4260 gatggtcatg tcaaacattt tttcaaaccc cctatattgt ccaggttcat tcgtatcatc 4320 cctaaaacat ggaatcaata tattgcactc cggatagaat tgtttggttg tgaagttttt 4380 taa 4383 <210> 7 <211> 1459 <212> PRT <213> Eastern brown snake <400> 7 Met Gly Arg Tyr Ser Val Ser Pro Val Pro Lys Cys Leu Leu Leu Met 1 5 10 15 Phe Leu Gly Trp Ser Gly Leu Lys Tyr Tyr Glu Val Asn Ala Ala Gln 20 25 30 Leu Arg Glu Tyr His Ile Ala Ala Gln Leu Glu Asp Trp Asp Tyr Asn 35 40 45 Pro Gln Pro Glu Glu Leu Ser Arg Leu Ser Glu Ser Asp Leu Thr Phe 50 55 60 Lys Lys Ile Val Tyr Arg Glu Tyr Glu Leu Asp Phe Lys Gln Glu Lys 65 70 75 80 Pro Arg Asp Glu Leu Ser Gly Leu Leu Gly Pro Thr Leu Arg Gly Glu 85 90 95 Val Gly Asp Ile Leu Ile Ile Tyr Phe Lys Asn Phe Ala Thr Gln Pro 100 105 110 Val Ser Ile His Pro Gln Ser Ala Val Tyr Asn Lys Trp Ser Glu Gly 115 120 125 Ser Ser Tyr Ser Asp Gly Thr Ser Asp Val Glu Arg Leu Asp Asp Ala 130 135 140 Val Pro Pro Gly Gln Ser Phe Lys Tyr Val Trp Asn Ile Thr Ala Glu 145 150 155 160 Ile Gly Pro Lys Lys Ala Asp Pro Pro Cys Leu Thr Tyr Ala Tyr Tyr 165 170 175 Ser His Val Asn Met Val Arg Asp Phe Asn Ser Gly Leu Ile Gly Ala 180 185 190 Leu Leu Ile Cys Lys Glu Gly Ser Leu Asn Ala Asn Gly Ser Gln Lys 195 200 205 Phe Phe Asn Arg Glu Tyr Val Leu Met Phe Ser Val Phe Asp Glu Ser 210 215 220 Lys Asn Trp Tyr Arg Lys Pro Ser Leu Gln Tyr Thr Ile Asn Gly Phe 225 230 235 240 Ala Asn Gly Thr Leu Pro Asp Val Gln Ala Cys Ala Tyr Asp His Ile 245 250 255 Ser Trp His Leu Ile Gly Met Ser Ser Ser Pro Glu Ile Phe Ser Val 260 265 270 His Phe Asn Gly Gln Thr Leu Glu Gln Asn His Tyr Lys Val Ser Thr 275 280 285 Ile Asn Leu Val Gly Gly Ala Ser Val Thr Ala Asn Met Ser Val Ser 290 295 300 Arg Thr Gly Lys Trp Leu Ile Ser Ser Leu Val Ala Lys His Leu Gln 305 310 315 320 Ala Gly Met Tyr Gly Tyr Leu Asn Ile Lys Asp Cys Gly Asn Pro Asp 325 330 335 Thr Leu Thr Arg Lys Leu Ser Phe Arg Glu Leu Arg Arg Ile Met Asn 340 345 350 Trp Glu Tyr Phe Ile Ala Ala Glu Glu Ile Thr Trp Asp Tyr Ala Pro 355 360 365 Glu Ile Pro Ser Ser Val Asp Arg Arg Tyr Lys Ala Gln Tyr Leu Asp 370 375 380 Asn Phe Ser Asn Phe Ile Gly Lys Lys Tyr Lys Lys Ala Val Phe Arg 385 390 395 400 Gln Tyr Lys Asp Ser Asn Phe Thr Lys Pro Thr Tyr Ala Ile Trp Pro 405 410 415 Lys Glu Arg Gly Ile Leu Gly Pro Val Ile Arg Ala Lys Val Arg Asp 420 425 430 Thr Ile Ser Ile Val Phe Lys Asn Leu Ala Ser Arg Pro Tyr Ser Ile 435 440 445 Tyr Val His Gly Val Ser Val Ser Lys Asp Ala Glu Gly Ala Ile Tyr 450 455 460 Pro Ser Asp Pro Lys Glu Asn Ile Thr His Gly Lys Ala Val Glu Pro 465 470 475 480 Gly Gln Val Tyr Thr Tyr Lys Trp Thr Val Leu Asp Thr Asp Glu Pro 485 490 495 Thr Val Lys Asp Ser Glu Cys Ile Thr Lys Leu Tyr His Ser Ala Val 500 505 510 Asp Met Thr Arg Asp Ile Ala Ser Gly Leu Ile Gly Pro Leu Leu Val 515 520 525 Cys Lys His Lys Ala Leu Ser Val Lys Gly Val Gln Asn Lys Ala Asp 530 535 540 Val Glu Gln His Ala Val Phe Ala Val Phe Asp Glu Asn Lys Ser Trp 545 550 555 560 Tyr Leu Glu Asp Asn Ile Lys Lys Tyr Cys Ser Asn Pro Ser Thr Val 565 570 575 Lys Lys Asp Asp Pro Lys Phe Tyr Lys Ser Asn Val Met Tyr Thr Leu 580 585 590 Asn Gly Tyr Ala Ser Asp Arg Thr Glu Val Leu Gly Phe His Gln Ser 595 600 605 Glu Val Val Glu Trp His Leu Thr Ser Val Gly Thr Val Asp Glu Ile 610 615 620 Val Pro Val His Leu Ser Gly His Thr Phe Leu Ser Lys Gly Lys His 625 630 635 640 Gln Asp Ile Leu Asn Leu Phe Pro Met Ser Gly Glu Ser Ala Thr Val 645 650 655 Thr Met Asp Asn Leu Gly Thr Trp Leu Leu Ser Ser Trp Gly Ser Cys 660 665 670 Glu Met Ser Asn Gly Met Arg Leu Arg Phe Leu Asp Ala Asn Tyr Asp 675 680 685 Asp Glu Asp Glu Gly Asn Glu Glu Glu Glu Glu Asp Asp Gly Asp Ile 690 695 700 Phe Ala Asp Ile Phe Ile Pro Pro Glu Val Val Lys Lys Lys Glu Lys 705 710 715 720 Asp Pro Val Asn Phe Val Ser Asp Pro Glu Ser Asp Lys Ile Ala Lys 725 730 735 Glu Leu Gly Leu Leu Asp Asp Glu Asp Asn Gln Glu Glu Ser His Asn 740 745 750 Val Gln Thr Glu Asp Asp Glu Glu Gln Leu Met Ile Ala Thr Met Leu 755 760 765 Gly Phe Arg Ser Phe Lys Gly Ser Val Ala Glu Glu Glu Leu Asn Leu 770 775 780 Thr Ala Leu Ala Leu Glu Glu Asp Ala His Ala Ser Asp Pro Arg Ile 785 790 795 800 Asp Ser Asn Ser Ala Arg Asn Pro Asp Asp Ile Ala Gly Arg Tyr Leu 805 810 815 Arg Thr Ile Asn Arg Gly Asn Lys Arg Arg Tyr Tyr Ile Ala Ala Glu 820 825 830 Glu Val Leu Trp Asp Tyr Ser Pro Ile Gly Lys Ser Gln Val Arg Ser 835 840 845 Arg Ala Ala Lys Thr Thr Phe Lys Lys Ala Ile Phe Arg Ser Tyr Leu 850 855 860 Asp Asp Thr Phe Gln Thr Pro Ser Thr Gly Gly Glu Tyr Glu Lys His 865 870 875 880 Leu Gly Ile Leu Gly Pro Ile Ile Arg Ala Glu Val Asp Asp Val Ile 885 890 895 Glu Val Gln Phe Arg Asn Leu Ala Ser Arg Pro Tyr Ser Leu His Ala 900 905 910 His Gly Leu Leu Tyr Glu Lys Ser Ser Glu Gly Arg Ser Tyr Asp Asp 915 920 925 Lys Ser Pro Glu Leu Phe Lys Lys Asp Asp Ala Ile Met Pro Asn Gly 930 935 940 Thr Tyr Thr Tyr Val Trp Gln Val Pro Pro Arg Ser Gly Pro Thr Asp 945 950 955 960 Asn Thr Glu Lys Cys Lys Ser Trp Ala Tyr Tyr Ser Gly Val Asn Pro 965 970 975 Glu Lys Asp Ile His Ser Gly Leu Ile Gly Pro Ile Leu Ile Cys Gln 980 985 990 Lys Gly Met Ile Asp Lys Tyr Asn Arg Thr Ile Asp Ile Arg Glu Phe 995 1000 1005 Val Leu Phe Phe Met Val Phe Asp Glu Glu Lys Ser Trp Tyr Phe 1010 1015 1020 Pro Lys Ser Asp Lys Ser Thr Arg Ala Glu Lys Leu Ile Gly Val 1025 1030 1035 Gln Ser Arg His Thr Phe Pro Ala Ile Asn Gly Ile Pro Tyr Gln 1040 1045 1050 Leu Gln Gly Leu Thr Met Tyr Lys Asp Glu Asn Val His Trp His 1055 1060 1065 Leu Leu Asn Met Gly Gly Pro Lys Asp Ile His Val Val Asn Phe 1070 1075 1080 His Gly Gln Thr Phe Thr Glu Glu Gly Arg Glu Asp Asn Gln Leu 1085 1090 1095 Gly Val Leu Pro Leu Leu Pro Gly Thr Phe Ala Ser Ile Lys Met 1100 1105 1110 Lys Pro Ser Lys Ile Gly Thr Trp Leu Leu Glu Thr Glu Val Gly 1115 1120 1125 Glu Asn Gln Glu Arg Gly Met Gln Ala Leu Phe Thr Val Ile Asp 1130 1135 1140 Lys Asp Cys Lys Leu Pro Met Gly Leu Ala Ser Gly Ile Ile Gln 1145 1150 1155 Asp Ser Gln Ile Ser Ala Ser Gly His Val Gly Tyr Trp Glu Pro 1160 1165 1170 Lys Leu Ala Arg Leu Asn Asn Thr Gly Lys Tyr Asn Ala Trp Ser 1175 1180 1185 Ile Ile Lys Lys Glu His Glu His Pro Trp Ile Gln Ile Asp Leu 1190 1195 1200 Gln Arg Gln Val Val Ile Thr Gly Ile Gln Thr Gln Gly Ala Met 1205 1210 1215 Gln Leu Leu Lys His Leu Tyr Thr Val Glu Tyr Phe Phe Thr Tyr 1220 1225 1230 Ser Lys Asp Gly Gln Asn Trp Ile Thr Phe Lys Gly Arg His Ser 1235 1240 1245 Glu Thr Gln Met His Phe Glu Gly Asn Ser Asp Gly Thr Thr Val 1250 1255 1260 Lys Glu Asn His Ile Asp Pro Pro Ile Ile Ala Arg Tyr Ile Arg 1265 1270 1275 Leu His Pro Thr Lys Phe His Asn Arg Pro Thr Phe Arg Ile Glu 1280 1285 1290 Leu Leu Gly Cys Glu Val Glu Gly Cys Ser Val Pro Leu Gly Met 1295 1300 1305 Glu Ser Gly Ala Ile Lys Asn Ser Glu Ile Thr Ala Ser Ser Tyr 1310 1315 1320 Lys Lys Thr Trp Trp Ser Ser Trp Glu Pro Ser Leu Ala Arg Leu 1325 1330 1335 Asn Leu Lys Gly Arg Thr Asn Ala Trp Gln Pro Lys Val Asn Asn 1340 1345 1350 Lys Asp Gln Trp Leu Gln Ile Asp Leu Gln His Leu Thr Lys Ile 1355 1360 1365 Thr Ser Ile Ile Thr Gln Gly Ala Thr Ser Met Thr Thr Ser Met 1370 1375 1380 Tyr Val Lys Thr Phe Ser Ile His Tyr Thr Asp Asp Asn Ser Thr 1385 1390 1395 Trp Lys Pro Tyr Leu Asp Val Arg Thr Ser Met Glu Lys Val Phe 1400 1405 1410 Thr Gly Asn Ile Asn Ser Asp Gly His Val Lys His Phe Phe Lys 1415 1420 1425 Pro Pro Ile Leu Ser Arg Phe Ile Arg Ile Ile Pro Lys Thr Trp 1430 1435 1440 Asn Gln Tyr Ile Ala Leu Arg Ile Glu Leu Phe Gly Cys Glu Val 1445 1450 1455 Phe <210> 8 <211> 1460 <212> PRT <213> Eastern brown snake <400> 8 Met Gly Arg Tyr Ser Val Ser Pro Val Pro Lys Cys Leu Leu Leu Met 1 5 10 15 Phe Leu Gly Trp Ser Gly Leu Lys Tyr Tyr Gln Val Asn Ala Ala Gln 20 25 30 Leu Arg Glu Tyr His Ile Ala Ala Gln Leu Glu Asp Trp Asp Tyr Asn 35 40 45 Pro Gln Pro Glu Glu Leu Ser Arg Leu Ser Glu Ser Asp Leu Thr Phe 50 55 60 Lys Lys Ile Val Tyr Arg Glu Tyr Glu Leu Asp Phe Lys Gln Glu Glu 65 70 75 80 Pro Arg Asp Ala Leu Ser Gly Leu Leu Gly Pro Thr Leu Arg Gly Glu 85 90 95 Val Gly Asp Ser Leu Ile Ile Tyr Phe Lys Asn Phe Ala Thr Gln Pro 100 105 110 Val Ser Ile His Pro Gln Ser Ala Val Tyr Asn Lys Trp Ser Glu Gly 115 120 125 Ser Ser Tyr Ser Asp Gly Thr Ser Asp Val Glu Arg Leu Asp Asp Ala 130 135 140 Val Pro Pro Gly Gln Ser Phe Lys Tyr Val Trp Asn Ile Thr Ala Glu 145 150 155 160 Ile Gly Pro Lys Lys Ala Asp Pro Pro Cys Leu Thr Tyr Ala Tyr Tyr 165 170 175 Ser His Val Asn Met Val Arg Asp Phe Asn Ser Gly Leu Ile Gly Ala 180 185 190 Leu Leu Ile Cys Lys Glu Gly Ser Leu Asn Ala Asn Gly Ser Gln Lys 195 200 205 Phe Phe Asn Arg Glu Tyr Val Leu Met Phe Ser Val Phe Asp Glu Ser 210 215 220 Lys Asn Trp Tyr Arg Lys Pro Ser Leu Gln Tyr Thr Ile Asn Gly Phe 225 230 235 240 Ala Asn Gly Thr Leu Pro Asp Val Gln Ala Cys Ala Tyr Asp His Ile 245 250 255 Ser Trp His Leu Ile Gly Met Ser Ser Ser Pro Glu Ile Phe Ser Val 260 265 270 His Phe Asn Gly Gln Thr Leu Glu Gln Asn His Tyr Lys Val Ser Thr 275 280 285 Ile Asn Leu Val Gly Gly Ala Ser Val Thr Ala Asp Met Ser Val Ser 290 295 300 Arg Thr Gly Lys Trp Leu Ile Ser Ser Leu Val Ala Lys His Leu Gln 305 310 315 320 Ala Gly Met Tyr Gly Tyr Leu Asn Ile Lys Asp Cys Gly Asn Pro Asp 325 330 335 Thr Leu Thr Arg Lys Leu Ser Phe Arg Glu Leu Met Lys Ile Lys Asn 340 345 350 Trp Glu Tyr Phe Ile Ala Ala Glu Glu Ile Thr Trp Asp Tyr Ala Pro 355 360 365 Glu Ile Pro Ser Ser Val Asp Arg Arg Tyr Lys Ala Gln Tyr Leu Asp 370 375 380 Asn Phe Ser Asn Phe Ile Gly Light Light Tyr Light Light Ala Val Phe Arg 385 390 395 400 Gln Tyr Glu Asp Gly Asn Phe Thr Lys Pro Thr Tyr Ala Ile Trp Pro 405 410 415 Lys Glu Arg Gly Ile Leu Gly Pro Val Ile Lys Ala Lys Val Arg Asp 420 425 430 Thr Val Thr Ile Val Phe Lys Asn Leu Ala Ser Arg Pro Tyr Ser Ile 435 440 445 Tyr Val His Gly Val Ser Val Ser Lys Asp Ala Glu Gly Ala Ile Tyr 450 455 460 Pro Ser Asp Pro Lys Glu Asn Ile Thr His Gly Lys Ala Val Glu Pro 465 470 475 480 Gly Gln Val Tyr Thr Tyr Lys Trp Thr Val Leu Asp Thr Asp Glu Pro 485 490 495 Thr Val Lys Asp Ser Glu Cys Ile Thr Lys Leu Tyr His Ser Ala Val 500 505 510 Asp Met Thr Arg Asp Ile Ala Ser Gly Leu Ile Gly Pro Leu Leu Val 515 520 525 Cys Lys His Lys Ala Leu Ser Val Lys Gly Val Gln Asn Lys Ala Asp 530 535 540 Val Glu Gln His Ala Val Phe Ala Val Phe Asp Glu Asn Lys Ser Trp 545 550 555 560 Tyr Leu Glu Asp Asn Ile Lys Lys Tyr Cys Ser Asn Pro Ser Ala Val 565 570 575 Lys Lys Asp Asp Pro Lys Phe Tyr Lys Ser Asn Val Met Tyr Thr Leu 580 585 590 Asn Gly Tyr Ala Ser Asp Arg Thr Glu Val Leu Arg Phe His Gln Ser 595 600 605 Glu Val Val Gln Trp His Leu Thr Ser Val Gly Thr Val Asp Glu Ile 610 615 620 Val Pro Val His Leu Ser Gly His Thr Phe Leu Ser Lys Gly Lys His 625 630 635 640 Gln Asp Ile Leu Asn Leu Phe Pro Met Ser Gly Glu Ser Ala Thr Val 645 650 655 Thr Met Asp Asn Leu Gly Thr Trp Leu Leu Ser Ser Trp Gly Ser Cys 660 665 670 Glu Met Ser Asn Gly Met Arg Leu Arg Phe Leu Asp Ala Asn Tyr Asp 675 680 685 Asp Glu Asp Glu Gly Asn Glu Glu Glu Glu Glu Asp Asp Gly Asp Ile 690 695 700 Phe Ala Asp Ile Phe Ile Pro Ser Glu Val Val Lys Lys Lys Glu Glu 705 710 715 720 Val Pro Val Asn Phe Val Pro Asp Pro Glu Ser Asp Ala Leu Ala Lys 725 730 735 Glu Leu Gly Leu Ile Asp Asp Glu Gly Asn Pro Ile Ile Gln Pro Arg 740 745 750 Arg Glu Gln Thr Glu Asp Asp Glu Glu Gln Leu Met Lys Ala Ser Met 755 760 765 Leu Gly Leu Arg Ser Phe Lys Gly Ser Val Ala Glu Glu Glu Leu Lys 770 775 780 His Thr Ala Leu Ala Leu Glu Glu Asp Ala His Ala Ser Asp Pro Arg 785 790 795 800 Ile Asp Ser Asn Ser Ala Arg Asn Pro Asp Asp Ile Ala Gly Arg Tyr 805 810 815 Leu Arg Thr Ile Asn Arg Gly Asn Lys Arg Arg Tyr Tyr Ile Ala Ala 820 825 830 Glu Glu Val Leu Trp Asp Tyr Ser Pro Ile Gly Lys Ser Gln Val Arg 835 840 845 Ser Arg Ala Ala Lys Thr Thr Phe Lys Lys Ala Ile Phe Arg Ser Tyr 850 855 860 Leu Asp Asp Thr Phe Gln Thr Pro Ser Thr Gly Gly Glu Tyr Glu Lys 865 870 875 880 His Leu Gly Ile Leu Gly Pro Ile Ile Arg Ala Glu Val Asp Asp Val 885 890 895 Ile Glu Ile Gln Phe Lys Asn Leu Ala Ser Arg Pro Tyr Ser Leu His 900 905 910 Ala His Gly Leu Leu Tyr Glu Lys Ser Ser Glu Gly Arg Ser Tyr Asp 915 920 925 Asp Lys Ser Pro Glu Leu Phe Lys Lys Asp Asp Ala Ile Met Pro Asn 930 935 940 Gly Thr Tyr Thr Tyr Val Trp Gln Val Pro Pro Arg Ser Gly Pro Thr 945 950 955 960 Asp Asn Thr Glu Lys Cys Lys Ser Trp Ala Tyr Tyr Ser Gly Val Asn 965 970 975 Pro Glu Lys Asp Ile His Ser Gly Leu Ile Gly Pro Ile Leu Ile Cys 980 985 990 Gln Lys Gly Met Ile Asp Lys Tyr Asn Arg Thr Ile Asp Ile Arg Glu 995 1000 1005 Phe Val Leu Phe Phe Met Val Phe Asp Glu Glu Lys Ser Trp Tyr 1010 1015 1020 Phe Pro Lys Ser Asp Lys Ser Thr Cys Glu Glu Lys Leu Ile Gly 1025 1030 1035 Val Gln Ser Leu His Thr Phe Pro Ala Ile Asn Gly Ile Pro Tyr 1040 1045 1050 Gln Leu Gln Gly Leu Thr Met Tyr Lys Asp Glu Asn Val His Trp 1055 1060 1065 His Leu Leu Asn Met Gly Gly Pro Lys Asp Ile His Val Val Asn 1070 1075 1080 Phe His Gly Gln Thr Phe Thr Glu Glu Gly Arg Glu Asp Asn Gln 1085 1090 1095 Leu Gly Val Leu Pro Leu Leu Pro Gly Thr Phe Ala Ser Ile Lys 1100 1105 1110 Met Lys Pro Ser Lys Ile Gly Thr Trp Leu Leu Glu Thr Glu Val 1115 1120 1125 Gly Glu Asn Gln Glu Arg Gly Met Gln Ala Leu Phe Thr Val Ile 1130 1135 1140 Asp Lys Asp Cys Lys Leu Pro Met Gly Leu Ala Ser Gly Ile Ile 1145 1150 1155 Gln Asp Ser Gln Ile Ser Ala Ser Gly His Val Gly Tyr Trp Glu 1160 1165 1170 Pro Lys Leu Ala Arg Leu Asn Asn Thr Gly Lys Tyr Asn Ala Trp 1175 1180 1185 Ser Ile Ile Lys Lys Glu His Glu His Pro Trp Ile Gln Ile Asp 1190 1195 1200 Leu Gln Arg Gln Val Val Ile Thr Gly Ile Gln Thr Gln Gly Thr 1205 1210 1215 Val Gln Leu Leu Gln His Ser Tyr Thr Val Glu Tyr Phe Val Thr 1220 1225 1230 Tyr Ser Glu Asp Gly Gln Asn Trp Ile Thr Phe Lys Gly Arg His 1235 1240 1245 Ser Glu Thr Gln Met His Phe Glu Gly Asn Ser Asp Gly Thr Thr 1250 1255 1260 Val Lys Glu Asn His Ile Asp Pro Pro Ile Ile Ala Arg Tyr Ile 1265 1270 1275 Arg Leu His Pro Thr Lys Phe Tyr Asn Arg Pro Thr Phe Arg Ile 1280 1285 1290 Glu Leu Leu Gly Cys Glu Val Glu Gly Cys Ser Val Pro Leu Gly 1295 1300 1305 Met Glu Ser Gly Ala Ile Lys Asn Ser Glu Ile Thr Ala Ser Ser 1310 1315 1320 Tyr Lys Lys Thr Trp Trp Ser Ser Trp Glu Pro Ser Leu Ala Arg 1325 1330 1335 Leu Asn Leu Glu Gly Gly Thr Asn Ala Trp Gln Pro Glu Val Asn 1340 1345 1350 Asn Lys Asp Gln Trp Leu Gln Ile Asp Leu Gln His Leu Thr Lys 1355 1360 1365 Ile Thr Ser Ile Ile Thr Gln Gly Ala Thr Ser Met Thr Thr Ser 1370 1375 1380 Met Tyr Val Lys Thr Phe Ser Ile His Tyr Thr Asp Asp Asn Ser 1385 1390 1395 Thr Trp Lys Pro Tyr Leu Asp Val Arg Thr Ser Met Glu Lys Val 1400 1405 1410 Phe Thr Gly Asn Ile Asn Ser Asp Gly His Val Lys His Phe Phe 1415 1420 1425 Lys Pro Pro Ile Leu Ser Arg Phe Ile Arg Ile Ile Pro Lys Thr 1430 1435 1440 Trp Asn Gln Tyr Ile Ala Leu Arg Ile Glu Leu Phe Gly Cys Glu 1445 1450 1455 Val Phe 1460 <210> 9 <211> 4380 <212> DNA <213> Taipan <400> 9 atgggaagat acagtgtgag ccctgtcccc aaatgtcttc tactgatgtt cctgggttgg 60 tcagggctga agtattacca agtgaatgca gctcagctca gggagtaccg tttagctgct 120 cagctggaag actgggatta caacccccaa cctgaggagc tatccagatt atcagagtca 180 gatcttacgt ttaaaaaaat tgtctataga gaatatgaac tagatttcaa acaagagaag 240 It should be noted that there may be some inaccuracies in the above translation due to the lack of specific context for some terms. For example, "太攀蛇" is directly translated as "Taipan", which is a common name for a snake species, but in a more specific scientific or technical context, a more accurate and detailed translation might be required. Also, the translation of DNA sequences is a very specialized area, and the above translation is a basic literal translation for reference purposes. If more accurate and professional translation is needed, it is recommended to consult relevant experts or refer to more authoritative databases.ccaagagatg agctctcagg gctcctaggg ccaacactac gtggagaagt gggagacagc 300 ctcataattt atttcaagaa ttttgctact cagcctgtga gcattcaccc gcagagtgcc 360 gtgtacaaca aatggtcaga aggttcttca tattctgatg gaacatcaga tgtggaaaga 420 ctggatgatg ctgtgcctcc aggccagtcg ttcaagtatg tgtggaatat cactgcagaa 480 attgggccaa agaaagctga tcctccctgt ctcacttatg cgtactactc acatgtaaac 540 atggtgcgag actttaattc tggtctcatt ggtgctttgc tgatatgtaa agaaggaagc 600 ctgaatgcag atggtgcaca aaaattcttc aacagagaat atgtgctgat gttttctgtg 660 tttgatgaaa gcaagaactg gtacagaaag ccctcattac agtacacaat taatgggttt 720 gccaatggaa cattgcctga tgttcaggct tgtgcttatg atcatattag ctggcatttg 780 ataggaatga gttccagtcc tgagatcttc tctgttcact tcaatggaca aaccttggaa 840 caaaaccatt acaaagtgtc aaccatcaac cttgtcggag gtgcctcagt aacagccaac 900 atgtcagtga gcaggacagg aaaatggcta atatcttctc tggttgcaaa gcatctacaa 960 gctgggatgt atggttatct aaatatcaaa gactgtggaa atccagatac tttaaaaga 1020 aagttatcct ttagagaacg gaggaggatt atgaaatggg aatatttcat tgctgcagaa 1080 gaaatcacct gggattatgc tccagaaatt cctagcagtg ttgacagaag atacaaagct 1140 foottctgg ataatttttc aaattttatt ggcaagaaat acaaaaaggc agttttcagg 1200 1260 attctgggcc ccgttatcaa agctaaagtc agacacag taacaattgt attcaaaaat 1320 ctggccagtc gaccttacag catttatgtg catggagttt ccgtttcaaa agatgcagaa 1380 ggagctgttt atccttcaga tcccaaagag aatataactc atggcaaagc agttgaacca 1440 ggacaggtct acacatataa atggactgtg ctggatacag atgaacctac agaaaggat 1500 tctgagtgca ttactaaatt atatcatagt gctgtggaca tgacaagaga tattgcttca 1560 ggacttattg ggccacctct ggtttgtaaa cgcaaggcac tcagcatcag gggggtacag 1620 aataaagctg atgtggaaca gcatgcagtc ttcgcagtgt ttgatgaaaa caagagctgg 1680 tacttggaag acaatca gaaatactgc agcaatcctt ccagtgttaa gaagatgac 1740 cctaaatttt acagtccaa tgttatgtac acaccaatg gctatgcatc agatagaaca 1800 gaggtttggg gtttcatca gtctgaagtt gttgaatggc acctcaccag cgtaggtaca 1860 gtggatgaga ttgttccagt acatctttct ggtcacacct tcttatcca gggaaaacat 1920 cagatattt taaatcttt tcccatgagt ggtgaatcgg ctactgtaac atggacaat 1980 ctaggaacct ggcttctgtc atcatggggc tcctgtgaga tgagcaatgg catgagattg 2040 agatttttgg atgccaatta tgatgatga gatgaggga atgagaga ggaagagat 2100 gatggtgata ttttgccga cattttcaat cctccagaag tagtataaa gaagaagag 2160 gttcccgtaa atttgtacc agacccagaa tcggatgcgc tagcaaaga attaggatta 2220 tttgatgacg aggataatcc aaaacagtca cgcagtgaac agacagagga tgatgagaa 2280 cagctaatga tagcttcaat gcttgggctt cgatcattta agggtcagt tgctgaagaa 2340 gattgaaac accagctct agctttagaa gagatgccc atgcttctga tcctcgaatt 2400 gacagtaata gtgcacataa ttctgacgac atagctggac gctacctgcg tactatcaac 2460 cgcagaaata aaaggaggta ctacattgca gcagaagaag ttttgtggga ctactcaccg 2520 atcggaaaaa gtcaagtgag aagtctccca gccaagacca cattcaaaaa agctattttc 2580 cgaagttatc ttgatgatac tttccagaca cctagcactg gaggagaata tgaaaagcat 2640 cttggtatac tgggtcctat cattagggct gaggtggatg atgtaatcga agttcagttc 2700 agaaatttgg cctctagacc atactcactt catgctcatg gccttctcta tgagaaatct 2760 tctgaaggca gaagctatga cgacaactct cctgaattgt tcaaaaaaga tgatgctatc 2820 atgccaaacg gcacatacac atatgtctgg caagtccctc cacggtcagg accaacagac 2880 aatacagaaa aatgtaaatc atgggcctat tactctggtg taaatccgga aaaagatatt 2940 cactctggct taattggacc tattttgatc tgccagaaag gcatgattga caagtacaac 3000 aggacaatag acataaggga atttgtcttg ttttttatgg tctttgatga ggagaaaagc 3060 tggtactttc caaaatctga caaaagcact tgtgaagaga aacttatagg agtccaatct 3120 cgccacacat ttcctgcaat taatgggatc ccttatcagc tgcaggctt gatgatgtac 3180 aaagatgaga atgtccactg gcatttgctg aacatgggtg ggcccaaaga tgtccatgtt 3240 gttaatttc atggtcagac attcactgaa gagggaaggg aagataatca acttggaggtc 3300 cttcctcttc ttcctggtac attcgcctcc atcaaatga aaccatccaa aattggcaca 3360 tggctttag aacagaagt tggtgaaat caggaagg gatgcaggc tctctttact 3420 gtcattgaca aagattgtaa attaccaatg ggactggcaa gtgggataat acagactca 3480 cagatcagtg cttcaggtca tgttggatat tgggagccta agctagcaag actgaataat 3540 actggaatgt ttaatgcttg gagcatcata agaaggaac atgaacatcc gtggatccag 3600 atagacctac aaagacaagt tgtcatcaca ggcattcaga cccagggaac cgtgcaacta 3660 ctgaaactt cgtatactgt ggaatatttt gttacctaca gcaagatgg gcaaactgg 3720 attacttta aaggaagaca ttccaaaca caaatgcatt ttgaggta ttcagatggc 3780 accacagtaa aagaaaacca cattgatcct cctattattg ccagatatat taggctgcat 3840 ccaaccaagt tctacaacac acctactttc cgcattgaac tgttaggttg tgaagttgaa 3900 ggttgctcag tgccattggg aatggaaagt ggggctatca aggattcaga gattacagcc 3960 tcttcttata aaaagacttg gtggagttca tgggaaccat tccttgcacg actcaatctg 4020 aaaggacgaa caaatgcttg gcaaccaaag gtaaacaaca aagatcaatg gctacaaatt 4080 gacctgcaac atcttacaaa aataacaagc ataataactc aaggagccac atcaatgact 4140 acatcaatgt atgtgaaaac attctccatc cattatactg atgacaattc aacatggaag 4200 ccttatttgg atgttcgcac ttccatggaa aaggttttca caggaaatat taacagtgat 4260 ggtcatgtca aacatttttt caacccccct atattgtcca ggttcattcg tatcatccct 4320 aaaacatgga atcaatatat tgcactccgg atagaattgt ttggttgtga agttttttaa 4380 <210> 10 <211> 4675 <212> DNA <213> Oxyuranus scutellatus <400> 10 atgggaagat acagtgtgag ccctgtcccc aaatgtcttc tactgatgtt cctgggttgg 60 tcagggctga agtattacca agtgaatgca gctcagctca gggagtaccg tatagctgct 120 cagctgggaag actgggatta caacccccaa cctgaggagc tatccagatt atcagagtca 180 gatcttacgt ttaaaaaat tgtctataga gaatatgaac tagatttcaa acaagagaag 240 ccaagagatg agctctcagg gctcctaggg ccaacactac gtggagaagt gggagacagc 300 ctcataattt atttcaagaa ttttgctact cagcctgtga gcattcaccc gcagagtgcc 360 gtgtacaaca aatggtcaga aggttcttca tattctgatg gaacatcaga tgtggaaaga 420 ctggatgatg ctgtgcctcc aggccagtcg ttcaagtatg tgtggaatat cactgcagaa 480 attgggccaa agaaagctga tcctccctgt ctcacttatg cgtactactc acatgtaaac 540 atggtgcgag actttaattc tggtctcatt ggtgctttgc tgatatgtaa agaaggaagc 600 ctgaatgcag atggtgcaca aaaattcttc aacagagaat atgtgctgat gttttctgtg 660 tttgatgaaa gcaagaactg gtacagaaag ccctcattac agtacacaat taatgggttt 720 gccaatggaa cattgcctga tgttcaggct tgtgcttatg atcatattag ctggcatttg 780 ataggaatga gttccagtcc tgagatcttc tctgttcact tcaatggaca aaccttggaa 840 caaaaccatt acaaagtgtc aaccatcaac cttgtcggag gtgcctcagt aacagccaac 900 atgtcagtga gcaggacagg aaaatggcta atactctctc tggttgcaaa gcatctacaa 960 gctgggatgt atggttatct tatatcaaa gactgtggaa atccagatac tttaacaaga 1020 aagttatcct ttagagaatg gaggaggatt atgaaatggg aatatttcat tgctgcagaa 1080 gaaatcacct gggattatgc tccagaaatt cctagcagtg ttgacagaag atacaaagct 1140 cagtatctgg atttttcaaa ttttattggc aagaaataca aaaaggcagt tttcaggcaa 1200 tatgaagaca gcaatttcac taaaccgacc tatgccattt ggcccaaaga acgtggaatt 1260 ctgggccccg ttatcaaagc taaagtcaga gacacagtaa caattgtatt caaaaatctg 1320 gccagtcgac cttacagcat tttgtgcat ggagtttccg tttcaaaaga tgcagaagga 1380 gctgttatc cttcagatcc caaagagaat ataactcatg gcaaagcagt tgaaccagga 1440 caggtctaca catataaatg gactgtgctg gatacagatg aacctacagt aaaggattct 1500 gagtgcatta ctaaattata tcatagtgct gtggacatga caagagatat tgcttcagga 1560 cttattgggc cacttctggt ttgtaaacgc aaggcactca gcatcagggg ggtacagaat 1620 aaagctgatg tggaacagca tgcagtctttc gcagtgtttg atgaaaacaa gagctggtac 1680 ttggaagaca atatcaagaa atactgcagc aatccttcca gtgttaagaa agatgaccct 1740 aaatttaca agtccaatgt tatgtacaca ctcaatggct atgcatcaga tagaacagag 1800 gtttgggggt ttcatcagtc tgaagttgtt gaatggcacc tcaccagcgt aggtacagtg 1860 gatgagattg ttccagtaca tctttctggt cacaccttct tatccaaggg aaaacatcaa 1920 gatattttaa atctttttcc catgagtggt gaatccgcta ctgtaacaat ggacaatcta 1980 ggaacctggc ttctgtcatc atggggctcc tgtgagatga gcaatggcat gagattgaga 2040 ttttggatg ccaattatga tgatgaagat gagggaaatg aagaagagga agaagatgat 2100 ggtgatattt ttgccgacat tttcaatcct ccagaagtag tataaagaa agaagaggtt 2160 cccgtaaatt ttgtaccaga cccagaatcg gatgcgctag caaaagaatt aggattatttt 2220 gatgacgagg ataatccaaa acagtcacgc agtgaacaga cagaggatga tgaagaacag 2280 ctaatgatag cttcaatgct tgggcttcga tcatttaagg ggtcagttgc tgaagaagaa 2340 ttgaaacaca cagctctagc tttagaagaa gatgcccatg cttctgatcc tcgaattgac 2400 agtaatagtg cacataattc tgacgacata gctggacgct acctgcgtac tatctaccgc 2460 agaaataaaa ggaggtacta cattgcagca gaagaagtttt tgtgggacta ctcaccgatc 2520 ggaaaaagtc aagtgagaag tctcccagcc aagaccacat tcaaaaaagc tattttccga 2580 agttatcttg atgatacttt ccagacacct agcactggag gagaatatga aaagcatctt 2640 ggtatactgg gtcctatcat tagggctgag gtggatgatg taatcgaagt tcagttcaga 2700 aatttggcct ctagaccata ctcacttcat gctcatggcc ttctctatga gaaatcttct 2760 gaaggcagaa gctatgacga caactctcct gaattgttca aaaaggatga tgctatcatg 2820 ccaaacggca catacacata tgtctggcaa gtccctccac ggtcaggacc aacagacaat 2880 acagaaaaat gtaaatcatg ggcctattac tctggtgtaa atccggaaaa agatattcac 2940 tctgggctta ttggacctat tttgatctgc cagaaaggca tgattgacaa gtacaacagg 3000 aaatagaca taagggaatt tgtcttgttt tttatggtct ttgatgagga gaaaagctgg 3060 tactttccaa aatctgacaa aagcacttgt gaagagaaac ttataggagt ccaatctcgc 3120 cacacatttc ctgcaattaa tgggatccct tatcagctgc aaggcttgat gatgtacaaa 3180 gatgagaatg tccactggca tttgctgaac atgggtgggc ccaaagatgt ccatgttgtt 3240 3300 cctcttcttc ctggtacatt cgcctccatc aaaatgaaac catccaaaat tggcacatgg 3360 cttttagaaa cagaagttgg tgaaaatcag gaagagaa tgcaggctct ctttactgtc 3420 attgacaaag attgtaaatt accaatggga ctggcaagtg ggataataca agactcacag 3480 atcagtgctt caggtcatgt tggatattgg gagcctaagc tagcaagaact gaataatact 3540 ggaatgttta atgcttggag catcataaag aaggaacatg aacatccgtg gatccagatc 3600 gacctacaaa gacaagttgt catcacaggc attcagaccc agggaaccgt gcacctactg 3660 aaacattcgt atactgtgga atattttgtt acctacagca aagatgggca aaactggatt acttttaaag gaagacattc caaaacacaa atgcattttg agggtaattc agatggcacc acagtaaaag aaaaccacat tgatcctcct attattgcca gatatattag gctgcatcca accaagttct acaacacacc tactttccgc attgaactgt taggttgtga agttgaaggt tgctcagtgc cattgggaat ggaaagtggg gctatcaagg attcagagat tacagcctct tcttataaa agacttggtg gagttcatgg gaccattcc ttgcacgact caatctgaaa 4080. ggacgaacaa atgcttggca accaaaggta aacaacaaag atcaatggct acaaattgac ctgcaacatc ttacaaaaat aacaagcata ataactcaag gagccacatc aatgactaca tcaatgtatg tgaaaacatt ctccatccat tatactgatg acaattcaac atggaagcct tatttggatg ttcgcacttc catggaaaag gttttcacag gaatattaa cagtgatggt catgtcaaac attttttcaa cccccctata ttgtccaggt tcattcgtat catcccctaa acatggaatc aatattgc actccggata gaattgtttg gttgtgaagt tttttaaggc ttggacagaa gactgtcaaa tcaagcaact tcaatgtttc aagttttctt attactaact 4440 ctgcttttta aaaggaaaca aaaacaaaag cataataaaa ctgtcttagc ataaaaaaaa 4500 ctatccttct caattttcag ccatagcttt caaatagctt tgaaaatatc aatcaaaata 4560 tcataactga agtgacgttt acaatgatta attcgtagtg ccacgtttaa tcatgaatgt 4620 aatcctaata caataaaatc gttattgttt ttgccccaaa aaaaaaaaaa aaaaa 4675 <210> 11 <211> 1458 <212> PRT <213> Oxyuranus scutellatus <400> 11 Met Gly Arg Tyr Ser Val Ser Pro Val Pro Lys Cys Leu Leu Leu Met 1 5 10 15 Phe Leu Gly Trp Ser Gly Leu Lys Tyr Tyr Gln Val Asn Ala Ala Gln 20 25 30 Leu Arg Glu Tyr Arg Ile Ala Ala Gln Leu Glu Asp Trp Asp Tyr Asn 35 40 45 Pro Gln Pro Glu Glu Leu Ser Arg Leu Ser Glu Ser Asp Leu Thr Phe 50 55 60 Lys Lys Ile Val Tyr Arg Glu Tyr Glu Leu Asp Phe Lys Gln Glu Lys 65 70 75 80 Pro Arg Asp Glu Leu Ser Gly Leu Leu Gly Pro Thr Leu Arg Gly Glu 85 90 95 Val Gly Asp Ser Leu Ile Ile Tyr Phe Lys Asn Phe Ala Thr Gln Pro 100 105 110 Val Ser Ile His Pro Gln Ser Ala Val Tyr Asn Lys Trp Ser Glu Gly 115 120 125 Ser Ser Tyr Ser Asp Gly Thr Ser Asp Val Glu Arg Leu Asp Asp Ala 130 135 140 Val Pro Pro Gly Gln Ser Phe Lys Tyr Val Trp Asn Ile Thr Ala Glu 145 150 155 160 Ile Gly Pro Lys Lys Ala Asp Pro Pro Cys Leu Thr Tyr Ala Tyr Tyr 165 170 175 Ser His Val Asn Met Val Arg Asp Phe Asn Ser Gly Leu Ile Gly Ala 180 185 190 Leu Leu Ile Cys Lys Glu Gly Ser Leu Asn Ala Asp Gly Ala Gln Lys 195 200 205 Phe Phe Asn Arg Glu Tyr Val Leu Met Phe Ser Val Phe Asp Glu Ser 210 215 220 Lys Asn Trp Tyr Arg Lys Pro Ser Leu Gln Tyr Thr Ile Asn Gly Phe 225 230 235 240 Ala Asn Gly Thr Leu Pro Asp Val Gln Ala Cys Ala Tyr Asp His Ile 245 250 255 Ser Trp His Leu Ile Gly Met Ser Ser Ser Pro Glu Ile Phe Ser Val 260 265 270 His Phe Asn Gly Gln Thr Leu Glu Gln Asn His Tyr Lys Val Ser Thr 275 280 285 Ile Asn Leu Val Gly Gly Ala Ser Val Thr Ala Asn Met Ser Val Ser 290 295 300 Arg Thr Gly Lys Trp Leu Ile Ser Ser Leu Val Ala Lys His Leu Gln 305 310 315 320 Ala Gly Met Tyr Gly Tyr Leu Asn Ile Lys Asp Cys Gly Asn Pro Asp 325 330 335 Thr Leu Thr Arg Lys Leu Ser Phe Arg Glu Trp Arg Arg Ile Met Lys 340 345 350 Trp Glu Tyr Phe Ile Ala Ala Glu Glu Ile Thr Trp Asp Tyr Ala Pro 355 360 365 Glu Ile Pro Ser Ser Val Asp Arg Arg Tyr Lys Ala Gln Tyr Leu Asp 370 375 380 Phe Ser Asn Phe Ile Gly Lys Lys Tyr Lys Lys Ala Val Phe Arg Gln 385 390 395 400 Tyr Glu Asp Ser Asn Phe Thr Lys Pro Thr Tyr Ala Ile Trp Pro Lys 405 410 415 Glu Arg Gly Ile Leu Gly Pro Val Ile Lys Ala Lys Val Arg Asp Thr 420 425 430 Val Thr Ile Val Phe Lys Asn Leu Ala Ser Arg Pro Tyr Ser Ile Tyr 435 440 445 Val His Gly Val Ser Val Ser Lys Asp Ala Glu Gly Ala Val Tyr Pro 450 455 460 Ser Asp Pro Lys Glu Asn Ile Thr His Gly Lys Ala Val Glu Pro Gly 465 470 475 480 Gln Val Tyr Thr Tyr Lys Trp Thr Val Leu Asp Thr Asp Glu Pro Thr 485 490 495 Val Lys Asp Ser Glu Cys Ile Thr Lys Leu Tyr His Ser Ala Val Asp 500 505 510 Met Thr Arg Asp Ile Ala Ser Gly Leu Ile Gly Pro Leu Leu Val Cys 515 520 525 Lys Arg Lys Ala Leu Ser Ile Arg Gly Val Gln Asn Lys Ala Asp Val 530 535 540 Glu Gln His Ala Val Phe Ala Val Phe Asp Glu Asn Lys Ser Trp Tyr 545 550 555 560 Leu Glu Asp Asn Ile Lys Lys Tyr Cys Ser Asn Pro Ser Ser Val Lys 565 570 575 Lys Asp Asp Pro Lys Phe Tyr Lys Ser Asn Val Met Tyr Thr Leu Asn 580 585 590 Gly Tyr Ala Ser Asp Arg Thr Glu Val Trp Gly Phe His Gln Ser Glu 595 600 605 Val Val Glu Trp His Leu Thr Ser Val Gly Thr Val Asp Glu Ile Val 610 615 620 Pro Val His Leu Ser Gly His Thr Phe Leu Ser Lys Gly Lys His Gln 625 630 635 640 Asp Ile Leu Asn Leu Phe Pro Met Ser Gly Glu Ser Ala Thr Val Thr 645 650 655 Met Asp Asn Leu Gly Thr Trp Leu Leu Ser Ser Trp Gly Ser Cys Glu 660 665 670 Met Ser Asn Gly Met Arg Leu Arg Phe Leu Asp Ala Asn Tyr Asp Asp 675 680 685 Glu Asp Glu Gly Asn Glu Glu Glu Glu Glu Asp Asp Gly Asp Ile Phe 690 695 700 Ala Asp Ile Phe Asn Pro Pro Glu Val Val Ile Lys Lys Glu Glu Val 705 710 715 720 Pro Val Asn Phe Val Pro Asp Pro Glu Ser Asp Ala Leu Ala Lys Glu 725 730 735 Leu Gly Leu Phe Asp Asp Glu Asp Asn Pro Lys Gln Ser Arg Ser Glu 740 745 750 Gln Thr Glu Asp Asp Glu Glu Gln Leu Met Ile Ala Ser Met Leu Gly 755 760 765 Leu Arg Ser Phe Lys Gly Ser Val Ala Glu Glu Glu Leu Lys His Thr 770 775 780 Ala Leu Ala Leu Glu Glu Asp Ala His Ala Ser Asp Pro Arg Ile Asp 785 790 795 800 Ser Asn Ser Ala His Asn Ser Asp Asp Ile Ala Gly Arg Tyr Leu Arg 805 810 815 Thr Ile Tyr Arg Arg Asn Lys Arg Arg Tyr Tyr Ile Ala Ala Glu Glu 820 825 830 Val Leu Trp Asp Tyr Ser Pro Ile Gly Lys Ser Gln Val Arg Ser Leu 835 840 845 Pro Ala Lys Thr Thr Phe Lys Lys Ala Ile Phe Arg Ser Tyr Leu Asp 850 855 860 Asp Thr Phe Gln Thr Pro Ser Thr Gly Gly Glu Tyr Glu Lys His Leu 865 870 875 880 Gly Ile Leu Gly Pro Ile Ile Arg Ala Glu Val Asp Asp Val Ile Glu 885 890 895 Val Gln Phe Arg Asn Leu Ala Ser Arg Pro Tyr Ser Leu His Ala His 900 905 910 Gly Leu Leu Tyr Glu Lys Ser Ser Glu Gly Arg Ser Tyr Asp Asp Asn 915 920 925 Ser Pro Glu Leu Phe Lys Lys Asp Asp Ala Ile Met Pro Asn Gly Thr 930 935 940 Tyr Thr Tyr Val Trp Gln Val Pro Pro Arg Ser Gly Pro Thr Asp Asn 945 950 955 960 Thr Glu Lys Cys Lys Ser Trp Ala Tyr Tyr Ser Gly Val Asn Pro Glu 965 970 975 Lys Asp Ile His Ser Gly Leu Ile Gly Pro Ile Leu Ile Cys Gln Lys 980 985 990 Gly Met Ile Asp Lys Tyr Asn Arg Thr Ile Asp Ile Arg Glu Phe Val 995 1000 1005 Leu Phe Phe Met Val Phe Asp Glu Glu Lys Ser Trp Tyr Phe Pro 1010 1015 1020 Lys Ser Asp Lys Ser Thr Cys Glu Glu Lys Leu Ile Gly Val Gln 1025 1030 1035 Ser Arg His Thr Phe Pro Ala Ile Asn Gly Ile Pro Tyr Gln Leu 1040 1045 1050 Gln Gly Leu Met Met Tyr Lys Asp Glu Asn Val His Trp His Leu 1055 1060 1065 Leu Asn Met Gly Gly Pro Lys Asp Val His Val Val Asn Phe His 1070 1075 1080 Gly Gln Thr Phe Thr Glu Glu Gly Arg Glu Asp Asn Gln Leu Gly 1085 1090 1095 Val Leu Pro Leu Leu Pro Gly Thr Phe Ala Ser Ile Lys Met Lys 1100 1105 1110 Pro Ser Lys Ile Gly Thr Trp Leu Leu Glu Thr Glu Val Gly Glu 1115 1120 1125 Asn Gln Glu Arg Gly Met Gln Ala Leu Phe Thr Val Ile Asp Lys 1130 1135 1140 Asp Cys Lys Leu Pro Met Gly Leu Ala Ser Gly Ile Ile Gln Asp 1145 1150 1155 Ser Gln Ile Ser Ala Ser Gly His Val Gly Tyr Trp Glu Pro Lys 1160 1165 1170 Leu Ala Arg Leu Asn Asn Thr Gly Met Phe Asn Ala Trp Ser Ile 1175 1180 1185 Ile Lys Lys Glu His Glu His Pro Trp Ile Gln Ile Asp Leu Gln 1190 1195 1200 Arg Gln Val Val Ile Thr Gly Ile Gln Thr Gln Gly Thr Val His 1205 1210 1215 Leu Leu Lys His Ser Tyr Thr Val Glu Tyr Phe Val Thr Tyr Ser 1220 1225 1230 Lys Asp Gly Gln Asn Trp Ile Thr Phe Lys Gly Arg His Ser Lys 1235 1240 1245 Thr Gln Met His Phe Glu Gly Asn Ser Asp Gly Thr Thr Val Lys 1250 1255 1260 Glu Asn His Ile Asp Pro Pro Ile Ile Ala Arg Tyr Ile Arg Leu 1265 1270 1275 His Pro Thr Lys Phe Tyr Asn Thr Pro Thr Phe Arg Ile Glu Leu 1280 1285 1290 Leu Gly Cys Glu Val Glu Gly Cys Ser Val Pro Leu Gly Met Glu 1295 1300 1305 Ser Gly Ala Ile Lys Asp Ser Glu Ile Thr Ala Ser Ser Tyr Lys 1310 1315 1320 Lys Thr Trp Trp Ser Ser Trp Glu Pro Phe Leu Ala Arg Leu Asn 1325 1330 1335 Leu Lys Gly Arg Thr Asn Ala Trp Gln Pro Lys Val Asn Asn Lys 1340 1345 1350 Asp Gln Trp Leu Gln Ile Asp Leu Gln His Leu Thr Lys Ile Thr 1355 1360 1365 Ser Ile Ile Thr Gln Gly Ala Thr Ser Met Thr Thr Ser Met Tyr 1370 1375 1380 Val Lys Thr Phe Ser Ile His Tyr Thr Asp Asp Asn Ser Thr Trp 1385 1390 1395 Lys Pro Tyr Leu Asp Val Arg Thr Ser Met Glu Lys Val Phe Thr 1400 1405 1410 Gly Asn Ile Asn Ser Asp Gly His Val Lys His Phe Phe Asn Pro 1415 1420 1425 Pro Ile Leu Ser Arg Phe Ile Arg Ile Ile Pro Lys Thr Trp Asn 1430 1435 1440 Gln Tyr Ile Ala Leu Arg Ile Glu Leu Phe Gly Cys Glu Val Phe 1445 1450 1455 <210> 12 <211> 1459 <212> PRT <213> Taipan <400> 12 Met Gly Arg Tyr Ser Val Ser Pro Val Pro Lys Cys Leu Leu Leu Met 1 5 10 15 Phe Leu Gly Trp Ser Gly Leu Lys Tyr Tyr Gln Val Asn Ala Ala Gln 20 25 30 Leu Arg Glu Tyr Arg Leu Ala Ala Gln Leu Glu Asp Trp Asp Tyr Asn 35 40 45 Pro Gln Pro Glu Glu Leu Ser Arg Leu Ser Glu Ser Asp Leu Thr Phe 50 55 60 Lys Lys Ile Val Tyr Arg Glu Tyr Glu Leu Asp Phe Lys Gln Glu Lys 65 70 75 80 Pro Arg Asp Glu Leu Ser Gly Leu Leu Gly Pro Thr Leu Arg Gly Glu 85 90 95 Val Gly Asp Ser Leu Ile Ile Tyr Phe Lys Asn Phe Ala Thr Gln Pro 100 105 110 Val Ser Ile His Pro Gln Ser Ala Val Tyr Asn Lys Trp Ser Glu Gly 115 120 125 Ser Ser Tyr Ser Asp Gly Thr Ser Asp Val Glu Arg Leu Asp Asp Ala 130 135 140 Val Pro Pro Gly Gln Ser Phe Lys Tyr Val Trp Asn Ile Thr Ala Glu 145 150 155 160 Ile Gly Pro Lys Lys Ala Asp Pro Pro Cys Leu Thr Tyr Ala Tyr Tyr 165 170 175 Ser His Val Asn Met Val Arg Asp Phe Asn Ser Gly Leu Ile Gly Ala 180 185 190 Leu Leu Ile Cys Lys Glu Gly Ser Leu Asn Ala Asp Gly Ala Gln Lys 195 200 205 Phe Phe Asn Arg Glu Tyr Val Leu Met Phe Ser Val Phe Asp Glu Ser 210 215 220 Lys Asn Trp Tyr Arg Lys Pro Ser Leu Gln Tyr Thr Ile Asn Gly Phe 225 230 235 240 Ala Asn Gly Thr Leu Pro Asp Val Gln Ala Cys Ala Tyr Asp His Ile 245 250 255 Ser Trp His Leu Ile Gly Met Ser Ser Ser Pro Glu Ile Phe Ser Val 260 265 270 His Phe Asn Gly Gln Thr Leu Glu Gln Asn His Tyr Lys Val Ser Thr 275 280 285 Ile Asn Leu Val Gly Gly Ala Ser Val Thr Ala Asn Met Ser Val Ser 290 295 300 Arg Thr Gly Lys Trp Leu Ile Ser Ser Leu Val Ala Lys His Leu Gln 305 310 315 320 Ala Gly Met Tyr Gly Tyr Leu Asn Ile Lys Asp Cys Gly Asn Pro Asp 325 330 335 Thr Leu Thr Arg Lys Leu Ser Phe Arg Glu Arg Arg Arg Ile Met Lys 340 345 350 Trp Glu Tyr Phe Ile Ala Ala Glu Glu Ile Thr Trp Asp Tyr Ala Pro 355 360 365 Glu Ile Pro Ser Ser Val Asp Arg Arg Tyr Lys Ala Gln Tyr Leu Asp 370 375 380 Asn Phe Ser Asn Phe Ile Gly Light Light Tyr Light Light Ala Val Phe Arg 385 390 395 400 Gln Tyr Glu Asp Ser Asn Phe Thr Lys Pro Thr Tyr Ala Ile Trp Pro 405 410 415 Lys Glu Arg Gly Ile Leu Gly Pro Val Ile Lys Ala Lys Val Arg Asp 420 425 430 Thr Val Thr Ile Val Phe Lys Asn Leu Ala Ser Arg Pro Tyr Ser Ile 435 440 445 Tyr Val His Gly Val Ser Val Ser Lys Asp Ala Glu Gly Ala Val Tyr 450 455 460 Pro Ser Asp Pro Lys Glu Asn Ile Thr His Gly Lys Ala Val Glu Pro 465 470 475 480 Gly Gln Val Tyr Thr Tyr Lys Trp Thr Val Leu Asp Thr Asp Glu Pro 485 490 495 Thr Val Lys Asp Ser Glu Cys Ile Thr Lys Leu Tyr His Ser Ala Val 500 505 510 Asp Met Thr Arg Asp Ile Ala Ser Gly Leu Ile Gly Pro Pro Leu Val 515 520 525 Cys Lys Arg Lys Ala Leu Ser Ile Arg Gly Val Gln Asn Lys Ala Asp 53...

Claims

1. A coagulation composition for preparing a serum sample, in, The blood coagulation composition comprises a prothrombin activator, a colloid and a surfactant, wherein the prothrombin activator is Ecarin and the colloid is succinylated gelatin.

2. The blood coagulation composition according to claim 1, in, The prothrombin activator consists of an amino acid sequence selected from SEQ ID NO: 1, 53, 54, 55, 56 or 57.

3. The blood coagulation composition according to claim 1, in, The surfactant is a hydrophilic surfactant.

4. The blood coagulation composition according to claim 1, in, The coagulation composition comprises a ratio of prothrombin activator to colloid in the range of 1:100 to 1:

800.

5. The blood coagulation composition according to claim 1, in, The coagulation composition comprises 0.2 μg to 10 μg of a prothrombin activator.

6. The blood coagulation composition according to any one of claims 1 to 5, in, The coagulation composition remained stable and active for a period of up to 18 months.

7. The blood coagulation composition according to any one of claims 1 to 5, in, When stored above room temperature, the coagulation composition remains stable and active for a period of up to 18 months.

8. The blood coagulation composition according to any one of claims 1 to 5, in, Following irradiation sterilization, the coagulation composition remained stable and active for a period of up to 18 months.

9. The blood coagulation composition according to any one of claims 1 to 5, in, The coagulation composition is dried onto the inner surface of the container.

10. The blood coagulation composition according to claim 9, in, The drying occurs at a temperature above room temperature.

11. The blood coagulation composition according to any one of claims 1 to 5, in, The coagulation composition is capable of separating coagulation cells from serum in 5 minutes or less.

12. A coagulation composition for preparing a serum sample, in, The coagulation composition comprises a prothrombin activator and a modified fluid gelatin, wherein the prothrombin activator is Ecarin and the modified fluid gelatin is 4% succinylated gelatin.

13. A method for preparing a coagulation composition according to any one of claims 1 to 12, in, The method comprises: (a) providing a prothrombin activator and a colloid, and optionally a surfactant; (b) contacting the colloid and optionally the surfactant with an inner surface of a container; and (c) drying the prothrombin activator onto the inner surface of the container at a temperature higher than room temperature Thus, a blood coagulation composition was prepared.

14. A container comprising the coagulation composition according to any one of claims 1 to 12.

15. The container according to claim 14, in, The container is a blood collection tube.

16. A kit for preparing a serum sample, in, The kit comprises the coagulation composition according to any one of claims 1 to 12 or the container according to claim 14 or 15.

17. A method for preparing a serum sample, in, The method comprises contacting the blood sample with a coagulation composition according to any one of claims 1 to 12 or a container according to claim 14 or 15 for a period of time and under conditions sufficient to cause coagulation of the blood sample, and optionally separating serum from coagulated cells, thereby preparing a serum sample.

18. Use of a coagulation composition according to any one of claims 1 to 12 or a container according to claim 14 or 15 in the preparation of a medicament for diagnosing a disease or condition in a subject.

19. Use of the coagulation composition according to any one of claims 1 to 12 or the container according to claim 14 or 15 for the preparation of a medicament indicative of a subject's prognosis.

20. Use of a coagulation composition according to any one of claims 1 to 12 or a container according to claim 14 or 15 for the preparation of a medicament for monitoring a subject's responsiveness to a treatment.

Citation Information

Patent Citations

  • Specimen collecting tube

    US4227620A

  • Fluid sample collection device

    US4256120A

  • Process for site specific mutagenesis without phenotypic selection

    US4873192A

  • Ecarin prothrombin protease and methods

    US6413737B1

  • Evacuated blood collection tube for rapid blood coagulation

    US6416717B1